

<b>Official Protocol Title:</b>	A Phase III Randomized Open-Label Study of Single Agent Pembrolizumab vs. Physicians' Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)
<b>NCT number:</b>	NCT02564263
<b>Document Date:</b>	25-Jun-2021

**THIS PROTOCOL AMENDMENT AND ALL OF THE INFORMATION RELATING TO IT ARE CONFIDENTIAL AND PROPRIETARY PROPERTY OF MERCK SHARP & DOHME CORP., A SUBSIDIARY OF MERCK & CO., INC., WHITEHOUSE STATION, NJ, U.S.A.**

**SPONSOR:**

Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.  
(hereafter referred to as the Sponsor or Merck)

One Merck Drive  
P.O. Box 100  
Whitehouse Station, New Jersey, 08889-0100, U.S.A.

Protocol-specific Sponsor Contact information can be found in the Investigator Trial File Binder (or equivalent).

**TITLE:**

A Phase III Randomized Open-Label Study of Single Agent Pembrolizumab vs. Physicians' Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

**IND NUMBER: 123,482**

**EudraCT NUMBER: 2015-002782-32**

## TABLE OF CONTENTS

<b>DOCUMENT HISTORY .....</b>	<b>11</b>
<b>SUMMARY OF CHANGES .....</b>	<b>13</b>
<b>1.0 TRIAL SUMMARY.....</b>	<b>15</b>
<b>2.0 TRIAL DESIGN.....</b>	<b>16</b>
<b>2.1 Trial Design .....</b>	<b>16</b>
<b>2.2 Trial Diagram.....</b>	<b>19</b>
<b>3.0 OBJECTIVE(S) &amp; HYPOTHESIS(ES).....</b>	<b>20</b>
<b>3.1 Primary Objective(s) &amp; Hypothesis(es) .....</b>	<b>20</b>
<b>3.2 Secondary Objective(s) &amp; Hypothesis(es).....</b>	<b>21</b>
<b>3.3 Exploratory Objectives.....</b>	<b>21</b>
<b>4.0 BACKGROUND &amp; RATIONALE.....</b>	<b>22</b>
<b>4.1 Background .....</b>	<b>22</b>
4.1.1 Pharmaceutical and Therapeutic Background .....	22
4.1.2 Pre-clinical and Clinical Trials .....	23
4.1.2.1 Preclinical Studies.....	23
4.1.3 Ongoing Clinical Trials.....	23
<b>4.2 Rationale .....</b>	<b>24</b>
4.2.1 Rationale for the Trial and Selected Subject Population .....	24
4.2.2 Rationale for Dose Selection/Regimen/Modification .....	25
4.2.2.1 Rationale for the Use of Pembrolizumab.....	25
4.2.2.2 Rationale for the Use of Comparator .....	26
4.2.2.3 Rationale for using the Intratumoral Immune-related Gene Expression Profile (GEP) in Esophageal Cancer .....	28
4.2.3 Rationale for Endpoints .....	28
4.2.3.1 Primary Efficacy Endpoints .....	28
4.2.3.2 Secondary Efficacy Endpoints .....	28
4.2.3.3 Safety Endpoints .....	29
4.2.3.4 Exploratory Endpoints .....	29
4.2.3.4.1 Immune-related RECIST (irRECIST) .....	29
4.2.3.4.2 Patient Reported Outcomes .....	30
4.2.3.5 Biomarker Research.....	31

4.2.3.5.1	Biomarker Research for Primary Objectives .....	31
4.2.3.5.2	Biomarker Research for Exploratory Objectives .....	31
4.2.3.6	Future Biomedical Research .....	32
<b>4.3</b>	<b>Benefit/Risk .....</b>	<b>33</b>
<b>5.0</b>	<b>METHODOLOGY .....</b>	<b>33</b>
<b>5.1</b>	<b>Entry Criteria.....</b>	<b>33</b>
5.1.1	Diagnosis/Condition for Entry into the Trial .....	33
5.1.2	Subject Inclusion Criteria.....	33
5.1.3	Subject Exclusion Criteria .....	36
<b>5.2</b>	<b>Trial Treatment(s) .....</b>	<b>38</b>
5.2.1	Dose Selection/Modification .....	39
5.2.1.1	Dose Selection (Preparation) .....	39
5.2.1.2	Dose Modification (Escalation/Titration/Other).....	39
5.2.1.2.1	Immune-Related Events and Dose Modification (Withhold, Treat, Discontinue).....	39
5.2.1.2.2	Dose Modification for Paclitaxel, Docetaxel and Irinotecan.....	44
5.2.2	Timing of Dose Administration .....	44
5.2.2.1	Pembrolizumab .....	44
5.2.2.2	Paclitaxel.....	45
5.2.2.3	Docetaxel .....	45
5.2.2.4	Irinotecan .....	46
5.2.3	Trial Blinding/Masking.....	46
<b>5.3</b>	<b>Randomization or Treatment Allocation.....</b>	<b>47</b>
<b>5.4</b>	<b>Stratification.....</b>	<b>47</b>
<b>5.5</b>	<b>Concomitant Medications/Vaccinations (Allowed &amp; Prohibited) .....</b>	<b>47</b>
5.5.1	Acceptable Concomitant Medications .....	47
5.5.2	Prohibited Concomitant Medication .....	48
<b>5.6</b>	<b>Rescue Medications &amp; Supportive Care .....</b>	<b>49</b>
5.6.1	Supportive Care Guidelines for Pembrolizumab .....	49
5.6.2	Supportive Care Guidelines for Paclitaxel, Docetaxel and Irinotecan.....	49
<b>5.7</b>	<b>Diet/Activity/Other Considerations.....</b>	<b>50</b>
5.7.1	Diet.....	50
5.7.2	Contraception.....	50

5.7.3	Use in Pregnancy .....	53
5.7.4	Use in Nursing Women.....	53
<b>5.8</b>	<b>Subject Withdrawal/Discontinuation Criteria.....</b>	<b>53</b>
5.8.1	Discontinuation of Treatment .....	53
5.8.2	Discontinuation of Study Therapy after Complete Response.....	54
5.8.3	Withdrawal from the Trial .....	55
<b>5.9</b>	<b>Subject Replacement Strategy.....</b>	<b>55</b>
<b>5.10</b>	<b>Beginning and End of the Trial .....</b>	<b>55</b>
<b>5.11</b>	<b>Clinical Criteria for Early Trial Termination .....</b>	<b>55</b>
<b>6.0</b>	<b>TRIAL FLOW CHART .....</b>	<b>57</b>
6.1	Trial Flow Chart – Initial Treatment Phase for Pembrolizumab Arm .....	57
6.2	Trial Flow Chart –Treatment Phase for Paclitaxel.....	61
6.3	Trial Flow Chart –Treatment Phase for Docetaxel .....	65
6.4	Trial Flow Chart –Treatment Phase for Irinotecan .....	68
6.5	Second Course Phase (Retreatment with Pembrolizumab).....	72
<b>7.0</b>	<b>TRIAL PROCEDURES .....</b>	<b>74</b>
<b>7.1</b>	<b>Trial Procedures .....</b>	<b>74</b>
7.1.1	Administrative Procedures .....	74
7.1.1.1	Informed Consent.....	74
7.1.1.1.1	General Informed Consent.....	74
7.1.1.1.2	Consent and Collection of Specimens for Future Biomedical Research.....	75
7.1.1.2	Inclusion/Exclusion Criteria .....	75
7.1.1.3	Subject Identification Card .....	75
7.1.1.4	Medical History .....	75
7.1.1.5	Disease Details.....	75
7.1.1.6	Prior and Concomitant Medications Review .....	75
7.1.1.6.1	Prior Medications.....	75
7.1.1.6.1.1	Prior Treatment Details for Esophageal or EGJ Carcinoma .....	76
7.1.1.6.2	Concomitant Medications .....	76
7.1.1.6.3	Subsequent Anti-Cancer Therapy Status .....	76
7.1.1.7	Assignment of Screening Number .....	76
7.1.1.8	Assignment of Treatment/Randomization Number.....	76

7.1.1.9 Trial Compliance (Medication/Diet/Activity/Other) .....	77
7.1.2 Clinical Procedures/Assessments.....	77
7.1.2.1 Adverse Event Monitoring.....	77
7.1.2.2 Physical Exam.....	77
7.1.2.2.1 Full Physical Exam .....	77
7.1.2.2.2 Directed Physical Exam.....	78
7.1.2.3 Height, Weight, and Vital Signs .....	78
7.1.2.4 12-Lead Electrocardiogram .....	78
7.1.2.5 Eastern Cooperative Oncology Group Performance Status.....	78
7.1.2.6 Patient Reported Outcome .....	78
7.1.3 Laboratory Procedures/Assessments .....	79
7.1.3.1 Laboratory Safety Evaluations.....	79
7.1.3.1.1 Pregnancy Tests .....	80
7.1.3.2 Central Laboratory Assessments.....	80
7.1.3.3 Pharmacokinetic/Pharmacodynamic Evaluations .....	80
7.1.3.3.1 Blood Collection for Serum MK-3475 .....	80
7.1.3.3.2 Blood Collection for Anti-pembrolizumab (MK-3475) Antibodies....	80
7.1.3.3.3 Correlative and Biomarker Blood Samples .....	81
7.1.3.4 Planned Genetic Analysis Sample Collection.....	81
7.1.3.5 Future Biomedical Research Sample Collection .....	81
7.1.3.6 Tumor Tissue .....	81
7.1.4 Efficacy Measurements.....	81
7.1.4.1 Tumor Imaging and Assessment of Disease.....	81
7.1.4.1.1 Initial Tumor Imaging.....	82
7.1.4.1.2 Tumor Imaging During the Trial .....	82
7.1.4.1.3 End of Treatment and Follow-up Tumor Imaging.....	83
7.1.4.1.4 Second Course (Retreatment) Tumor Imaging.....	83
7.1.4.1.5 RECIST 1.1 Assessment of Disease .....	84
7.1.4.1.6 irRECIST Assessment of Disease.....	84
7.1.5 Other Procedures.....	87
7.1.5.1 Withdrawal/Discontinuation.....	87
7.1.5.1.1 Withdrawal From Future Biomedical Research .....	88

7.1.5.1.2	Lost to Follow-up.....	88
7.1.5.2	Blinding/Unblinding .....	89
7.1.5.3	Calibration of Equipment.....	89
7.1.6	Visit Requirements.....	89
7.1.6.1	Screening.....	89
7.1.6.2	Treatment Period.....	90
7.1.6.3	Post-Trial Visits .....	91
7.1.6.3.1	Safety Follow-up Visits .....	91
7.1.6.3.2	Follow-up Visits .....	91
7.1.6.3.3	Survival Follow-up .....	92
7.1.6.3.3.1	Survival Status.....	92
<b>7.2</b>	<b>Assessing and Recording Adverse Events .....</b>	<b>92</b>
7.2.1	Definition of an Overdose for This Protocol and Reporting of Overdose to the Sponsor.....	93
7.2.2	Reporting of Pregnancy and Lactation to the Sponsor .....	93
7.2.3	Immediate Reporting of Adverse Events to the Sponsor.....	94
7.2.3.1	Serious Adverse Events .....	94
7.2.3.2	Events of Clinical Interest.....	95
7.2.3.3	Protocol-Specific Exceptions to Serious Adverse Event Reporting .....	96
7.2.4	Evaluating Adverse Events .....	96
7.2.5	Sponsor Responsibility for Reporting Adverse Events .....	99
<b>7.3</b>	<b>TRIAL GOVERNANCE AND OVERSIGHT .....</b>	<b>99</b>
7.3.1	Scientific Advisory Committee.....	99
7.3.2	Executive Oversight Committee .....	99
7.3.3	Data Monitoring Committee .....	99
<b>8.0</b>	<b>STATISTICAL ANALYSIS PLAN .....</b>	<b>100</b>
<b>8.1</b>	<b>Statistical Analysis Plan Summary .....</b>	<b>100</b>
<b>8.2</b>	<b>Responsibility for Analyses/In-House Blinding .....</b>	<b>102</b>
<b>8.3</b>	<b>Hypotheses/Estimation .....</b>	<b>102</b>
<b>8.4</b>	<b>Analysis Endpoints .....</b>	<b>102</b>
8.4.1	Efficacy Endpoints .....	102
8.4.2	Safety Endpoints .....	103
<b>8.5</b>	<b>Analysis Populations.....</b>	<b>103</b>

8.5.1	Efficacy Analysis Populations .....	103
8.5.2	Safety Analysis Populations .....	103
<b>8.6</b>	<b>Statistical Methods.....</b>	<b>104</b>
8.6.1	Statistical Methods for Efficacy Analyses .....	104
8.6.1.1	Overall Survival (OS) .....	104
8.6.1.2	Progression-Free Survival (PFS).....	105
8.6.1.3	Objective Response Rate (ORR) .....	106
8.6.2	Statistical Methods for Safety Analyses .....	107
8.6.3	Summaries of Demographic and Baseline Characteristics .....	109
<b>8.7</b>	<b>Interim Analyses .....</b>	<b>109</b>
<b>8.8</b>	<b>Multiplicity .....</b>	<b>112</b>
<b>8.9</b>	<b>Sample Size and Power Calculations .....</b>	<b>113</b>
<b>8.10</b>	<b>Subgroup Analyses and Effect of Baseline Factors .....</b>	<b>114</b>
<b>8.11</b>	<b>Compliance (Medication Adherence).....</b>	<b>114</b>
<b>8.12</b>	<b>Extent of Exposure.....</b>	<b>114</b>
<b>9.0</b>	<b>LABELING, PACKAGING, STORAGE AND RETURN OF CLINICAL SUPPLIES .....</b>	<b>115</b>
9.1	Investigational Product .....	115
9.2	Packaging and Labeling Information .....	115
9.3	Clinical Supplies Disclosure.....	116
9.4	Storage and Handling Requirements.....	116
9.5	Discard/Destruction/Returns and Reconciliation .....	116
9.6	Standard Policies.....	116
<b>10.0</b>	<b>ADMINISTRATIVE AND REGULATORY DETAILS.....</b>	<b>117</b>
<b>10.1</b>	<b>Confidentiality.....</b>	<b>117</b>
10.1.1	Confidentiality of Data .....	117
10.1.2	Confidentiality of Subject Records .....	117
10.1.3	Confidentiality of Investigator Information.....	117
10.1.4	Confidentiality of IRB/IEC Information.....	118
<b>10.2</b>	<b>Compliance with Financial Disclosure Requirements.....</b>	<b>118</b>
<b>10.3</b>	<b>Compliance with Law, Audit and Debarment .....</b>	<b>118</b>
<b>10.4</b>	<b>Compliance with Trial Registration and Results Posting Requirements .....</b>	<b>120</b>
<b>10.5</b>	<b>Quality Management System.....</b>	<b>120</b>

<b>10.6 Data Management.....</b>	<b>121</b>
<b>10.7 Publications .....</b>	<b>121</b>
<b>11.0 LIST OF REFERENCES .....</b>	<b>123</b>
<b>12.0 APPENDICES.....</b>	<b>128</b>
<b>12.1 Merck Code of Conduct for Clinical Trials.....</b>	<b>128</b>
<b>12.2 Collection and Management of Specimens for Future Biomedical Research.....</b>	<b>130</b>
<b>12.3 Understanding the Intent, Scope and Public Health Benefits of Exploratory Biomarker Research: A Guide for IRBs/IECs and Investigational Site Staff .....</b>	<b>134</b>
<b>12.4 Response Evaluation Criteria in Solid Tumors .....</b>	<b>145</b>
<b>12.5 ECOG Performance Status.....</b>	<b>146</b>
<b>12.6 Common Terminology Criteria for Adverse Events .....</b>	<b>147</b>
<b>12.7 List of Abbreviations .....</b>	<b>148</b>
<b>13.0 SIGNATURES.....</b>	<b>151</b>
<b>13.1 Sponsor's Representative .....</b>	<b>151</b>
<b>13.2 Investigator.....</b>	<b>151</b>

## LIST OF TABLES

Table 1	Adequate Organ Function Laboratory Values .....	35
Table 2	Trial Treatment .....	38
Table 3	Dose Modification and Toxicity Management Guidelines for Immune-related Adverse Events Associated with Pembrolizumab Monotherapy, Coformulations or IO Combinations .....	40
Table 4	Pembrolizumab Infusion Reaction Dose modification and Treatment Guidelines .....	43
Table 5	Laboratory Tests .....	79
Table 6	Imaging and Treatment after First Radiologic Evidence of PD .....	86
Table 7	Evaluating Adverse Events .....	97
Table 8	Statistical Plan Analysis Summary .....	100
Table 9	Censoring rules for Primary and Sensitivity Analyses of PFS .....	106
Table 10	Analysis Strategy for Key Efficacy Endpoints .....	107
Table 11	Analysis Strategy for Safety Parameters .....	109
Table 12	Summary of Timing, Sample Size and Decision Guidance of Interim Efficacy Analysis and Final Analysis .....	111
Table 13	Product Descriptions .....	115

## LIST OF FIGURES

Figure 1	China Enrollment Strategy.....	19
Figure 2	Trial Design Schematic .....	20
Figure 3	Imaging and Treatment for Clinically Stable Subjects after First Radiologic Evidence of PD Assessed by the Site .....	87
Figure 4	Multiplicity Strategy .....	112

## DOCUMENT HISTORY

<b>Document</b>	<b>Date of Issue</b>	<b>Overall Rationale</b>
3475-181-06	25-JUN-2021	To update the dose modification and toxicity management guidelines for irAEs. To clarify the concomitant use of COVID-19 vaccines.
3475-181-05	08-MAR-2018	The alpha spending function to control the Type-I error based on information fraction was replaced with one based on specified calendar time fraction (0.76). Due to potential delayed treatment effects that have been observed with immunotherapy, the stratified log-rank test was replaced by a stratified max-combo test for testing the OS and PFS hypotheses in all subjects. Max-combo test statistic is the maximum of test statistics based on the log-rank test and a test that down-weights the early events, and hence, is sensitive to the non-proportional hazards assumption.
3475-181-04	03-AUG-2017	The primary objectives were changed from dual endpoints of OS and PFS to a single endpoint of OS, based on recommendations from emerging data in MK-3475-KEYNOTE-180. The timing of the interim and final analyses was updated in order to wait for more mature OS data and account for a potential delayed separation in survival curves observed in immuno-oncology studies.
3475-181-03	29-MAR-2017	To extend the enrollment period beyond the Global Cohort to achieve the required sample size of the China Cohort and the number of events to investigate efficacy and safety in Chinese 2L EC subjects.
3475-181-02	09-DEC-2016	Sections were revised to identify GEP low, intermediate, and high tumors; to describe the development of GEP cut-off “GEP intermediate or high” and/or to describe how the primary, secondary, and exploratory objectives and endpoints will be met and analyzed, respectively, based on these tumor designations

<b>Document</b>	<b>Date of Issue</b>	<b>Overall Rationale</b>
3475-181-01	20-JUL-2016	All sections were revised to describe the development of 2 GEP cutpoints to identify GEP low, intermediate, and high tumors; and/or to describe how the primary, secondary, and exploratory objectives and endpoints will be met and analyzed, respectively, based on these tumor designations.
3475-181-00	25-AUG-2015	Original protocol.

## SUMMARY OF CHANGES

### PRIMARY REASON FOR THIS AMENDMENT:

Section Number	Section Title	Description of Change	Rationale
5.2.1.2.1	Immune-Related Events and Dose Modification (Withhold, Treat, Discontinue)	The dose modification and toxicity management guidelines for immune-related adverse events (irAEs) and table were updated.	The dose modification and toxicity management guidelines for irAEs and table were updated as requested by the U.S. Food and Drug Administration (FDA) in an effort to harmonize the presentation of safety information across all FDA-approved programmed cell death 1/ligand 1 (PD-1/L1) antibody prescribing information.

### ADDITIONAL CHANGE FOR THIS AMENDMENT:

Section Number (s)	Section Title (s)	Description of Change (s)	Rationale
5.11	Clinical Criteria for Early Trial Termination	The criteria for early trial termination was updated.	To add flexibility to allow the study to terminate before the planned completion date.
5.10	Beginning and End of the Trial	Added language to state that upon study completion, subjects may be enrolled in a pembrolizumab extension study upon study completion.	Subjects may be enrolled in a pembrolizumab extension study upon study completion.
5.5.2	Prohibited Medication Concomitant	Added a note that any COVID-19 vaccine that is licensed in a given country is allowed in the study.	To clarify the concomitant use of COVID-19 vaccines.

<b>Section Number (s)</b>	<b>Section Title (s)</b>	<b>Description of Change (s)</b>	<b>Rationale</b>
7.1.1.8	Assignment of Treatment/Randomization Number	Added language to state that if subjects are rerandomized, each subject will retain his/her original treatment/randomization number.	To clarify that each subjects' original treatment/randomization will be retained if subjects are enrolled in an extension study.
1.0, 5.1.2, 5.10, 7.1.1.1.2, 7.1.1.3	Trial Summary, Subject Inclusion Criteria, Beginning and End of the Trial, Consent and Collection of Specimens for Future Biomedical Research, Subject Identification Card	Updated informed consent language to provide for documentation of consent.	To align text with legal requirements to obtain informed consent.
Overall	Overall	Minor editorial changes.	For clarity.

## 1.0 TRIAL SUMMARY

Abbreviated Title	A Phase III study of Pembrolizumab vs. Physicians' choice of Docetaxel, Paclitaxel or Irinotecan in 2L Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus
Trial Phase	Phase III
Clinical Indication	Advanced/metastatic adenocarcinoma and squamous cell carcinoma of the esophagus and advanced/metastatic Siewert type I adenocarcinoma of the esophagogastric junction (EGJ)
Trial Type	Interventional
Type of control	Active control without placebo
Route of administration	Intravenous
Trial Blinding	Unblinded Open-label
Treatment Groups	Arm 1: Pembrolizumab (MK-3475) 200 mg IV every 3-weeks Arm 2: Investigator's choice of: - Paclitaxel 80-100 mg/m <sup>2</sup> on Days 1, 8, and 15 of every 28-day (4-week) cycle, OR - Docetaxel 75 mg/m <sup>2</sup> on Day 1 of every 21-day (3-week) cycle, OR - Irinotecan 180 mg/m <sup>2</sup> on Day 1 of every 14-day (2-week) cycle
Number of trial subjects	The Global Cohort: Approximately 600 subjects will be enrolled. The China Cohort: Approximately 120 Chinese subjects overall will be enrolled in the China Cohort. The China Cohort will enroll 120 subjects in two enrollment periods: 1) The <b>Global enrollment period</b> : part of enrollment in the China cohort will contribute towards enrollment in the Global Cohort until the Global Cohort completes enrollment of approximately 600 subjects. 2) The <b>China extension enrollment period</b> : Remaining enrollment in China cohort will occur in the China extension period until approximately 120 total subjects are enrolled in the China cohort.
Estimated duration of trial	The Global Cohort: The Sponsor estimates that the cohort will require approximately 36 months from the time the first subject provides informed consent until the last subject's last study-related phone call or visit. The China Cohort: The Sponsor estimates that the cohort will require approximately 2 additional years from the time the first subject provides informed consent until the last subject's last visit.
Duration of Participation	Each subject will participate in the trial from the time the subject provides documented informed consent through the final contact. After a screening phase of up to 28 days, eligible subjects will receive treatment beginning on Day 1 of each 3-week dosing cycle for pembrolizumab or investigator's choice of paclitaxel (Days 1, 8, and 15 of every 28-day cycle), docetaxel (Day 1, every 21-day cycle), or irinotecan (Day 1, every 14-day cycle). Treatment with pembrolizumab or paclitaxel/docetaxel/irinotecan will continue until documented disease progression, unacceptable adverse event(s), intercurrent illness that prevents further administration of treatment, Investigator's decision to discontinue the subject, subject withdraws consent, pregnancy of the subject, noncompliance with trial treatment or procedure requirements, subject receives 35 administrations

	<p>(approximately 2 years) of pembrolizumab, or administrative reasons requiring cessation of treatment. After the end of treatment, each subject will be followed for 30 days for adverse event (AE) monitoring. Serious adverse events (SAE) will be collected for 90 days after the end of treatment or for 30 days after the end of treatment if the subject initiates new anticancer therapy, whichever is earlier.</p> <p>Subjects who discontinue pembrolizumab as a result of obtaining an investigator-determined confirmed complete response (CR) or those subjects who stop after receiving 35 trial treatments (approximately 2 years) may be eligible, at the discretion of the investigator, for an additional 17 trial treatments (approximately 1 year) after experiencing radiographic progressive disease if they meet the criteria for re-treatment (Second Course Phase) and the study is ongoing. Subjects who discontinue for reasons other than disease progression will have post-treatment follow-up for disease status until disease progression, initiating a non-study cancer treatment, withdrawing consent, or becoming lost to follow-up. All subjects will be followed (e.g. by telephone) for overall survival until death, withdrawal of consent, or the end of the study.</p>
--	------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Randomization Ratio	1:1
---------------------	-----

A list of abbreviations used in this document can be found in Section 12.7.

## 2.0 TRIAL DESIGN

### 2.1 Trial Design

This is a randomized, multi-center, open-label trial of pembrolizumab (MK-3475) versus the investigator's choice of paclitaxel, docetaxel, or irinotecan in subjects with advanced/metastatic adenocarcinoma or squamous cell carcinoma of the esophagus, or advanced/metastatic Siewert type I adenocarcinoma of the esophagogastric junction (EGJ). Siewert type I tumors are adenocarcinomas of the lower esophagus with the center located within 1cm to 5cm above the anatomic EGJ. Subjects will be required to have an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1, and to have been previously treated with one prior line of standard therapy per local/global guidelines. Subjects will be required to provide a tumor sample, to be evaluated at a central laboratory, for analysis of PD-L1 and immune-related gene expression profile (GEP), both for response prediction for pembrolizumab efficacy. An adequate tumor specimen for both PD-L1 and GEP biomarker status must be available and confirmed evaluable prior to randomization.

Subjects will be randomized in a 1:1 ratio to receive pembrolizumab or investigator's choice of paclitaxel, docetaxel, or irinotecan. Investigator's choice of paclitaxel, docetaxel, or irinotecan should be determined prior to randomization and should not be in conflict with local regulations or guidance. Subjects will be stratified by tumor histology and by geographic region (See Section 5.4 for stratification).

The study will be enrolling into two cohorts: Global and China Cohorts. The enrollment period is divided into two periods: Global and China extension enrollment ([Figure 1](#)).

## The Global Cohort

The Global Cohort will enroll approximately 600 patients without regard to GEP biomarker status. This cohort will include any subject enrolled in China during the global enrollment period. Subjects enrolled during the China extension enrollment period are not part of the Global Cohort.

Prior to starting this study, the estimated prevalence of GEP intermediate or high grade tumors was around 60%. The prevalence of subjects with GEP intermediate or high tumors is 42.6% based on 357 randomized subjects' sample results from Keynote 181. The prevalence of subjects with GEP intermediate or high tumors at the end of enrollment is expected to be between 40%-45%, and it is estimated that approximately 240-270 subjects with GEP intermediate or high tumors will be enrolled. The prevalence of subjects with PD-L1 CPS $\geq$ 10 is 47.6% in esophageal cancer subjects based on emerging results from 105 subjects enrolled in MK-3475 KN180. It is expected PD-L1 CPS $\geq$ 10 prevalence rate will be around 40%-48% in KN181. Beginning with screening, all imaging assessments will be submitted for central imaging vendor review and will be evaluated using Response Evaluation Criteria in Solid Tumors (RECIST 1.1) for determining eligibility and assessment of response. On study imaging assessments will be performed every 9 weeks (+/- 7 days) following the date of randomization until progression of disease is documented with radiologic imaging (computed tomography or magnetic resonance imaging). Imaging timing should follow calendar days and should not be adjusted for delays in cycle starts.

The primary efficacy endpoint is overall survival (OS). Progression free survival (PFS) and Objective response rate (ORR) are secondary efficacy endpoints. The PFS analysis will be based on RECIST 1.1 by central imaging vendor review. Images read by central imaging vendor will be blinded to treatment assignment to minimize bias in the response assessments. RECIST 1.1 will be used by the site for treatment decisions until verification of progressive disease (PD) by the central imaging vendor. Following verification of PD by the central imaging vendor, treatment decisions may be made by the adaption of RECIST 1.1 as described in Section 7.1.4.1.5 termed immune-related RECIST (irRECIST) to accommodate for the tumor response patterns seen with pembrolizumab treatment (e.g., tumor flare). This was first described by Nishino, et al. 2013 [1], but is further modified for the PD-1 program. For a clinically stable subject with first radiologic evidence of PD, it is at the discretion of the site investigator to continue treating the subject with pembrolizumab until PD is confirmed at least 4 weeks from the date of the first tumor imaging suggesting PD per the site investigator. If radiologic PD is confirmed by the subsequent tumor imaging the subject should be discontinued from treatment unless, in the opinion of the investigator, the subject is achieving a clinically meaningful benefit; an exception to continue treatment may be considered following consultation with the Sponsor.

Adverse events will be monitored throughout the trial and graded in severity according to the guidelines outlined in the NCI Common Terminology Criteria for Adverse Events (CTCAE) version 4.0.

Except as noted above, treatment with pembrolizumab, paclitaxel, docetaxel, or irinotecan will continue until documented disease progression, unacceptable adverse event(s),

intercurrent illness that prevents further administration of treatment, Investigator's decision to discontinue the subject, subject withdraws consent, pregnancy of the subject, noncompliance with trial treatment or procedure requirements or administrative reasons requiring the cessation of treatment. For subjects in the pembrolizumab arm, treatment may be continued until the subject has received 35 trial treatments (approximately 2 years) with pembrolizumab.

Subjects on the pembrolizumab arm who attain an investigator-determined confirmed complete response (CR) may consider stopping trial treatment after receiving at least 8 trial treatments (approx. 6 months) of pembrolizumab and had at least 2 treatments with pembrolizumab beyond the date when the initial CR was declared. Subjects who discontinue after 35 administrations (approximately 2 years) of pembrolizumab for reasons other than disease progression or intolerance or who discontinue after attaining a CR may be eligible for up to one year (17 trial treatments) of retreatment after they have experienced radiographic disease progression. The decision to retreat will be at the discretion of the Investigator only if no cancer treatment was administered since the last dose of pembrolizumab, the subject still meets the safety parameters listed in the Inclusion/Exclusion criteria and the trial remains open. Subjects within the paclitaxel/docetaxel/irinotecan arm will continue on treatment until disease progression or unacceptable toxicity. A cross-over of treatment groups after documented disease progression on the study treatment will not be allowed.

After the end of treatment, each subject will be followed for 30 days for adverse event monitoring. Serious adverse events (SAE) will be collected for 90 days after the end of treatment or for 30 days after the end of treatment if the subject initiates new anticancer therapy, whichever is earlier. Subjects who discontinue treatment for reasons other than disease progression will have post-treatment follow-up for disease status until disease progression, initiating a non-study cancer treatment, withdrawing consent, or becoming lost to follow-up. All subjects will be followed (e.g. by telephone contact) for OS until death, withdrawal of consent or the end of the study, whichever comes first.

This study will be conducted in conformance with Good Clinical Practices.

Specific procedures to be performed during the trial, as well as their prescribed times and associated visit windows, are outlined in the Trial Flow Chart - Section 6.0. Details of each procedure are provided in Section 7.0 – Trial Procedures.

This trial will use a group sequential design, using an independent, external Data Monitoring Committee (eDMC) to monitor safety and efficacy. The role of the eDMC will be clearly elucidated in the eDMC Charter. There will be one formal interim efficacy analysis. See Section 8.7 for more details.

### **The China Cohort**

Approximately 120 subjects from China will be enrolled in the China Cohort, this will include subjects enrolled in China during the global enrollment period as well as the China extension enrollment period (see [Figure 1](#)). After the enrollment of the Global Cohort is

closed, subjects from China will continue to be enrolled in the China cohort designed to meet local regulatory needs. The China Cohort will be identical to the Global Cohort (e.g., inclusion and exclusion criteria, study endpoints, primary and secondary objectives, study procedures). The details of the analysis will be provided in supplemental SAP.





Figure 1 China Enrollment Strategy

## 2.2 Trial Diagram

The trial design is depicted in [Figure 2](#).



\*Stratification by 1: Tumor histology 2. Geographic region

Figure 2 Trial Design Schematic

### 3.0 OBJECTIVE(S) & HYPOTHESIS(ES)

#### 3.1 Primary Objective(s) & Hypothesis(es)

For subjects with advanced/metastatic adenocarcinoma or squamous cell carcinoma of the esophagus or advanced/metastatic Siewert type I adenocarcinoma of the EGJ who have progressed on one previous line of standard therapy.

- 1) **Objective:** to compare OS in subjects with squamous cell carcinoma of the esophagus.

**Hypothesis (H1):** Pembrolizumab 200 mg every 3 weeks (Q3W) prolongs OS in subjects with squamous cell carcinoma of the esophagus compared to investigator's choice of paclitaxel, docetaxel, or irinotecan.

- 2) **Objective:** To compare OS in subjects with PD-L1 Combined Positive Score (CPS)  $\geq 10$ .

**Hypothesis (H2):** In subjects with PD-L1 CPS  $\geq 10$ , pembrolizumab 200 mg every 3 weeks (Q3W) prolongs OS compared to investigator's choice of paclitaxel, docetaxel, or irinotecan.

3) **Objective:** To compare OS in all subjects.

**Hypothesis (H3):** Pembrolizumab 200 mg Q3W prolongs OS in all subjects, compared to investigator's choice of paclitaxel, docetaxel, or irinotecan.

The study is considered to have met its primary objective if pembrolizumab is superior to investigator's choice of paclitaxel, docetaxel, or irinotecan in any one of the three primary objectives.

### 3.2 Secondary Objective(s) & Hypothesis(es)

1) **Objective:** To evaluate the progression free survival (PFS) per RECIST 1.1 assessed by central vendor review in all subjects, when treated with pembrolizumab compared to investigator's choice of paclitaxel, docetaxel, or irinotecan.

**Hypotheses (H4):** Pembrolizumab 200 mg Q3W improves PFS per RECIST 1.1 by central vendor review in all subjects, compared to investigator's choice of paclitaxel, docetaxel, or irinotecan.

2) **Objective:** To evaluate the Objective Response Rate (ORR) per RECIST 1.1 assessed by central vendor review in all subjects, when treated with pembrolizumab compared to investigator's choice of paclitaxel, docetaxel, or irinotecan.

**Hypotheses (H5):** Pembrolizumab 200 mg Q3W improves ORR per RECIST 1.1 by central vendor review in all subjects, compared to investigator's choice of paclitaxel, docetaxel, or irinotecan.

3) **Objective:** To evaluate the PFS and ORR per RECIST 1.1 assessed by central vendor review in subjects with squamous cell carcinoma of the esophagus and subjects with PD-L1 CPS $\geq$ 10, when treated with pembrolizumab compared to investigator's choice of paclitaxel, docetaxel, or irinotecan.

4) **Objective:** Evaluate the safety and tolerability profile of pembrolizumab in all subjects, when treated with pembrolizumab compared to investigator's choice of paclitaxel, docetaxel, or irinotecan.

### 3.3 Exploratory Objectives

- 1) To evaluate PFS per irRECIST assessed by blinded central vendor review in all subjects when treated with pembrolizumab 200 mg Q3W compared to investigator's choice of paclitaxel, docetaxel, or irinotecan.
- 2) To evaluate efficacy by GEP expression.
- 3) To explore the concordance of PD-L1 in archival compared to newly obtained tumor tissue.
- 4) To evaluate score change of health related quality of life using the EORTC QLQ-C30 and the EORTC QLQ-OES18 from baseline among subjects when treated with pembrolizumab 200 mg Q3W compared to investigator's choice of paclitaxel, docetaxel, or irinotecan.

- 5) To characterize utilities using EuroQol EQ-5D among subjects when treated with pembrolizumab 200 mg Q3W compared to investigator's choice of paclitaxel, docetaxel, or irinotecan.
- 6) To explore the relationship between genetic variation and response to the treatment administered. Variation across the human genome will be analyzed for association with clinical data collected in this study.

## 4.0 BACKGROUND & RATIONALE

### 4.1 Background

Refer to the Investigator's Brochure (IB)/approved labeling for detailed background information on MK-3475.

#### 4.1.1 Pharmaceutical and Therapeutic Background

Pembrolizumab (MK-3475) is a potent and highly selective humanized monoclonal antibody (mAb) of the IgG4/kappa isotype designed to directly block the interaction between PD-1 and its ligands, PD-L1 and PD-L2. Keytruda® (pembrolizumab) has recently been approved in the United States for the treatment of patients with unresectable or metastatic melanoma and disease progression following treatment with ipilimumab, a BRAF inhibitor, and if BRAF V600 mutation positive.

The importance of intact immune surveillance in controlling outgrowth of neoplastic transformation has been known for decades [2]. Accumulating evidence shows a correlation between tumor-infiltrating lymphocytes (TILs) in cancer tissue and favorable prognosis in various malignancies. In particular, the presence of CD8+ T-cells and the ratio of CD8+ effector T-cells / FoxP3+ regulatory T-cells seems to correlate with improved prognosis and long-term survival in many solid tumors.

The PD-1 receptor-ligand interaction is a major pathway hijacked by tumors to suppress immune control. The normal function of PD-1, expressed on the cell surface of activated T-cells under healthy conditions, is to down-modulate unwanted or excessive immune responses, including autoimmune reactions. PD-1 (encoded by the gene PDCD1) is an Ig superfamily member related to CD28 and Cytotoxic T-Lymphocyte-Associated Antigen-4 (CTLA-4) which has been shown to negatively regulate antigen receptor signaling upon engagement of its ligands (PD-L1 and/or PD-L2) [3] [4].

The structure of murine PD-1 has been resolved [5]. PD-1 and family members are type I transmembrane glycoproteins containing an Ig Variable-type (V-type) domain responsible for ligand binding and a cytoplasmic tail which is responsible for the binding of signaling molecules. The cytoplasmic tail of PD-1 contains 2 tyrosine-based signaling motifs, an immunoreceptor tyrosine-based inhibition motif (ITIM) and an immunoreceptor tyrosine-based switch motif (ITSM). Following T-cell stimulation, PD-1 recruits the tyrosine phosphatases SHP-1 and SHP-2 to the ITSM motif within its cytoplasmic tail, leading to the dephosphorylation of effector molecules such as CD3 $\zeta$ , PKC $\theta$  and ZAP70 which are involved in the CD3 T-cell signaling cascade [3], [6], [7], [8]. The mechanism by which

PD-1 down modulates T-cell responses is similar to, but distinct from that of CTLA-4 as both molecules regulate an overlapping set of signaling proteins [9], [10]. PD-1 was shown to be expressed on activated lymphocytes, including peripheral CD4+ and CD8+ T-cells, B-cells, Tregs and Natural Killer cells [6] [11]. Expression has also been shown during thymic development on CD4-CD8- (double negative) T-cells, as well as subsets of macrophages and dendritic cells [12]. The ligands for PD-1 (PD-L1 and PD-L2) are constitutively expressed or can be induced in a variety of cell types, including non-hematopoietic tissues, as well as in various tumors [13] [14] [15] [16]. Both ligands are type I transmembrane receptors containing both IgV- and IgC-like domains in the extracellular region and contain short cytoplasmic regions with no known signaling motifs. Binding of either PD-1 ligand to PD-1 inhibits T-cell activation triggered through the T-cell receptor. PD-L1 is expressed at low levels on various non-hematopoietic tissues, most notably on vascular endothelium, whereas PD-L2 protein is only detectably expressed on antigen-presenting cells found in lymphoid tissue or chronic inflammatory environments. PD-L2 is thought to control immune T-cell activation in lymphoid organs, whereas PD-L1 serves to dampen unwarranted T-cell function in peripheral tissues [16]. Although healthy organs express little (if any) PD-L1, a variety of cancers were demonstrated to express abundant levels of this T-cell inhibitor. PD-1 has been suggested to regulate tumor-specific T-cell expansion in subjects with melanoma (MEL) [17].

#### **4.1.2 Pre-clinical and Clinical Trials**

##### **4.1.2.1 Preclinical Studies**

Therapeutic studies in mouse models have shown that administration of antibodies blocking PD-1/PD-L1 interaction enhances infiltration of tumor-specific CD8+ T-cells and leads ultimately to tumor rejection, either as a monotherapy or in combination with other treatment modalities. Anti-mouse PD-1 or anti-mouse PD-L1 antibodies have demonstrated anti-tumor responses as a monotherapy in models of squamous cell carcinoma, pancreatic carcinoma, MEL and colorectal carcinoma. Blockade of the PD-1 pathway effectively promoted CD8+ T-cell infiltration into the tumor and the presence of IFN- $\gamma$ , granzyme B and perforin, indicating that the mechanism of action involved local infiltration and activation of effector T-cell function in vivo [18] [19] [20] [21] [4] [3]. Experiments have confirmed the in vivo efficacy of PD-1 blockade as a monotherapy as well as in combination with chemotherapy in syngeneic mouse tumor models (see the IB).

Clinical trials have demonstrated efficacy in subjects with advanced melanoma, non-small cell lung cancer, head and neck cancer, bladder cancer, Hodgkin's lymphoma, triple-negative breast cancer, and gastric adenocarcinoma. In addition, emerging data demonstrated single agent activity in additional tumor types such as mesothelioma, urothelial cancer, ovarian cancer, neuroendocrine carcinoma and small cell lung cancer.

#### **4.1.3 Ongoing Clinical Trials**

Ongoing clinical trials of pembrolizumab are being conducted in advanced melanoma, non-small cell lung cancer, and a number of other advanced solid tumor indications and hematologic malignancies. For study details refer to the IB.

## 4.2 Rationale

### 4.2.1 Rationale for the Trial and Selected Subject Population

Esophageal cancer is the 6th most common cause of cancer deaths in the world and is more prevalent in men than women. However, in the developing countries esophageal cancer is endemic and is the 4th most common cause of cancer deaths. Globally, close to 480,000 cases occur annually with 53% of these cases arising in China [22] [23]. In the United States, in 2015, an estimated 15,980 esophageal cancers will be diagnosed, and it is estimated that 15,590 people will eventually die of their disease [24]. In Japan, esophageal cancer is the 6th leading cause of cancer deaths and in 2008, there were 11,746 deaths from esophageal carcinoma with male patients outnumbering female patients 6:1 [25]. Majority of the patients are diagnosed with advanced/metastatic cancer and in this setting, response to chemotherapeutic agents is poor. Given the high incidence and mortality worldwide and lack of good therapeutic options, esophageal cancer patients represent a high unmet need for drug development.

The incidence of esophageal cancer represents one of the widest variations with a 60-fold difference between high and low prevalence regions. High prevalence areas include Asia, Africa and France where squamous esophageal cancers predominate [26]. A dramatic shift in the histology and location of upper gastrointestinal (GI) tumors has occurred over the past decades. In Western countries, the most common site of esophageal cancer is in the lower third of the esophagus, which often involves the EGJ [27] [28] [29]. For the purpose of our study, we will use the Siewert classification for adenocarcinoma of the EGJ and thus type I patients (about 20% of the EGJ adenocarcinoma patients) will be eligible. Siewert type I tumors are adenocarcinomas of the lower esophagus with the center located within 1cm to 5cm above the anatomic EGJ. Type II and III Siewert adenocarcinomas of the EGJ are managed as gastric cancer patients and therefore eligible to participate in the second line (2L) gastric trial, KEYNOTE-061. Adenocarcinoma has been gradually increasing in men of all ethnic backgrounds and also in women. Squamous cell carcinoma (SCC) seems to be more sensitive to chemotherapy, chemoradiation, and radiation therapy than adenocarcinoma, but the long-term outcome is similar for both histologies [30] [31] thus emphasizing the need for better improved therapies in both histologies.

Phase III trials specifically designed for metastatic esophageal cancers have not been performed. Docetaxel, paclitaxel, and irinotecan are included as options for second-line therapy for patients with locally advanced or metastatic disease. Other regimens included in the guidelines for patients with locally advanced or metastatic disease are derived from the gastric adenocarcinoma phase III trials that have included patients with lower esophageal and/or EGJ cancer. The use of gefitinib as a second-line treatment for unselected patients does not improve OS [32].

KEYNOTE-028, a nonrandomized, multicohort, Phase 1b trial of pembrolizumab for PD-L1<sup>+</sup> advanced solid tumors includes esophageal cancer patients. Key eligibility criteria for this cohort included SCC or adenocarcinoma of the esophagus or gastroesophageal junction, measurable disease, PD-L1 expression in  $\geq 1\%$  of cells in tumor nests or PD-L1<sup>+</sup> stromal bands determined centrally by IHC, failure of standard therapy, ECOG PS 0-1, and no

autoimmune disease. Pembrolizumab 10 mg/kg is being given every 2 weeks for up to 2 years or until confirmed progression. Of the 90 patients with esophageal cancer who were screened, 37 (44.6%) had PD-L1<sup>+</sup> tumors. Of the 23 patients treated between March and December 2014, 83% were men and median age was 65 years. Histology was squamous in 17 patients (73.9%), adenocarcinoma in 5 patients (21.7%), and mucoepidermoid in 1 patient (4.3%). Eighty-seven percent of patients received  $\geq 2$  prior therapies for metastatic disease; all patients received  $\geq 1$  platinum-based therapy. Nine patients (39.1%) experienced drug-related adverse events (DRAEs), including 4 (17.4%) who experienced Grade 3 DRAEs. There were no Grade 4 DRAEs, and no patients died or discontinued due to a DRAE. Tumor shrinkage was seen in 52% of patients and objective response rate (ORR) was 30.4% (n = 7; 5 squamous (29.4%) and 2 adenocarcinoma (40.0%)); best response was stable disease in 13% (n = 3; 2 squamous and 1 adenocarcinoma) and progressive disease in 59% (n = 13). Six patients still remain on therapy. Median time to response is 16 weeks (Range: 7.9-36.0 weeks) and median duration of response (DOR) is 40.0 weeks (Range: 0.1+ to 40.0 weeks) for the patients in the esophageal cohort.

Thus, pembrolizumab has an acceptable safety profile and provides highly promising antitumor activity in patients with heavily pretreated, advanced esophageal carcinoma. The high unmet need, lack of efficacious approved therapies and the above data with pembrolizumab strongly support further development of this drug in patients with second-line esophageal carcinoma, across both the squamous cell and adenocarcinoma histologies.

#### **4.2.2 Rationale for Dose Selection/Regimen/Modification**

##### **4.2.2.1 Rationale for the Use of Pembrolizumab**

The planned dose of pembrolizumab for this trial is 200 mg every 3 weeks (Q3W). Based on the totality of data generated in the Keytruda development program, 200 mg Q3W is the appropriate dose of pembrolizumab across all indications, regardless of tumor type. As outlined below, this dose is justified by:

- Clinical data from 8 randomized studies demonstrating flat dose- and exposure- efficacy relationships from 2 mg/kg Q3W to 10 mg/kg every 2 weeks (Q2W)
- Clinical data showing meaningful improvement in benefit-risk, including OS at 200 mg Q3W across multiple indications
- Pharmacology data showing full target saturation in both systemic circulation (inferred from pharmacokinetic [PK] data) and tumor (inferred from physiologically based pharmacokinetic [PBPK] analysis) at 200 mg Q3W

Among the 8 randomized dose-comparison studies, a total of 2262 subjects were enrolled with melanoma and non-small cell lung cancer (NSCLC), covering different disease settings (treatment naïve, previously treated, PD-L1 enriched and all-comers) and different treatment settings (monotherapy and in combination with chemotherapy). Five studies compared 2 mg/kg Q3W versus 10 mg/kg Q2W (KN001 B2, KN001 D, KN002, KN010 and KN021),

and 3 studies compared 10 mg/kg Q3W versus 10 mg/kg Q2W (KN001 B3, KN001 F2 and KN006). All of these studies demonstrated flat dose- and exposure-response relationships across the doses studied representing an approximate 5- to 7.5-fold difference in exposure. The 2 mg/kg (or 200 mg fixed-dose) Q3W provided similar responses to the highest doses studied. Subsequently, flat dose-/exposure-response relationships were also observed in other tumor types, including head and neck cancer, bladder cancer, gastric cancer and classical Hodgkin Lymphoma, confirming 200 mg Q3W as the appropriate dose independent of the tumor type. These findings are consistent with the mechanism of action of pembrolizumab, which acts by interaction with immune cells, and not via direct binding to cancer cells.

Additionally, pharmacology data clearly show target saturation at 200 mg Q3W. First, PK data in KN001 evaluating target-mediated drug disposition (TMDD) conclusively demonstrated saturation of PD-1 in systemic circulation at doses much lower than 200 mg Q3W. Secondly, a PBPK analysis was conducted to predict tumor PD-1 saturation over a wide range of tumor penetration and PD-1 expression. This evaluation concluded that pembrolizumab at 200 mg Q3W achieves full PD-1 saturation in both blood and tumor.

Finally, population PK analysis of pembrolizumab, which characterized the influence of body weight and other subject covariates on exposure, has shown that the fixed-dosing provides similar control of PK variability as weight-based dosing, with considerable overlap in the distribution of exposures from the 200 mg Q3W fixed dose and 2 mg/kg Q3W dose. Supported by these PK characteristics, and given that fixed-dose has advantages of reduced dosing complexity and reduced potential of dosing errors, the 200 mg Q3W fixed-dose was selected for evaluation across all pembrolizumab protocols.

#### 4.2.2.2 Rationale for the Use of Comparator

Various palliative chemotherapy regimens have been investigated in studies including esophageal cancer patients and have been shown to have at least some activity in the first-line setting, with responses ranging from 20% to 48% and 5-year survival rates of approximately 15% with significant toxicity rates [33]. Current guidelines recommend the combination of fluorouracil and cisplatin, either alone or in combination with a third drug such as epirubicin or a taxane, as the most effective first-line treatment option. In case of relapse or refractoriness, however, data on application of second-line therapy are scarce, and there is no consensus on the optimal second-line chemotherapy [34]. Approximately 40% of patients for whom first-line treatment fails will be potential candidates for second line therapy. NCCN guidelines endorse use of docetaxel, paclitaxel and irinotecan (level 1 evidence) in second-line treatment of esophageal cancer. There are no clinically significant differences in response rates, PFS and OS that have been documented when using paclitaxel, docetaxel, or irinotecan in the treatment of second-line esophageal cancer.

The survival benefit of second-line chemotherapy compared to “best supportive care” has been demonstrated in a small cohort of patients with lower esophageal or EGJ adenocarcinoma included in gastric adenocarcinoma phase III trials [35] [36]. In a randomized phase III study, second-line chemotherapy with irinotecan significantly prolonged OS compared to best supportive care in patients with metastatic or locally advanced gastric or EGJ adenocarcinoma (n = 40) [35]. The study was closed prematurely

due to poor accrual. Median survival was 4 months in the irinotecan arm compared to 2.4 months in the “best supportive care” only arm.

In a recent open-label, multicenter, phase III, randomized trial, the addition of docetaxel to active symptom control was associated with a survival benefit for patients with advanced, histologically confirmed adenocarcinoma of the esophagus, EGJ junction, or stomach that had progressed on or within 6 months of treatment with combination chemotherapy with platinum and fluoropyrimidine [36]. In this study, patients (n = 168) with an ECOG PS score of 0-2 were randomly assigned to receive docetaxel plus active symptom control or active symptom control alone. After a median follow-up of 12 months, the median OS was 5.2 months for patients with the docetaxel group compared to 3.6 months for those in the active symptom control group ( $P = .01$ ). Docetaxel was associated with higher incidence of Grade 3-4 neutropenia, infection, and febrile neutropenia. However, disease-specific, health-related quality of life measures also showed benefits for docetaxel in reducing dysphagia and abdominal pain.

In a phase II study by Ilson et al. [37], one hundred and two patients with advanced esophageal cancer were treated with paclitaxel 80 mg/m<sup>2</sup> weekly. Sixty-six patients had adenocarcinoma (66%) and 65 patients (68%) had no prior chemotherapy. In terms of responses, in patients without prior chemotherapy, partial response(s) (PR)s were seen in 10 patients (15%, 95% CI 6% to 24%), with comparable response in adenocarcinoma (8/50, 16%) and squamous carcinoma (2/15, 13%). Limited response was seen in patients with prior chemotherapy, in the second line setting (1/21, 5%). Therapy was well tolerated with minimal hematologic or Grade 3 or 4 toxicity.

Taxanes have been shown to be effective in the first-line treatment of advanced esophageal cancer, with remission rates of approximately 20% [34]. Twenty-three patients were enrolled in a phase II study [38] of either paclitaxel or docetaxel to determine the efficacy and safety of these agents for second-line treatment of metastatic or recurrent esophageal SCC (n = 15) and adenocarcinoma (AC) (n = 8). Patients (13 evaluable) received paclitaxel 175 mg/m<sup>2</sup> (n=11) or docetaxel 100mg/m<sup>2</sup> (n=12). For both agents, cycles were repeated every 3 weeks for a maximum of six courses of therapy. Two CRs (4.7%) and two PRs (4.7%) were achieved, and 30% of patients had stable disease (SD). In this limited number of patients, no apparent differences were seen between the single agents in terms of efficacy or adverse effects.

In another study [39], paclitaxel 140 mg/m<sup>2</sup> administered as a continuous infusion over 4 days every 3 weeks was found to be ineffective because no responses were observed in patients with either AC or SCC (n=13). Application of docetaxel at various doses (i.e., 100 mg/m<sup>2</sup>, 75 mg/m<sup>2</sup>, or 70 mg/m<sup>2</sup> every 3 weeks) was tested in the setting of platinum-pretreated relapse [40], [41] and in [42] that included 25, 11, and 36 patients, respectively. The objective response rates were poor at 28% (three CRs and four PRs in 25 patients), 0%, and 17% (six PRs in 36 patients), respectively, with the OS being 8.1 months (range, 6.6 to 11.3 months) in one study.

From the data presented above, we see that although the use of taxanes as monotherapies has resulted in at least some activity with up to 30% response rate, only approximately 40% of

patients qualify for second-line therapy because of their general condition and performance status. Even in these selected few individuals, response rates are low and accompanied by an extremely high rate of hematologic adverse effects that resulted in therapy-related deaths in some studies. In addition, these taxane-based second-line approaches have been used in patients who were taxane-naïve, a practice that is changing, given the relatively high use of taxanes currently in the first-line setting. Apart from response rates, the time to progression was short in most studies, being less than 4 months in 13 trials. However, as second line combination regimens have seen World Health Organization (WHO) Grades 3 to 4 hematologic toxicities in half the patients enrolled, taxane monotherapy or combinations are preferred in the second-line setting [43].

#### **4.2.2.3 Rationale for using the Intratumoral Immune-related Gene Expression Profile (GEP) in Esophageal Cancer**

Gene expression signatures measuring mRNA for key immune-related genes have been confirmed to be associated with clinical benefit to pembrolizumab treatment in melanoma, head & neck, and gastric cancers [44] [45] [46] as well as in the esophageal cancer cohort in KEYNOTE-028. The predominant pattern indicates that tumors with relatively low expression of these genes have a low probability of response to pembrolizumab.

Gene expression profiling of tumor specimens from clinical studies KEYNOTE-001 (Melanoma), KEYNOTE-012 (Head and Neck, Bladder, Gastric cancers) and KEYNOTE-028 (Ovarian, Esophageal, and other cancers) [44] [45] [46] led to the identification of an 18-gene immune-related intratumoral GEP that is associated with response to pembrolizumab. Using data from KEYNOTE-012 and KEYNOTE-028, a GEP combining expression levels of 18 genes into a scalar score was developed and two cut-offs on that score which divide tumors into “low”, “intermediate”, and “high” were determined using data from KEYNOTE-028, KEYNOTE-012, and KEYNOTE-052. The lower cut-off was defined to favor sensitivity in capturing responders by centrally reviewed RECIST and the higher cut-off was selected to enrich for higher response rates at potentially some cost in sensitivity. In this study, the hypothesis is that subjects whose tumors are above the lower cut-off (i.e. are either GEP intermediate or GEP high) may show greater clinical benefit under treatment with pembrolizumab relative to the comparator in a manner that will be more substantial than what is observed in an all subjects population that includes subjects whose tumors are GEP low.

#### **4.2.3 Rationale for Endpoints**

##### **4.2.3.1 Primary Efficacy Endpoints**

The primary efficacy endpoint is OS. The endpoint of OS is the standard for demonstrating superiority of antineoplastic therapy in clinical studies in the area of oncology.

##### **4.2.3.2 Secondary Efficacy Endpoints**

The key secondary efficacy objectives of this study are to evaluate PFS and ORR per RECIST 1.1 as assessed by the central imaging vendor for all subjects.

Other secondary efficacy objectives of this study are to evaluate PFS and ORR per RECIST 1.1 as assessed by the central imaging vendor for subjects with SCC of the esophagus and subjects with PD-L1 CPS $\geq$ 10.

RECIST 1.1 as assessed by central imaging vendor will be used to determine the dates of progression as this methodology is accepted by regulatory authorities. If the treatment assignment is unblinded, images read by central imaging vendor blinded to treatment assignment can minimize bias in the response assessments. In addition, final determination of radiologic progressive disease (PD) will be based on the central imaging vendor assessment of progression, rather than local site investigator/radiology assessment.

RECIST 1.1 will also be used by the local site for treatment decisions for both arms of the study. When feasible, subjects within the pembrolizumab arm should not be discontinued until progression is confirmed. This allowance to continue treatment despite initial radiologic progression takes into account the observation that some subjects can have a transient tumor flare in the first few months after the start of immunotherapy, but with subsequent disease response.

#### **4.2.3.3 Safety Endpoints**

The safety objective of this trial is to characterize the safety and tolerability of pembrolizumab in subjects with advanced/metastatic adenocarcinoma or SCC of the esophagus or advanced/metastatic Siewert type I adenocarcinoma of the EGJ who have progressed on one previous line of therapy. The safety analysis will be based on subjects who experienced toxicities as defined by CTCAE version 4.0 (Section 12.6). Safety will be assessed by quantifying the toxicities and grades experienced by subjects who have received pembrolizumab compared to investigator's choice of paclitaxel, docetaxel, or irinotecan including serious adverse events (SAEs) and events of clinical interest (ECIs).

The attribution to drug, time-of-onset, duration of the event, its resolution, and any concomitant medications administered will be recorded. AEs will be analyzed including but not limited to all AEs, SAEs, fatal AEs, and laboratory changes.

#### **4.2.3.4 Exploratory Endpoints**

##### **4.2.3.4.1 Immune-related RECIST (irRECIST)**

RECIST 1.1 will be adapted to account for the unique tumor response characteristics seen with treatment of pembrolizumab. Immunotherapeutic agents such as pembrolizumab may produce antitumor effects by potentiating endogenous cancer-specific immune responses. The response patterns seen with such an approach may extend beyond the typical time course of responses seen with cytotoxic agents, and can manifest a clinical response after an initial increase in tumor burden or even the appearance of new lesions. Standard RECIST 1.1 may, thus, not provide an accurate response assessment of immunotherapeutic agents such as pembrolizumab. Based on an analysis of patients with melanoma enrolled in KEYNOTE-001, 7% of evaluable patients experienced delayed or early tumor pseudoprogression. Of note, patients who had progressive disease by RECIST 1.1 but not by immune related

Response Criteria had longer OS than patients with progressive disease by both criteria. Additionally, the data suggest that RECIST 1.1 may underestimate the benefit of pembrolizumab in approximately 15% of patients. These findings support the need to apply a modification to RECIST 1.1 that takes into account the unique patterns of atypical response in immunotherapy and enable treatment beyond initial radiographic progression.

Immune-related RECIST (irRECIST) is RECIST 1.1 adapted to account for the unique tumor response seen with immunotherapeutics as described in Nishino et al., 2013 [1]. The assessment of unidimensional target lesions and response categories per irRECIST are identical to RECIST 1.1. However, Merck has implemented an adaptation related to new lesions, non-target and tumor burden assessment in order to confirm radiographic progression. irRECIST will be used by local site investigators to assess tumor response and progression, and make treatment decisions as well as by central imaging vendor in support of efficacy endpoint.

#### **4.2.3.4.2 Patient Reported Outcomes**

As part of the exploratory analyses, subjects will provide information regarding their health-related quality of life (HRQoL) via the following assessment tools: EORTC QLQ-C30 and QLQ-OES18, eEuroQol-5D (EQ-5D) questionnaires. These measures are not pure efficacy or safety endpoints because they are affected by both disease progression and treatment tolerability.

##### EORTC QLQ-C30 and EORTC QLQ-OES18

The EORTC-QLQC30 is the most widely used cancer specific HRQoL instrument, which contains 30 items and measures five functioning dimensions (physical, role, cognitive, emotional, and social), three symptom items (fatigue, nausea/vomiting, pain), six single items (dyspnea, sleep disturbance, appetite loss, constipation, diarrhea, and financial impact), and a global health and quality of life scale [47]. This instrument has been translated and validated into 81 languages and used in more than 3,000 studies worldwide.

The EORTC QLQ-OES18 is a disease-specific questionnaire developed and validated to address measurements specific to esophageal cancer. It is one of multiple disease-specific modules developed by the EORTC QLG (Quality of Life Group) designed for use in clinical trials, to be administered in addition to the EORTC-QLQ-C30 to assess disease-specific treatment measurements. It contains 18 items with symptoms of dysphagia, pain, reflux, eating, trouble with swallowing saliva, choking, dry mouth, taste, cough, and speech [48].

The EORTC QLQ-C30 and EORTC QLQ-OES18 are to be completed at various time points as specified in the Trial Flow Chart, beginning with Cycle 1 until 30 days post-treatment discontinuation.

##### eEuroQol-5D

The eEuroQol-5D (eEQ-5D) is a standardized instrument for use as a measure of health outcome. The eEQ-5D will provide data for use in economic models and analyses including developing health utilities or quality adjusted life years (QALYs). The five health state

dimensions in this instrument include the following: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression [49]. Each dimension is rated on a three point scale from 1 (extreme problem) to 3 (no problem). The eEQ-5D also includes a graded (0 to 100) vertical visual analog scale on which the subject rates his or her general state of health at the time of the assessment. The eEQ-5D will always be completed by subjects first before completing the EORTC QLQ-C30 and QLQ-OES18 and is to be completed at various time points as specified in the Trial Flow Chart, beginning with Cycle 1 until 30 days post-treatment discontinuation.

#### **4.2.3.5 Biomarker Research**

##### **4.2.3.5.1 Biomarker Research for Primary Objectives**

###### Immune related Gene Expression Profile (GEP)

Intratumoral expression levels of 18 genes will be analyzed and the GEP score determined using the NanoString nCounter Analysis System.

Two pre-specified, analytically validated, cut-offs will be used to divide tumors into “low”, “intermediate”, and “high” for the GEP. Hypothesis testing to address the study’s objectives will be conducted in subjects whose tumors are “intermediate or high” and in the all subjects population (i.e. including those subjects whose tumors are GEP low).

###### Tumor PD-L1 expression

In the pembrolizumab KEYNOTE-001 and KEYNOTE-012 studies, PD-L1 immunohistochemistry (IHC) has successfully been used as a biomarker in the NSCLC and head and neck cancer cohorts, respectively, to enrich for a subpopulation with high response to pembrolizumab [50]. Therefore, the relationship between PD-L1 expression in esophageal tumor tissue and response to treatment with pembrolizumab will be evaluated. PD-L1 expression in tumor cells and inflammatory cells within pre-treatment tumor tissue samples will be characterized by IHC and retrospectively tested for association with response to pembrolizumab. Tumor bank-derived, EC tissues matched for stage and grade with subjects in pembrolizumab studies, as well as EC tissues from KN180, were used to determine the prevalence of PD-L1 positivity greater than or equal to a combined positive score (CPS) of 1 or 10. CPS is the number of PD-L1 positive cells (tumor cells, macrophages, lymphocytes) over total tumor cells, expressed as a percentage. The prevalence of  $PD-L1 \geq 10$  CPS in tumor bank or KN180, respectively was 52% or 47.2%. The prevalence of  $PD-L1 \geq 1$  CPS was greater in both the tumor bank (72%) as well as the KN180 study (85.8%). Utility of the PD-L1 CPS measure to enrich for EC patient response to pembrolizumab will be determined in KN180. Further studies of both prevalence as well as utility as a prognostic marker are being evaluated in epidemiology studies.

##### **4.2.3.5.2 Biomarker Research for Exploratory Objectives**

Additional biomarker research to identify factors important for pembrolizumab (MK-3475) therapy may also be pursued. For example, tumor and blood samples (including serum and

plasma) from this study may undergo proteomic, genomic, metabolomic and transcriptional analyses. Additional research may evaluate factors important for predicting responsiveness or resistance to pembrolizumab therapy and other immunologic targets.

Assays may include but are not be limited to:

#### Transcriptional Analyses

In addition to examining immune-related set of genes via the GEP, broad messenger RNA profiling may also be pursued. Expression of individual genes related to the immune system may also be evaluated such as immune signatures and critical cytokines (e.g., IL-10). MicroRNA profiling may also be pursued in serum samples.

#### Proteomic analysis

In addition to expression on the tumor tissue, PD-L1 can be shed from tumor and released into the blood. Enzyme-linked immunoassay can measure PD-L1 in serum and correlate this expression with response to pembrolizumab (MK-3475) therapy, as well as levels of PD-L1 IHC or protein in the tumor. Blood would be a less invasive compartment compared to tumor from which to measure PD-L1 protein biomarker. In addition to this specific protein biomarker, both tissue and blood derivatives can be subjected to proteomic profiling studies using a variety of platforms that could include but are not limited to immunoassay, liquid chromatography/mass spectrometry. This approach could identify novel protein biomarkers that could aid in patient selection for pembrolizumab (MK-3475) therapy.

#### Gene Analyses

The application of new technologies, such as next generation sequencing, has provided scientists the opportunity to define certain tumor types at the genetic level as being 'hypermutated' or it can detect the presence of specific T-cell clones within the tumor microenvironment. There is a potential that this hypermutated state and the detection of increased T-cell clonality may correlate with response to pembrolizumab therapy, and/or that the converse, 'hypomutated' state or lack of T-cell clones may correlate with non-response.

#### **Planned Genetic Analysis**

Understanding genetic determinants of drug response is an important endeavor during medical research. This research will evaluate whether genetic variation within a clinical trial population correlates with response to the treatment(s) under evaluation. If genetic variation is found to predict efficacy or adverse events, the data might inform optimal use of therapies in the patient population. This research contributes to understanding genetic determinants of efficacy and safety associated with the treatments in this study.

#### **4.2.3.6 Future Biomedical Research**

The Sponsor will conduct Future Biomedical Research on specimens collected for future biomedical research during this clinical trial. This research may include genetic analyses

(DNA), gene expression profiling (RNA), proteomics, metabolomics (serum, plasma) and/or the measurement of other analytes.

Such research is for biomarker testing to address emergent questions not described elsewhere in the protocol (as part of the main trial) and will only be conducted on specimens from appropriately consented subjects. The objective of collecting specimens for Future Biomedical Research is to explore and identify biomarkers that inform the scientific understanding of diseases and/or their therapeutic treatments. The overarching goal is to use such information to develop safer, more effective drugs/vaccines, and/or to ensure that subjects receive the correct dose of the correct drug/vaccine at the correct time. The details of this Future Biomedical Research sub-trial are presented in Section 12.2 - Collection and Management of Specimens for Future Biomedical Research. Additional informational material for institutional review boards/ethics committees (IRBs/ERCs) and investigational site staff is provided in Section 12.3.

#### **4.3 Benefit/Risk**

Subjects in clinical trials generally cannot expect to receive direct benefit from treatment during participation, as clinical trials are designed to provide information about the safety and effectiveness of an investigational medicine.

Additional details regarding specific benefits and risks for subjects participating in this clinical trial may be found in the accompanying IB and Informed Consent documents.

### **5.0 METHODOLOGY**

#### **5.1 Entry Criteria**

##### **5.1.1 Diagnosis/Condition for Entry into the Trial**

Male/Female subjects with advanced/metastatic adenocarcinoma or squamous cell carcinoma of the esophagus or advanced/metastatic Siewert type I adenocarcinoma of the esophagogastric junction of at least 18 years of age will be enrolled in this trial.

##### **5.1.2 Subject Inclusion Criteria**

In order to be eligible for participation in this trial, the subject must:

1. Be willing and able to provide documented informed consent for the trial. The subject may also provide consent for Future Biomedical Research. However, the subject may participate in the main trial without participating in Future Biomedical Research.
2. Be  $\geq$  18 years of age on the day of providing documented informed consent (or acceptable age according to local regulations, whichever is older).
3. Have histologically or cytologically-confirmed diagnosis of adenocarcinoma or SCC of the esophagus or Siewert type I adenocarcinoma of the EGJ (defined as adenocarcinomas of the lower esophagus with the center located within 1cm to 5cm above the anatomic EGJ).

- a. Subjects with Siewert type 1 adenocarcinoma of the EGJ with HER-2/neu negative tumors are eligible. Subjects with HER2/neu positive tumors, or those with an unknown tumor status, need to match the following:
  - i. If HER2/neu positive, subject must have documentation of disease progression on a prior line of therapy containing trastuzumab.
  - ii. Subjects with unknown status must have their HER2/neu status determined locally. If HER2/neu negative, the subject will be eligible. If HER2/neu positive, the subject must have documentation of disease progression on a prior line of therapy containing trastuzumab.
4. Have metastatic disease or locally advanced, unresectable disease. Subjects with direct invasion into adjacent organs such as the aorta or trachea (T4b disease) should be closely evaluated for bleeding risk prior to enrollment and a sponsor consultation before enrollment is required.
5. Have a life expectancy of greater than 3 months.
6. Have measurable disease based on RECIST 1.1 as determined by local site investigator/radiology assessment. A lesion(s) situated in a previously irradiated area can be considered a target lesion(s) if progression has been demonstrated and the lesion(s) is considered measurable per RECIST 1.1 criteria.

Note: The same image acquisition and processing parameters should be used throughout the study for a given subject.

7. Have a performance status of 0 or 1 on the Eastern Cooperative Oncology Group (ECOG) Performance Scale.
8. Have experienced documented radiographic or clinical disease progression on one previous line of standard therapy. This study will only include second-line subjects. Second-line subjects are defined as those who have progressed during or after receiving at least one dose of standard therapy given in a first line setting.
  - a. Disease progression should be confirmed by CT scan. In certain situations, clinical evidence of disease progression such as any new or worsening malignant effusion (documented by ultrasound) and confirmation by pathologic criteria (histology and/or cytology) may be acceptable.
  - b. Treatment with curative intent, including neoadjuvant/adjuvant treatment, given as chemotherapy or chemoradiotherapy, using standard of care agents or definitive chemoradiation, will count as a line of therapy if disease progression occurs during treatment or within 6 months of cessation of treatment.
  - c. Dose reduction and/or switching of one or more first line agents due to toxicity/intolerability as deemed clinically appropriate by the investigator will not constitute a new line of therapy.
9. Provide either a newly obtained or archival tissue sample for intratumoral immune-related GEP analysis and PD-L1 by immunohistochemistry analysis. Newly-obtained tissue is preferred. Formalin-fixed, paraffin-embedded (FFPE) block specimens are

preferred to slides. Repeat samples will be required if none of the samples submitted (archived or newly obtained) is adequate. For purposes of this study, newly-obtained tissue refers to tissue that was collected between the last line of therapy and the first dose of study medication.

- a. Central laboratory confirmation of tumor tissue sample adequacy is required *prior to* subject randomization in the study. If multiple tumor samples are submitted, at least one of the samples must be confirmed to be adequate by the central laboratory prior to subject being enrolled.
- b. Subjects from whom newly-obtained samples cannot be obtained (e.g. inaccessible or subject safety concern) an archived specimen may be submitted.
- c. If newly obtained tissue is provided and an archived tissue sample is available, it should also be provided to support evaluation of the clinical utility of immune-related GEP assessment and PD-L1 analysis by immunohistochemistry in newly obtained vs. archived tissue samples; however, a subject will not be excluded from participating in the study if he/she has provided newly obtained tissue and an archived tissue sample is not available or is otherwise insufficient for analysis.

10. Demonstrate adequate organ function as defined in [Table 1](#).

Table 1 Adequate Organ Function Laboratory Values

System	Laboratory Value
<b>Hematological</b>	
Absolute neutrophil count (ANC)	$\geq 1,500 / \text{mcL}$
Platelets	$\geq 100,000 / \text{mcL}$
Hemoglobin	$\geq 9 \text{ g/dL}$ or $\geq 5.6 \text{ mmol/L}$ without transfusion or EPO dependency within 14 days.
<b>Renal</b>	
Creatinine <b>OR</b> Measured or calculated creatinine clearance <sup>a</sup>  (GFR can also be used in place of creatinine or CrCl)	$\leq 1.5 \times$ upper limit of normal (ULN) <b>OR</b> $\geq 60 \text{ mL/min}$ for subject with creatinine levels $> 1.5 \times$ institutional ULN
<b>Hepatic</b>	
Total bilirubin	$\leq 1.5 \times$ ULN <b>OR</b> Direct bilirubin $\leq$ ULN for subjects with total bilirubin levels $> 1.5 \text{ ULN}$
AST (SGOT) and ALT (SGPT)	$\leq 2.5 \times$ ULN <b>OR</b> $\leq 5 \times$ ULN for subjects with liver metastases
Albumin	$\geq 2.5 \text{ g/dL}$
<b>Coagulation</b>	
International Normalized Ratio (INR) or Prothrombin Time (PT)	$\leq 1.5 \times$ ULN unless subject is receiving anticoagulant therapy as long as PT or aPTT is within therapeutic range of intended use of anticoagulants
Activated Partial Thromboplastin Time (aPTT)	$\leq 1.5 \times$ ULN unless subject is receiving anticoagulant therapy as long as PT or aPTT is within therapeutic range of intended use of anticoagulants

<sup>a</sup> Creatinine clearance should be calculated per institutional standard.

11. Female subjects of childbearing potential must have a negative urine or serum pregnancy test within 72 hours prior to receiving the first dose of study medication. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required.
12. Female subjects of childbearing potential (Section 5.7.2) must be willing to use an adequate method of contraception, as outlined in Section 5.7.2 – Contraception, for the course of the study through 120 days after the last dose of pembrolizumab or through 180 days after the last dose of paclitaxel, docetaxel, or irinotecan.

Note: Abstinence is acceptable if this is the usual lifestyle and preferred contraception for the subject.

13. Male subjects of childbearing potential (Section 5.7.2) must agree to use an adequate method of contraception, as outlined in Section 5.7.2- Contraception, and not to donate sperm starting with the first dose of study therapy through 120 days after the last dose of pembrolizumab or through 180 days after the last dose of paclitaxel, docetaxel, or irinotecan.

Note: Abstinence is acceptable if this is the usual lifestyle and preferred contraception for the subject.

### 5.1.3 Subject Exclusion Criteria

The subject must be excluded from participating in the trial if the subject:

1. Is currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatment.

Note: Subjects who have entered the follow-up phase of an investigational study may participate as long as it has been 4 weeks since the last dose of the previous investigational agent or device.

2. Has active autoimmune disease that has required systemic treatment in past 2 years (i.e., with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment.
3. Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatment. The use of physiologic doses of corticosteroids may be approved after consultation with the Sponsor.
4. Has known central nervous system (CNS) metastases and/or carcinomatous meningitis (includes past history or current metastasis).
5. Has received prior anti-cancer monoclonal antibody (mAb), chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study Day 1. The specified 2-week period between last dose of prior therapy and first dose of

pembrolizumab is the minimum amount of time required. Subjects may not receive study medication less than 2 weeks from the last dose of a prior therapy. However, a period of more than 2 weeks may be used if indicated both clinically and due to concern between possible negative interactions between prior therapy and study therapy. Subjects must have recovered from adverse events due to a previously administered agent to baseline toxicity grade or to Grade 1 or less prior to enrollment.

Note: Subjects with  $\leq$  Grade 2 neuropathy or  $\leq$  Grade 2 alopecia are an exception to this criterion and may qualify for the study.

Note: If subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy.

6. Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent, or if the subject has previously participated in Merck pembrolizumab (MK-3475) clinical trials.
7. Previously had a severe hypersensitivity reaction to treatment with another monoclonal antibody (mAb).
8. Has experienced documented objective radiographic or clinical disease progression during or after receiving more than 1 line of therapy.
9. Has a known additional malignancy that progressed or required active treatment within the last 5 years. Exceptions include curatively treated basal cell and SCC of the skin and/or curatively resected in situ cervical and/or breast cancers and in situ or intramucosal pharyngeal cancer.
10. Has received a live vaccine within 30 days of planned start of pembrolizumab.

Note: The killed virus vaccines used for seasonal influenza vaccines for injection are allowed; however intranasal influenza vaccines (e.g., FluMist<sup>®</sup>) are live attenuated vaccines, and are not allowed.

11. Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the subject's participation for the full duration of the trial, or is not in the best interest of the subject to participate, in the opinion of the treating investigator.
12. Has a known history of Human Immunodeficiency Virus (HIV) infection. No HIV testing is required unless mandated by local health authority.
13. Has known history of or is positive for hepatitis B (hepatitis B surface antigen reactive) or known active hepatitis C (hepatitis C virus RNA or hepatitis C antibody is detected). No hepatitis testing is required unless mandated by local health authority.
14. Has a history of (non-infectious) pneumonitis that required steroids or current pneumonitis.
15. Has an active infection requiring systemic therapy.
16. Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.

17. Is pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the trial, starting with the screening visit through 120 days after the last dose of pembrolizumab or through 180 days after the last dose of paclitaxel, docetaxel, or irinotecan.
18. Has a known allergy, hypersensitivity, or contraindication to preselected chemotherapy agent (i.e., paclitaxel, docetaxel, or irinotecan) or any components used in their preparation.
19. Experienced weight loss > 10% over approximately 2 months prior to first dose of study therapy.
20. Has clinically apparent ascites or pleural effusion by physical exam. (Note that small amount of ascites which is only detectable on imaging studies is allowed.)

## 5.2 Trial Treatment(s)

The treatments to be used in this trial are outlined below in [Table 2](#).

Table 2 Trial Treatment

Drug	Dose	Dose Frequency	Route of Administration	Regimen/Treatment Period	Use
Pembrolizumab (MK-3475)	200 mg	Every 3 weeks	IV infusion	Day 1 of each 21-day (3-week) cycle	Experimental
Paclitaxel	80-100 mg/m <sup>2</sup>	3 weeks on, 1 week off	IV infusion	Days 1, 8, and 15 of each 28-day (4-week) cycle	Active comparator
Docetaxel	75 mg/m <sup>2</sup>	Every 3 weeks	IV infusion	Day 1 of each 21-day (3-week) cycle	Active comparator
Irinotecan	180 mg/m <sup>2</sup>	Every 2 weeks	IV infusion	Day 1 of each 14-day (2-week) cycle	Active comparator

Trial treatment for Cycle 1 should begin within 3 days of randomization. However, every effort should be made to begin trial treatment on day of randomization.

All supplies indicated in [Table 2](#) above will be provided centrally by the Sponsor or locally by the trial site, subsidiary or designee, depending on local country operational or regulatory requirements.

For any commercially available product that is provided by the trial site, subsidiary or designee every attempt will be made to source these supplies from a single lot/batch number. Per local guidelines the trial site may be responsible for recording the lot number, manufacturer and expiry date of any locally purchased product.

The investigator shall take responsibility for and shall take all steps to maintain appropriate records and ensure appropriate supply, storage, handling, distribution and usage of trial treatments in accordance with the protocol and any applicable laws and regulations.

## 5.2.1 Dose Selection/Modification

### 5.2.1.1 Dose Selection (Preparation)

The rationale for selection of doses to be used in this trial is provided in Section 4.0 – Background & Rationale. Details on preparation and administration of pembrolizumab are provided in the Pharmacy Manual.

Preparation and administration of paclitaxel, docetaxel, or irinotecan should be completed as per the approved product label. Body surface area (BSA) in  $\text{m}^2$  should be calculated per local guidance.

### 5.2.1.2 Dose Modification (Escalation/Titration/Other)

#### 5.2.1.2.1 Immune-Related Events and Dose Modification (Withhold, Treat, Discontinue)

##### **Dose Modification and Toxicity Management for Immune-related AEs Associated with Pembrolizumab**

AEs associated with pembrolizumab exposure may represent an immune-related response. These irAEs may occur shortly after the first dose or several months after the last dose of pembrolizumab treatment and may affect more than one body system simultaneously. Therefore, early recognition and initiation of treatment is critical to reduce complications. Based on existing clinical study data, most irAEs were reversible and could be managed with interruptions of pembrolizumab, administration of corticosteroids and/or other supportive care. For suspected irAEs, ensure adequate evaluation to confirm etiology or exclude other causes. Additional procedures or tests such as bronchoscopy, endoscopy, skin biopsy may be included as part of the evaluation. Based on the severity of irAEs, withhold or permanently discontinue pembrolizumab and administer corticosteroids.

Dose Modification and Toxicity Management Guidelines for irAEs associated with pembrolizumab monotherapy, coformulations, or IO combinations are provided in [Table 3](#).

Table 3 Dose Modification and Toxicity Management Guidelines for Immune-related Adverse Events Associated with Pembrolizumab Monotherapy, Coformulations or IO Combinations

General instructions:				
irAEs	Toxicity Grade (CTCAEv4.0)	Action With Pembrolizumab Monotherapy, Coformulations or IO Combinations	Corticosteroid and/or Other Therapies	Monitoring and Follow-up
Pneumonitis	Grade 2	Withhold	<ul style="list-style-type: none"> <li>Administer corticosteroids (initial dose of 1-2 mg/kg prednisone or equivalent) followed by taper</li> </ul>	<ul style="list-style-type: none"> <li>Monitor participants for signs and symptoms of pneumonitis</li> <li>Evaluate participants with suspected pneumonitis with radiographic imaging and initiate corticosteroid treatment</li> <li>Add prophylactic antibiotics for opportunistic infections</li> </ul>
	Recurrent Grade 2 or Grade 3 or 4	Permanently discontinue		
Diarrhea / Colitis	Grade 2 or 3	Withhold	<ul style="list-style-type: none"> <li>Administer corticosteroids (initial dose of 1-2 mg/kg prednisone or equivalent) followed by taper</li> </ul>	<ul style="list-style-type: none"> <li>Monitor participants for signs and symptoms of enterocolitis (ie, diarrhea, abdominal pain, blood or mucus in stool with or without fever) and of bowel perforation (ie, peritoneal signs and ileus)</li> <li>Participants with <math>\geq</math>Grade 2 diarrhea suspecting colitis should consider GI consultation and performing endoscopy to rule out colitis</li> <li>Participants with diarrhea/colitis should be advised to drink liberal quantities of clear fluids. If sufficient oral fluid intake is not feasible, fluid and electrolytes should be substituted via IV infusion.</li> </ul>
	Recurrent Grade 3 or Grade 4	Permanently discontinue		

irAEs	Toxicity Grade (CTCAEv4.0)	Action With Pembrolizumab Monotherapy, Coformulations or IO Combinations	Corticosteroid and/or Other Therapies	Monitoring and Follow-up
AST / ALT Elevation or Increased Bilirubin	Grade 2	Withhold	<ul style="list-style-type: none"> <li>Administer corticosteroids (initial dose of 0.5-1 mg/kg prednisone or equivalent) followed by taper</li> </ul>	<ul style="list-style-type: none"> <li>Monitor with liver function tests (consider weekly or more frequently until liver enzyme value returned to baseline or is stable)</li> </ul>
	Grade 3 or 4	Permanently discontinue	<ul style="list-style-type: none"> <li>Administer corticosteroids (initial dose of 1-2 mg/kg prednisone or equivalent) followed by taper</li> </ul>	
T1DM or Hyperglycemia	New onset T1DM or Grade 3 or 4 hyperglycemia associated with evidence of $\beta$ -cell failure	Withhold <sup>a</sup>	<ul style="list-style-type: none"> <li>Initiate insulin replacement therapy for participants with T1DM</li> <li>Administer anti-hyperglycemic in participants with hyperglycemia</li> </ul>	<ul style="list-style-type: none"> <li>Monitor participants for hyperglycemia or other signs and symptoms of diabetes</li> </ul>
Hypophysitis	Grade 2	Withhold	<ul style="list-style-type: none"> <li>Administer corticosteroids and initiate hormonal replacements as clinically indicated</li> </ul>	<ul style="list-style-type: none"> <li>Monitor for signs and symptoms of hypophysitis (including hypopituitarism and adrenal insufficiency)</li> </ul>
	Grade 3 or 4	Withhold permanently discontinue <sup>a</sup>		
Hyperthyroidism	Grade 2	Continue	<ul style="list-style-type: none"> <li>Treat with non-selective beta-blockers (eg, propranolol) or thionamides as appropriate</li> </ul>	<ul style="list-style-type: none"> <li>Monitor for signs and symptoms of thyroid disorders</li> </ul>
	Grade 3 or 4	Withhold or Permanently discontinue <sup>a</sup>		

irAEs	Toxicity Grade (CTCAEv4.0)	Action With Pembrolizumab Monotherapy, Coformulations or IO Combinations	Corticosteroid and/or Other Therapies	Monitoring and Follow-up
Hypothyroidism	Grade 2-4	Continue	<ul style="list-style-type: none"> <li>Initiate thyroid replacement hormones (eg, levothyroxine or liothyronine) per standard of care</li> </ul>	<ul style="list-style-type: none"> <li>Monitor for signs and symptoms of thyroid disorders</li> </ul>
Nephritis and renal dysfunction	Grade 2	Withhold	<ul style="list-style-type: none"> <li>Administer corticosteroids (prednisone 1-2 mg/kg or equivalent) followed by taper</li> </ul>	<ul style="list-style-type: none"> <li>Monitor changes of renal function</li> </ul>
	Grade 3 or 4	Permanently discontinue		
Myocarditis	Grade 1	Withhold	<ul style="list-style-type: none"> <li>Based on severity of AE administer corticosteroids</li> </ul>	<ul style="list-style-type: none"> <li>Ensure adequate evaluation to confirm etiology and/or exclude other causes</li> </ul>
	Grade 2, 3 or 4	Permanently discontinue		
All Other irAEs	Persistent Grade 2	Withhold	<ul style="list-style-type: none"> <li>Based on severity of AE administer corticosteroids</li> </ul>	<ul style="list-style-type: none"> <li>Ensure adequate evaluation to confirm etiology or exclude other causes</li> </ul>
	Grade 3	Withhold or discontinue <sup>b</sup>		
	Recurrent Grade 3 or Grade 4	Permanently discontinue		

AE(s)=adverse event(s); ALT= alanine aminotransferase; AST=aspartate aminotransferase; CTCAE=Common Terminology Criteria for Adverse Events; DRESS=Drug Rash with Eosinophilia and Systemic Symptom; GI=gastrointestinal; IO=immuno-oncology; ir=immune related; IV=intravenous; SJS=Stevens-Johnson Syndrome; T1DM=type 1 diabetes mellitus; TEN=Toxic Epidermal Necrolysis; ULN=upper limit of normal.

**Note: Non-irAE will be managed as appropriate, following clinical practice recommendations.**

<sup>a</sup> The decision to withhold or permanently discontinue pembrolizumab monotherapy, coformulations or IO combinations is at the discretion of the investigator or treating physician. If control achieved or  $\leq$  Grade 2, pembrolizumab monotherapy, coformulations or IO combinations may be resumed.

<sup>b</sup> Events that require discontinuation include, but are not limited to: Guillain-Barre Syndrome, encephalitis, myelitis, DRESS, SJS, TEN and other clinically important irAEs (eg, vasculitis and sclerosing cholangitis).

**Dose modification and toxicity management of infusion-reactions related to pembrolizumab**

Pembrolizumab may cause severe or life threatening infusion-reactions including severe hypersensitivity or anaphylaxis. Signs and symptoms usually develop during or shortly after drug infusion and generally resolve completely within 24 hours of completion of infusion. Dose modification and toxicity management guidelines on pembrolizumab associated infusion reaction are provided in [Table 4](#).

Table 4 Pembrolizumab Infusion Reaction Dose modification and Treatment Guidelines

NCI CTCAE Grade	Treatment	Premedication at Subsequent Dosing
<b>Grade 1</b> Mild reaction; infusion interruption not indicated; intervention not indicated	Increase monitoring of vital signs as medically indicated until the subject is deemed medically stable in the opinion of the investigator.	None
<b>Grade 2</b> Requires therapy or infusion interruption but responds promptly to symptomatic treatment (e.g., antihistamines, NSAIDs, narcotics, IV fluids); prophylactic medications indicated for $\leq 24$ hrs	<b>Stop Infusion.</b> Additional appropriate medical therapy may include but is not limited to: IV fluids Antihistamines NSAIDs Acetaminophen Narcotics Increase monitoring of vital signs as medically indicated until the subject is deemed medically stable in the opinion of the investigator. If symptoms resolve within 1 hour of stopping drug infusion, the infusion may be restarted at 50% of the original infusion rate (e.g. from 100 mL/hr to 50 mL/hr). Otherwise dosing will be held until symptoms resolve and the subject should be premedicated for the next scheduled dose. Subjects who develop Grade 2 toxicity despite adequate premedication should be permanently discontinued from further study drug treatment	Subject may be premedicated 1.5h ( $\pm$ 30 minutes) prior to infusion of pembrolizumab with: Diphenhydramine 50 mg po (or equivalent dose of antihistamine). Acetaminophen 500-1000 mg po (or equivalent dose of analgesic).
<b>Grades 3 or 4</b> Grade 3: Prolonged (i.e., not rapidly responsive to symptomatic medication and/or brief interruption of infusion); recurrence of symptoms following initial improvement; hospitalization indicated for other clinical sequelae (e.g., renal impairment, pulmonary infiltrates)	<b>Stop Infusion.</b> Additional appropriate medical therapy may include but is not limited to: Epinephrine** IV fluids Antihistamines NSAIDs Acetaminophen Narcotics Oxygen Pressors Corticosteroids Increase monitoring of vital signs as medically indicated until the subject is deemed medically stable in the opinion of the investigator.	No subsequent dosing

NCI CTCAE Grade	Treatment	Premedication at Subsequent Dosing
Grade 4: Life-threatening; pressor or ventilatory support indicated	Hospitalization may be indicated. **In cases of anaphylaxis, epinephrine should be used immediately. <b>Subject is permanently discontinued from further study drug treatment.</b>	
Appropriate resuscitation equipment should be available at the bedside and a physician readily available during the period of drug administration. For further information, please refer to the Common Terminology Criteria for Adverse Events v4.0 (CTCAE) at <a href="http://ctep.cancer.gov">http://ctep.cancer.gov</a>		

### **Other allowed dose interruption for pembrolizumab**

Pembrolizumab may be interrupted for situations other than treatment-related AEs such as medical / surgical events or logistical reasons not related to study therapy. Subjects should be placed back on study therapy within 3 weeks of the scheduled interruption, unless otherwise discussed with the Sponsor. The reason for interruption should be documented in the patient's study record.

#### **5.2.1.2.2 Dose Modification for Paclitaxel, Docetaxel and Irinotecan**

Investigators may follow the local label for dose modifications. If a toxicity is not otherwise specified, investigators should refer to the label or local standard of care for dose adjustments. These dose modification decisions must be documented in the subject's study records and in the case report form.

Subjects who started therapy with paclitaxel, docetaxel, or irinotecan may not switch to one of the other chemotherapies. Subjects who permanently discontinue treatment with paclitaxel, docetaxel, or irinotecan may continue to be monitored in the trial.

Subjects receiving docetaxel should avoid concomitant use of strong inhibitors of CYP3A4; however, if strong inhibitors of CYP3A4 cannot be avoided, the docetaxel dose should be reduced per the drug label.

Caution should be exercised for subjects receiving paclitaxel concomitantly with substrates, inhibitors or inducers of CYP2C8 or CYP3A4.

### **5.2.2 Timing of Dose Administration**

All trial treatments may be administered on an outpatient basis.

#### **5.2.2.1 Pembrolizumab**

Cycle 1 Day 1 dose may be administered up to 3 days after subject is randomized. Trial treatment of pembrolizumab may be administered up to 3 days before or after the scheduled Day 1 of each 21-day (3-week) cycle after Cycle 1 due to administrative reasons. Pembrolizumab should be administered after all procedures/assessments have been completed as detailed on the Trial Flow Chart (Section 6.0).

Pembrolizumab 200 mg will be administered as a 30 minute intravenous (IV) infusion Q3W. Sites should make every effort to target infusion timing to be as close to 30 minutes as possible. However, given the variability of infusion pumps from site to site, a window of -5 minutes and +10 minutes is permitted (i.e., infusion time is 30 minutes: -5 min/+10 min).

The Pharmacy Manual contains specific instructions for the preparation of the pembrolizumab infusion fluid and administration of infusion solution.

### **5.2.2.2 Paclitaxel**

Trial treatment of paclitaxel may be administered up to 3 days after randomization for Cycle 1 Day 1 due to administrative reasons or if the subject requires premedication. The required premedication should be administered as close to randomization as possible. After Cycle 1 there is a 3 day window for all trial treatment. If dosing is delayed due to administrative reasons, the subsequent dosing visit should be re-calculated to account for future dosing visits.

Trial treatment of paclitaxel should be administered on Days 1, 8, and 15 of each 28 day (4 week) cycle after all procedures/assessments have been completed as detailed on the Trial Flow Chart (Section 6.0).

Paclitaxel should be administered as an IV infusion according to manufacturer standards or local guidance, at a dose of 80-100 mg/m<sup>2</sup>. The first dose of paclitaxel is dependent upon the subject's baseline body surface area. Subsequent doses of paclitaxel must be recalculated per local or institutional guidelines if there is a  $\geq 10\%$  change (increase or decrease) in body surface area from baseline or since the last recalculation of dose; subsequent doses may be recalculated if there is a  $< 10\%$  change (increase or decrease) in body surface area from baseline or since the last recalculation of dose.

Premedication is recommended prior to infusion of paclitaxel according to the manufacturer's instructions and local standards. Premedication will consist of an oral steroid (such as dexamethasone 8-20 mg or equivalent administered (PO) 12 and 6 hours or (IV) 30-60 minutes before paclitaxel), an antihistamine (H1 antagonist) such as diphenhydramine hydrochloride 50 mg I.V. (or equivalent), cimetidine (H2 antagonist) 300 mg I.V. or equivalent, and an antiemetic (such as odansetron 8 mg/kg I.V. or equivalent), administered 30 to 120 minutes before paclitaxel. Premedication may be provided per local guidance and all medications should be captured on the appropriate case report form.

### **5.2.2.3 Docetaxel**

Trial treatment of docetaxel may be administered up to 3 days after randomization for Cycle 1 Day 1 due to administrative reasons or if the subject requires premedication. The required premedication should be administered as close to randomization as possible. After Cycle 1 there is a 3 day window for all trial treatment. If dosing is delayed due to administrative reasons, the subsequent dosing visit should be re-calculated to account for future dosing visits.

Docetaxel should be administered on Day 1 of each 21-day (3-week) cycle after all procedures/assessments have been completed as detailed on the Trial Flow Chart (Section 6.0).

Docetaxel should be administered as an IV infusion administered over 1 hour according to manufacturer standards, at a dose of  $75 \text{ mg/m}^2$ . The first dose of docetaxel is dependent upon the subject's baseline body surface area. Subsequent doses of docetaxel must be recalculated if there is a  $\geq 10\%$  change (increase or decrease) in body surface area from baseline or since the last recalculation of dose; subsequent doses may be recalculated if there is a  $< 10\%$  change (increase or decrease) in body surface area from baseline.

All subjects should be premedicated with oral corticosteroids, such as dexamethasone 16 mg per day (e.g., 8 mg twice daily) for 3 days starting 1 day prior to docetaxel administration in order to reduce the incidence and severity of fluid retention as well as the severity of hypersensitivity reactions. The appropriate premedication regimen may be determined by the investigator and all medications should be captured on the appropriate case report form.

#### **5.2.2.4 Irinotecan**

Trial treatment of irinotecan may be administered up to 3 days after randomization for Cycle 1 Day 1 due to administrative reasons or if the subject requires premedication. The required premedication should be administered as close to randomization as possible. After Cycle 1 there is a 3 day window for all trial treatment. If dosing is delayed due to administrative reasons, the subsequent dosing visit should be re-calculated to account for the weekly dosing visits.

Subjects should be tested locally for the UGT1A1\*28 allele at investigator discretion. The starting dose for irinotecan can be adjusted as outlined in the prescribing information or according to local guidelines. Tests performed prior to the subject signing consent is acceptable for screening.

Irinotecan should be administered on Day 1 of each 14-day (2-week) cycle after all procedures/assessments have been completed as detailed on the Trial Flow Chart (Section 6.0).

Irinotecan should be administered as an IV infusion administered according to manufacturer standards, at a dose of  $180 \text{ mg/m}^2$ . The first dose of irinotecan is dependent upon the subject's baseline body surface area. Subsequent doses of irinotecan must be recalculated if there is a  $\geq 10\%$  change (increase or decrease) in body surface area from baseline or since the last recalculation of dose; subsequent doses may be recalculated if there is a  $< 10\%$  change (increase or decrease) in body surface area from baseline.

Premedication is recommended prior to infusion of irinotecan according to the manufacturer's instructions and local standards. Premedication may consist of atropine and antiemetic agents, such as dexamethasone 10 mg given with another antiemetic agent (e.g., ondansetron) on the day of treatment in order to reduce the incidence and severity of fluid loss. The appropriate premedication regimen may be determined by the investigator and all medications should be captured on the appropriate case report form.

#### **5.2.3 Trial Blinding/Masking**

This is an open-label trial; therefore, the Sponsor, investigator and subject will know the treatment administered.

Imaging data will be reviewed by central imaging vendor without knowledge of subject treatment assignment.

See Section 7.1.5.2, Blinding/Unblinding, for a description of the method of unblinding a subject during the trial, should such action be warranted.

### **5.3 Randomization or Treatment Allocation**

Treatment allocation/randomization will occur centrally using an interactive voice response system / integrated web response system (IVRS/IWRS). There are 2 treatment arms. Subjects will be assigned randomly in a 1:1 ratio to pembrolizumab or investigator's choice of chemotherapy (i.e. paclitaxel, docetaxel, or irinotecan). The selected regimen should not be in conflict with local regulations or guidance for patients randomized to the investigator's choice treatment arm (paclitaxel, docetaxel, or irinotecan).

### **5.4 Stratification**

Treatment allocation/randomization will be stratified according to the following factors:

1. Tumor histology: Squamous cell carcinoma vs. adenocarcinoma/Siewert type I adenocarcinoma of the EGJ
2. Geographic region: Asia (including but not limited to China, Japan, Korea, Hong Kong, Taiwan, Malaysia, Thailand, Singapore) vs. Rest of World (including but not limited to Europe/Israel/North America, Australia, South America)

### **5.5 Concomitant Medications/Vaccinations (Allowed & Prohibited)**

Medications or vaccinations specifically prohibited in the exclusion criteria are not allowed during the ongoing trial. If there is a clinical indication for any medication or vaccination specifically prohibited during the trial, discontinuation from trial therapy or vaccination may be required. The investigator should discuss any questions regarding this with the Sponsor Clinical Director. The final decision on any supportive therapy or vaccination rests with the investigator and/or the subject's primary physician. However, the decision to continue the subject on trial therapy or vaccination schedule requires the mutual agreement of the investigator, the Sponsor and the subject.

#### **5.5.1 Acceptable Concomitant Medications**

All treatments that the investigator considers necessary for a subject's welfare may be administered at the discretion of the investigator in keeping with the community standards of medical care. All concomitant medication will be recorded on the electronic case report form (eCRF) including all prescription, over-the-counter (OTC), herbal supplements, and IV medications and fluids. If changes occur during the trial period, documentation of drug dosage, frequency, route, and date may also be included on the eCRF.

All concomitant medications received within 30 days before the first dose of trial treatment and 30 days after the last dose of trial treatment should be recorded. Concomitant

medications administered within 30 days after the last dose of trial treatment should be recorded for SAEs and ECIs as defined in Section 7.2.

Subjects receiving docetaxel should avoid concomitant use of strong inhibitors of CYP3A4; however, if strong inhibitors of CYP3A4 cannot be avoided, the docetaxel dose should be reduced per the product label.

Caution should be exercised for subjects receiving paclitaxel concomitantly with substrates, inhibitors or inducers of CYP2C8 or CYP3A4.

### **5.5.2 Prohibited Concomitant Medication**

Subjects are prohibited from receiving the following therapies during the Screening and Treatment Phase (including retreatment for post-complete response relapse) of this trial:

- Antineoplastic systemic chemotherapy or biological therapy not specified in this protocol
- Immunotherapy not specified in this protocol
- Investigational agents other than pembrolizumab
- Radiation therapy for tumor control
  - Note: Radiation therapy to a symptomatic solitary lesion may be allowed after consultation with Sponsor.
- For all subjects, live vaccines within 30 days prior to the first dose of trial treatment are prohibited. For subjects randomized to treatment with pembrolizumab, live vaccines while participating in the trial are prohibited. Examples of live vaccines include, but are not limited to, the following: measles, mumps, rubella, chickenpox, yellow fever, rabies, BCG, and typhoid (oral) vaccine. The killed virus vaccines used as seasonal influenza vaccines for injection are allowed; however live attenuated intranasal influenza vaccines (e.g., FluMist<sup>®</sup>) are not allowed.

Note: Any licensed COVID 19 vaccine (including for emergency use) in a particular country is allowed in the study as long as they are mRNA vaccines, adenoviral vaccines, or inactivated vaccines. These vaccines will be treated just as any other concomitant therapy.

Investigational vaccines (i.e., those not licensed or approved for emergency use) are not allowed.

- Pembrolizumab arm only: Glucocorticoids (inhaled steroids as part of a stable regimen for the treatment of asthma/chronic obstructive pulmonary disease [COPD] or topical steroids for skin conditions are permitted) for any purpose other than to modulate symptoms from an adverse event. The use of physiologic doses of corticosteroids may be approved after consultation with the Sponsor.
  - Note: Use of prophylactic corticosteroids to avoid allergic reactions (e.g. IV contrast dye) is permitted.

Subjects who, in the assessment by the investigator, require the use of any of the aforementioned treatments for clinical management should be discontinued from study treatment. Subjects may receive other medications that the investigator deems to be medically necessary.

The Exclusion Criteria describes other medications which are prohibited in this trial.

There are no prohibited therapies during the Post-Treatment Follow-up Phase.

Pre-medication with steroids is acceptable for those subjects randomized to the paclitaxel/docetaxel/irinotecan arm of the study.

## **5.6 Rescue Medications & Supportive Care**

### **5.6.1 Supportive Care Guidelines for Pembrolizumab**

Subjects should receive appropriate supportive care measures as deemed necessary by the treating investigator. Suggested supportive care measures for the management of adverse events with potential immunologic etiology are outlined below. Where appropriate, these guidelines include the use of oral or intravenous treatment with corticosteroids as well as additional anti-inflammatory agents (other than immunotherapy) if symptoms do not improve with administration of corticosteroids. Note that several courses of steroid tapering may be necessary as symptoms may worsen when the steroid dose is decreased. For each disorder, attempts should be made to rule out other causes such as metastatic disease or bacterial or viral infection, which might require additional supportive care. The treatment guidelines are intended to be applied when the investigator determines the events to be related to pembrolizumab.

Note: If after the evaluation the event is determined not to be related to pembrolizumab, the investigator does not need to follow the treatment guidance (as outlined below). Refer to Section 5.2.1 for dose modification.

It may be necessary to perform conditional procedures such as bronchoscopy, endoscopy, or skin photography as part of evaluation of the event.

### **5.6.2 Supportive Care Guidelines for Paclitaxel, Docetaxel and Irinotecan**

Palliative and supportive care for other disease-related symptoms and for toxicity associated with treatment will be offered to subjects within the paclitaxel/docetaxel/irinotecan arm of this trial. Supportive care measures may include but are not limited to antidiarrheal agents, antiemetic agents, opiate and non-opiate analgesic agents, appetite stimulants, and granulocyte and erythroid growth factors. Non-drug supportive care procedures may be performed as medically necessary and appropriate in the opinion of the investigator. Details of interventions, procedures, or blood products (e.g., blood cells, platelets, or fresh frozen plasma transfusions) should be recorded on the eCRF. The use of other specific supportive care agents is presented below.

**Diarrhea:** In the event of Grade 3 or 4 diarrhea, supportive measures may include hydration, loperamide, octreotide, and antidiarrheals. If diarrhea is severe (i.e., requires intravenous hydration) and associated with fever or severe (Grade 3 or 4) neutropenia, broad-spectrum antibiotics may be prescribed. Subjects with severe diarrhea or any diarrhea associated with severe nausea or vomiting must be hospitalized for intravenous hydration and correction of electrolyte imbalance. In cases of irinotecan induced diarrhea, antibiotic therapy should be initiated if the subject develops ileus, fever or severe neutropenia.

**Nausea/Vomiting:** The use of antiemetic agents is permitted at the discretion of the investigator.

### **Additional Supportive Care Guidelines:**

**Analgesic Agents:** The use of analgesic agents is permitted at the discretion of the investigator. The chronic use of non-steroidal anti-inflammatory drugs (NSAIDs) with a high risk of bleeding (e.g., indomethacin, ibuprofen, naproxen, or similar agents) is strongly discouraged unless at the discretion and responsibility of the investigator after careful assessment of the individual bleeding risk of the subject. Chronic use of analgesic agents with no or low bleeding risk (e.g., paracetamol/acetaminophen, metamizole, dipyrone, propyphenazone) is acceptable.

**Granulocyte-Colony Stimulating Factors (G-CSF):** The use of G-CSF is permitted during investigational therapy at the discretion of the investigator. G-CSF or similar agents are strongly recommended following Grade 3 or 4 neutropenia of duration > 5 days or following any incidence of febrile neutropenia (ANC <  $1.0 \times 10^9/L$  with temperature  $\geq 38.5^{\circ}\text{C}$ ).

**Erythroid Growth Factors:** The use of erythroid-stimulating factors (e.g., erythropoietin) is permitted at the discretion of the investigator based on American Society of Clinical Oncology (ASCO) and Food and Drug Administration (FDA) guidelines, or according to local guidelines.

Refer to the product label or local standards of care for additional paclitaxel, docetaxel, or irinotecan supportive measures.

## **5.7 Diet/Activity/Other Considerations**

### **5.7.1 Diet**

Subjects should maintain a normal diet unless modifications are required to manage an AE such as diarrhea, nausea or vomiting.

### **5.7.2 Contraception**

Pembrolizumab, paclitaxel, docetaxel, or irinotecan may have adverse effects on a fetus in utero. Furthermore, it is not known if pembrolizumab, paclitaxel, docetaxel, or irinotecan has transient adverse effects on the composition of sperm.

For this trial, male subjects will be considered to be of non-reproductive potential if they have azoospermia (whether due to having had a vasectomy or due to an underlying medical condition).

Female subjects will be considered of non-reproductive potential if they are either:

- 1) postmenopausal (defined as at least 12 months with no menses without an alternative medical cause; in women < 45 years of age a high follicle stimulating hormone (FSH) level in the postmenopausal range may be used to confirm a post-menopausal state in women not using hormonal contraception or hormonal replacement therapy. In the absence of 12 months of amenorrhea, a single FSH measurement is insufficient.);

OR

- 2) have had a hysterectomy and/or bilateral oophorectomy, bilateral salpingectomy or bilateral tubal ligation/occlusion, at least 6 weeks prior to screening;

OR

- 3) has a congenital or acquired condition that prevents childbearing.

Female and male subjects of reproductive potential must agree to avoid becoming pregnant or impregnating a partner, respectively, while receiving study drug and through 120 days after the last dose of pembrolizumab or through 180 days after the last dose of paclitaxel, docetaxel, or irinotecan by complying with one of the following:

- 1) practice abstinence† from heterosexual activity;

OR

- 2) use (or have their partner use) acceptable contraception during heterosexual activity.

Acceptable methods of contraception are‡:

Single method (one of the following is acceptable):

- intrauterine device (IUD)
- vasectomy of a female subject's male partner
- contraceptive rod implanted into the skin

Combination method (requires use of two of the following):

- diaphragm with spermicide (cannot be used in conjunction with cervical cap/spermicide)
- cervical cap with spermicide (nulliparous women only)
- contraceptive sponge (nulliparous women only)
- male condom or female condom (cannot be used together)
- hormonal contraceptive: oral contraceptive pill (estrogen/progestin pill or progestin-only pill), contraceptive skin patch, vaginal contraceptive ring, or subcutaneous contraceptive injection

†Abstinence (relative to heterosexual activity) can be used as the sole method of contraception if it is consistently employed as the subject's preferred and usual lifestyle and if considered acceptable by local regulatory agencies and ERCs/IRBs. Periodic abstinence (e.g., calendar, ovulation, sympto-thermal, post-ovulation methods, etc.) and withdrawal are not acceptable methods of contraception.

‡If a contraceptive method listed above is restricted by local regulations/guidelines, then it does not qualify as an acceptable method of contraception for subjects participating at sites in this country/region.

Subjects should be informed that taking the study medication may involve unknown risks to the fetus (unborn baby) if pregnancy were to occur during the study. In order to participate in the study, subjects of childbearing potential must adhere to the contraception requirement (described above) from the day of study medication initiation (or 14 days prior to the initiation of study medication for oral contraception) throughout the study period up to 120 days after the last dose of pembrolizumab or through 180 days after the last dose of paclitaxel, docetaxel, or irinotecan. If there is any question that a subject of childbearing potential will not reliably comply with the requirements for contraception, that subject should not be entered into the study.

Below are the required contraceptions for countries where the health authority requests compliance with the Clinical Trial Facilitation Group (CTFG) Guidance:

Subjects should use birth control methods that can achieve a failure rate of less than 1% per year when used consistently and correctly and are considered as highly effective birth control methods. Such methods include:

- Combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation:
  - Oral
  - Intravaginal
  - Transdermal
- Progestogen-only hormonal contraception associated with inhibition of ovulation:
  - Oral
  - Injectable
  - Implantable
  - Intrauterine device (IUD)
  - Intrauterine hormone-releasing system (IUS)
  - Bilateral tubal occlusion
  - Vasectomised partner
  - Sexual abstinence

### **5.7.3 Use in Pregnancy**

If a subject inadvertently becomes pregnant while on treatment with pembrolizumab or paclitaxel/docetaxel/irinotecan, the subject will immediately be removed from the study treatment. The site will contact the subject at least monthly and document the subject's status until the pregnancy has been completed or terminated. The outcome of the pregnancy will be reported to the Sponsor without delay and within 24 hours if the outcome is a serious adverse experience (e.g., death, abortion, congenital anomaly, or other disabling or life-threatening complication to the mother or newborn). The study investigator will make every effort to obtain permission to follow the outcome of the pregnancy and report the condition of the fetus or newborn to the Sponsor. If a male subject impregnates his female partner the study personnel at the site must be informed immediately and the pregnancy reported to the Sponsor and followed as described above and in Section 7.2.2.

### **5.7.4 Use in Nursing Women**

It is unknown whether pembrolizumab, paclitaxel, docetaxel, or irinotecan are excreted in human milk, and because of the potential for serious adverse reactions in the nursing infant, subjects who are breast-feeding are not eligible for enrollment.

## **5.8 Subject Withdrawal/Discontinuation Criteria**

### **5.8.1 Discontinuation of Treatment**

Discontinuation of treatment does not represent withdrawal from the trial.

As certain data on clinical events beyond treatment discontinuation may be important to the study, they must be collected through the subject's last scheduled follow-up, even if the subject has discontinued treatment. Therefore, all subjects who discontinue trial treatment prior to completion of the treatment will still continue to participate in the trial as specified in Section 6.0 - Trial Flow Chart and Section 7.1.5.1 – Withdrawal/Discontinuation.

Subjects may discontinue treatment at any time for any reason or be dropped from treatment at the discretion of the investigator should any untoward effect occur. In addition, a subject may be discontinued from treatment by the investigator or the Sponsor if treatment is inappropriate, the trial plan is violated, or for administrative and/or other safety reasons. Specific details regarding procedures to be performed at treatment discontinuation are provided in Section 7.1.5 – Other Procedures.

A subject must be discontinued from treatment but continue to be monitored in the trial for any of the following reasons:

- The subject or subject's legally acceptable representative requests to discontinue treatment.
- Confirmed radiographic disease progression outlined in Section 7.1.5 (exception if the Sponsor approves treatment continuation).
- Unacceptable adverse experiences as described in Section 7.2

- Progression of current malignancy or recurrence of previously treated malignancy, or any occurrence of another malignancy that requires active treatment
- Intercurrent illness other than another malignancy as noted above that prevents further administration of treatment
- Recurrent Grade 2 pneumonitis
- A confirmed positive serum pregnancy test
- Noncompliance with trial treatment or procedure requirements
- Investigator's decision to discontinue the subject
- Discontinuation of treatment may be considered for subjects who have attained a confirmed complete response (CR) and have been treated for at least 8 cycles (at least 24 weeks), receiving at least 2 doses of pembrolizumab beyond the date when the initial CR was declared.
- Completed 35 cycles of pembrolizumab
  - Note: 35 treatments (approx. 2 years) are calculated from the first dose. Subjects who stop pembrolizumab after receiving 35 treatments may be eligible for retreatment if they progress after stopping study treatment provided they meet the requirements detailed in Section 7.1.6.2. Subjects may be retreated in the Second Course Phase with up to 17 (approx. 1 year) additional trial treatments.

The End of Treatment and Follow-up visit procedures are listed in Section 7.1.6.3 and the Trial Flow Chart in Section 6.0. After the end of treatment, each subject will be followed for a minimum of 30 days for adverse event monitoring (serious adverse events will be collected for up to 90 days after the end of treatment as described in Section 7.2.3). Subjects who discontinue for reasons other than PD will have post-treatment follow-up for disease status until PD, initiating a non-study cancer treatment, withdrawing consent or becoming lost to follow-up. After documented PD each subject will be followed (e.g. by telephone) for OS until death, withdrawal of consent, or the end of the study, whichever occurs first.

For subjects who are discontinued from treatment but continue to be monitored in the trial, all visits and procedures, as outlined in the trial flowchart, should be completed.

Discontinuation from treatment is “permanent.” Once a subject is discontinued, he/she shall not be allowed to restart treatment unless the conditions in Section 5.8.2 – Discontinuation of Study Therapy after CR are met.

### **5.8.2 Discontinuation of Study Therapy after Complete Response**

Discontinuation of treatment may be considered for subjects who have attained a centrally confirmed CR, and who have received at least 8 cycles (approx. 6 months) of pembrolizumab, and who received at least 2 cycles of pembrolizumab beyond the date when initial CR was declared. Subjects who discontinue pembrolizumab therapy due to CR and then experience radiographic disease progression may be eligible for up to 17 additional

cycles (approx. 1 year) of pembrolizumab in the Second Course Phase, at the discretion of the investigator if:

- No cancer treatment was administered since the last dose of pembrolizumab
- The subject meets the parameters listed in the Inclusion/Exclusion criteria
- The trial is ongoing

Subjects will resume pembrolizumab therapy at the same dose level and on the same schedule at the time of initial discontinuation. Additional details are provided in Section 7.1.6.2. Response or progression in this Second Course Phase will not count towards the primary endpoint in this trial.

### **5.8.3 Withdrawal from the Trial**

A subject must be withdrawn from the trial if the subject or subject's legally acceptable representative withdraws consent from the trial.

If a subject withdraws from the trial, they will no longer receive treatment or be followed at scheduled protocol visits.

Specific details regarding procedures to be performed at the time of withdrawal from the trial including the procedures to be performed should a subject repeatedly fail to return for scheduled visits and/or if the study site is unable to contact the subject, as well as specific details regarding withdrawal from Future Biomedical Research are outlined in Section 7.1.5 – Other Procedures.

### **5.9 Subject Replacement Strategy**

A subject who discontinues from the trial will not be replaced.

### **5.10 Beginning and End of the Trial**

The overall trial begins when the first subject provides documented informed consent. The overall trial ends when the last subject completes the last study-related phone-call or visit, discontinues from the trial or is lost to follow-up (i.e. the subject is unable to be contacted by the investigator).

Upon study completion, participants are discontinued and may be enrolled in a pembrolizumab extension study, if available.

### **5.11 Clinical Criteria for Early Trial Termination**

There are no pre-specified criteria for terminating the trial early.

Early trial termination will be the result of the criteria specified below:

1. Quality or quantity of data recording is inaccurate or incomplete
2. Poor adherence to protocol and regulatory requirements

3. Incidence or severity of adverse drug reaction in this or other studies indicates a potential health hazard to subjects
4. Plans to modify or discontinue the development of the study drug.

In the event of Sponsor decision to no longer supply study drug, ample notification will be provided so that appropriate adjustments to subject treatment can be made.

5. Any medical, safety, regulatory, administrative, or other reasons consistent with applicable laws, regulations, and GCP.

In the event the Sponsor prematurely terminates a particular study site, the Sponsor will promptly notify that study site's IRB/IEC.

## 6.0 TRIAL FLOW CHART

### 6.1 Trial Flow Chart – Initial Treatment Phase for Pembrolizumab Arm

Trial Period:	Screening Phase	Treatment Cycles							End of Treatment	Post-treatment		
		1	2	3	4	5	6	7		Safety Follow-up	Follow Up Visits	Survival Follow-Up <sup>a</sup>
Treatment Cycle/Title:	Screening (Visit 1)								Discon	30 Days Post-discon	Every 9 Weeks Post-discon	Every 9 Weeks
Scheduling Window (Days) <sup>b</sup>	-28 to -1		± 3	± 3	± 3	± 3	± 3	± 3	At time of Discon	± 3	± 7	± 7
<b>Administrative Procedures</b>												
Informed Consent	X											
Informed Consent for Future Biomedical Research (optional)	X											
Inclusion/Exclusion Criteria	X											
Subject Identification Card	X											
Demographics and Medical History	X											
Prior and Concomitant Medication Review	X	X	X	X	X	X	X	X	X	X		
Post-study Anticancer Therapy Status											X	X
<b>Clinical Procedures/Assessments</b>												
Review Adverse Events	X	X	X	X	X	X	X	X	X	X	X	X <sup>c</sup>
Full Physical Examination	X									X		
Directed Physical Examination		X	X	X	X	X	X	X	X			
Height, Weight, and Vital Signs (T,P,RR,BP) <sup>d</sup>	X	X	X	X	X	X	X	X	X			
12-Lead Electrocardiogram (Local)	X											
ECOG Performance Status	X <sup>e</sup>	X	X	X	X	X	X	X	X			
PROs (HRQoL Measures) <sup>f</sup>		X	X	X	X	X	X	X <sup>f</sup>	X	X		
Survival Status			<----->									X

Trial Period:	Screening Phase	Treatment Cycles							End of Treatment	Post-treatment		
		1	2	3	4	5	6	7		Safety Follow-up	Follow Up Visits	Survival Follow-Up <sup>a</sup>
Treatment Cycle/Title:	Screening (Visit 1)								Discon	30 Days Post-discon	Every 9 Weeks Post-discon	Every 9 Weeks
Scheduling Window (Days) <sup>b</sup>	-28 to -1		± 3	± 3	± 3	± 3	± 3	± 3	At time of Discon	± 3	± 7	± 7
<b>Trial Treatment Administration</b>												
Pembrolizumab Administration		X <sup>b</sup>	X	X	X	X	X	X				
<b>Laboratory Procedures/Assessments: Analysis performed by LOCAL laboratory</b>												
Pregnancy Test <sup>g</sup>	X	X	X	X	X	X	X	X		X		
PT/INR and aPTT	X <sup>e</sup>											
CBC with Differential <sup>h</sup>	X <sup>e</sup>		X	X	X	X	X	X	X <sup>h</sup>	X	X	
Chemistry Panel <sup>h</sup>	X <sup>e</sup>	X	X	X	X	X	X	X <sup>h</sup>		X	X	
Urinalysis <sup>h</sup>	X <sup>e</sup>		X		X		X		X <sup>h</sup>	X		
T3, FT4, and TSH <sup>h</sup>	X <sup>e</sup>		X		X		X		X <sup>h</sup>	X	X	
<b>Laboratory Procedures/Assessments: Analysis performed by CENTRAL laboratory</b>												
Pembrolizumab Pharmacokinetics <sup>i</sup>		X <sup>i</sup>	X		X		X		X <sup>i</sup>			
Pembrolizumab Anti-Drug Antibodies (ADA) <sup>i</sup>		X	X		X		X		X <sup>i</sup>			
Blood for Genetics <sup>j</sup>		X										
Whole Blood for Correlative Studies (DNA and RNA) <sup>k</sup>		X	X	X					X			
Whole Blood for Biomarkers Studies (plasma and serum) <sup>k</sup>		X										

Trial Period:	Screening Phase	Treatment Cycles							End of Treatment	Post-treatment		
		1	2	3	4	5	6	7		Safety Follow-up	Follow Up Visits	Survival Follow-Up <sup>a</sup>
Treatment Cycle/Title:	Screening (Visit 1)								Discon	At time of Discon	30 Days Post-discon	Every 9 Weeks Post-discon
<b>Scheduling Window (Days)<sup>b</sup></b>	-28 to -1		± 3	± 3	± 3	± 3	± 3	± 3	± 3	± 3	± 7	± 7
<b>Tumor Tissue Collection</b>												
Newly-Obtained Tumor Tissue <sup>l</sup>	X <sup>l</sup>											
Archival Tumor Tissue <sup>m</sup>	X											
<b>Efficacy Measurements</b>												
Tumor Imaging	X <sup>n</sup>	<-----X <sup>o</sup> ----->						X <sup>p</sup>		X		

- a. After centrally verified PD, or the start of new anticancer treatment; contacts are approximately every 9 weeks by telephone. Updated survival status may be requested by the Sponsor at any time during the course of the study. Upon Sponsor notification, all participants who do not/will not have a scheduled study visit or study contact during the Sponsor defined time period will be contacted for their survival status (excluding participants that have a death event previously recorded).
- b. Cycle 1 treatment must be given within 3 days of allocation. Trial treatment of pembrolizumab (administered on Day 1 of every 21-day [3-week] cycle) may be administered up to 3 days after randomization for Cycle 1 Day 1 due to administrative reasons or if the subject requires premedications. The window for each visit is  $\pm$  3 days unless otherwise noted.
- c. SAEs will be followed through 90 days following cessation of treatment, or 30 days following cessation of treatment if the subject initiates new anticancer therapy, whichever is earlier.
- d. Height will be measured at Visit 1 only.
- e. ECOG Performance Status and Laboratory tests for screening are to be performed within 3 days prior to the first dose of trial treatment.
- f. See Section 7.1.2.6 for details regarding administration of Patient Reported Outcomes (PROs). All PROs are to be performed at Cycle 1, Cycle 2, Cycle 3, Cycle 4, Cycle 5, and Cycle 7. After Cycle 7 (Week 18), PROs are to be performed every 3 cycles (e.g., Week 27, Week 36, Week 45). PROs are to be performed up to a year or End of Treatment, whichever comes first, and the 30-day post-treatment discontinuation follow-up visit. A visit window of  $\pm$  7 days will apply to PRO visit assessment.
- g. For women of reproductive potential, a urine or serum pregnancy test should be performed within 72 hours prior to Day 1 of each treatment cycle and 30 days post treatment. A serum test can be done if urine is not appropriate. Additionally, if urine test is positive or is not evaluable, a serum test is required. Subjects must be excluded/discontinued in the event of positive test results. Pregnancy tests (serum and/or urine tests) should be repeated if required by local guidelines.
- h. Urinalysis and thyroid function tests to be performed every other cycle. CBC (Hematology) and Chemistry to be performed every cycle (excluding Cycle 1 Day 1).
- i. Both PK and Anti-pembrolizumab-antibody Samples: pre-dose (trough) PK and anti-pembrolizumab antibody samples will be collected at within 24 hours before infusion at Cycles 1, 2, 4, 6, 8 and every 4 cycles thereafter.
- j. Detailed instructions for the collection and management of specimens are provided in the Central Lab Manual and in Section 7.1.3 Laboratory Procedure/Assessments.
- k. Whole blood samples for biomarker studies (DNA and RNA) should be collected pre-dose on Day 1 of Cycle 1, Cycle 2, and Cycle 3, and again at treatment discontinuation. Whole blood for correlative studies (plasma and serum) to be collected pre-dose on Day 1 of Cycle 1 only. Leftover samples will be stored for FBR if the subject signs the FBR consent.
- l. Newly-obtained tissue is preferred (no intervening treatment [local or systemic] involving the site of tissue biopsy once tissue biopsy is obtained and time of study enrollment). Formalin-fixed, paraffin-embedded (FFPE) block specimens are preferred to slides.
- m. Archival tumor tissue will also be requested (where available) to assess the clinical utility of immune-related GEP assessment in newly obtained vs. archived tissue samples.
- n. Screening tumor imaging will be performed within 14 days prior to randomization. At sites where the local regulatory body and/or IRB/ERC will not permit a second tumor imaging within a 28-day period, an already available imaging scan obtained within 28 days prior to first dose may be used with the approval of the Sponsor Clinical Director. For all subjects, already available imaging scans performed as part of routine clinical management are acceptable if they are of diagnostic quality and performed within the acceptable timeframe.
- o. The first on-study imaging time point will be performed at 9 weeks (63 days  $\pm$  7 days) calculated from the date of allocation and will continue to be performed Q9W (63 days  $\pm$  7 days), or earlier if clinically indicated. Imaging timing should follow calendar days and should not be adjusted for delays in cycle starts.
- p. In order to follow irRECIST criteria, this protocol requires confirmation of disease progression by repeat imaging  $\geq$  4 weeks from initial disease progression. If a subject is discontinued from study therapy prior to PD being confirmed at the site then that subject should have tumor imaging performed at the time of treatment discontinuation. If previous tumor imaging was obtained within 4 weeks prior to the date of discontinuation, then additional tumor imaging at treatment discontinuation is not required.

## 6.2 Trial Flow Chart –Treatment Phase for Paclitaxel

Trial Period:	Screening Phase	Treatment Cycles										End of Treatment	Post-treatment		
		1			2			3 and Beyond			Discon	Safety Follow-up	Follow Up Visits	Survival Follow-Up <sup>a</sup>	
Treatment Cycle/Title:	Screening (Visit 1)	Day 1	Day 8	Day 15	Day 1	Day 8	Day 15	Day 1	Day 8	Day 15	At time of Discon	30 Days Post-discon	Every 9 Weeks Post-discon	Every 9 Weeks	
Scheduling Window (Days) <sup>b</sup>	-28 to -1	± 3	± 3	± 3	± 3	± 3	± 3	± 3	± 3	± 3	± 3	± 7	± 7	± 7	
<b>Administrative Procedures</b>															
Informed Consent	X														
Informed Consent for Future Biomedical Research (optional)	X														
Inclusion/Exclusion Criteria	X														
Subject Identification Card	X														
Demographics and Medical History	X														
Prior and Concomitant Medication Review	X	X	X	X	X	X	X	X	X	X	X	X			
Post-study Anticancer Therapy Status													X	X	
<b>Clinical Procedures/Assessments</b>															
Review Adverse Events	X	X	X	X	X	X	X	X	X	X	X	X	X	X <sup>c</sup>	
Full Physical Examination	X											X			
Directed Physical Examination		X			X			X							
Height, Weight, and Vital Signs (T,P,RR,BP) <sup>d</sup>	X	X	X	X	X	X	X	X	X	X	X				
12-Lead Electrocardiogram (Local)	X														
ECOG Performance Status	X <sup>e</sup>	X			X			X			X				
PROs (HRQoL Measures) <sup>f</sup>		<-----X <sup>f</sup> ----->								X	X				

Trial Period:	Screening Phase	Treatment Cycles									End of Treatment	Post-treatment		
		1			2			3 and Beyond				Safety Follow-up	Follow Up Visits	Survival Follow-Up <sup>a</sup>
		Day 1	Day 8	Day 15	Day 1	Day 8	Day 15	Day 1	Day 8	Day 15	At time of Discon	30 Days Post-discon	Every 9 Weeks Post-discon	Every 9 Weeks
<b>Scheduling Window (Days)<sup>b</sup></b>	-28 to -1	± 3	± 3	± 3	± 3	± 3	± 3	± 3	± 3	± 3	± 3	± 7	± 7	± 7
Survival Status		<----->											X	
<b>Trial Treatment Administration</b>														
Paclitaxel Administration		X <sup>b</sup>	X	X	X	X	X	X	X	X				
<b>Laboratory Procedures/Assessments:</b> <b>Analysis performed by LOCAL laboratory</b>														
Pregnancy Test <sup>g</sup>	X	X			X			X			X			
PT/INR and aPTT	X <sup>e</sup>													
CBC with Differential <sup>h</sup>	X <sup>e</sup>				X			X <sup>h</sup>			X	X		
Chemistry Panel <sup>h</sup>	X <sup>e</sup>				X			X <sup>h</sup>			X	X		
Urinalysis <sup>h</sup>	X <sup>e</sup>				X			X <sup>h</sup>			X			
T3, FT4, and TSH <sup>h</sup>	X <sup>e</sup>				X			X <sup>h</sup>			X	X		
<b>Laboratory Procedures/Assessments:</b> <b>Analysis performed by CENTRAL laboratory</b>														
Blood for Genetics <sup>i</sup>		X												
Whole Blood for Correlative Studies (DNA and RNA) <sup>j</sup>		X			X			X <sup>j</sup>			X			
Whole Blood for Biomarkers Studies (plasma and serum) <sup>j</sup>		X												

Trial Period:	Screening Phase	Treatment Cycles									End of Treatment	Post-treatment		
		1			2			3 and Beyond				Safety Follow-up	Follow Up Visits	Survival Follow-Up <sup>a</sup>
		Day 1	Day 8	Day 15	Day 1	Day 8	Day 15	Day 1	Day 8	Day 15	At time of Discon	30 Days Post-discon	Every 9 Weeks Post-discon	Every 9 Weeks
<b>Scheduling Window (Days)<sup>b</sup></b>	-28 to -1	± 3	± 3	± 3	± 3	± 3	± 3	± 3	± 3	± 3	± 3	± 7	± 7	± 7
<b>Tumor Tissue Collection</b>														
Newly-Obtained Tumor Tissue <sup>k</sup>	X													
Archival Tumor Tissue <sup>l</sup>	X													
<b>Efficacy Measurements</b>														
Tumor Imaging	X <sup>m</sup>	<-----X <sup>n</sup> ----->									X		X	

- a. After centrally verified PD, or the start of new anticancer treatment; contacts are approximately every 9 weeks by telephone. Updated survival status may be requested by the Sponsor at any time during the course of the study. Upon Sponsor notification, all participants who do not/will not have a scheduled study visit or study contact during the Sponsor defined time period will be contacted for their survival status (excluding participants that have a death event previously recorded).
- b. Cycle 1 treatment must be given within 3 days of allocation. Trial treatment of paclitaxel (administered on Days 1, 8, and 15 of every 28-day [4-week] cycle) may be administered up to 3 days after randomization for Cycle 1 Day 1 due to administrative reasons or if the subject requires premedications. The required premedications should be administered as close to randomization as possible. After Cycle 1 there is a 3 day window for all trial treatment. The window for each visit is  $\pm$  3 days unless otherwise noted.
- c. SAEs will be followed through 90 days following cessation of treatment, or 30 days following cessation of treatment if the subject initiates new anticancer therapy, whichever is earlier.
- d. Height will be measured at Visit 1 only.
- e. Laboratory tests for screening and ECOG performance status are to be performed within 3 days prior to the first dose of trial treatment.
- f. See Section 7.1.2.6 for details regarding administration of Patient Reported Outcomes (PROs). All PROs are to be performed prior to Cycle 1-Day 1, Cycle 2-Day 1, Cycle 2-Day 15, Cycle 3-Day 8, Cycle 4-Day 1, Cycle 5-Day 15, Cycle 7-Day 22, Cycle 10-Day 1, and Cycle 12-Day 8. PROs are to be performed up to a year or End of Treatment, whichever comes first, and the 30-day post-treatment discontinuation follow-up visit. A visit window of  $\pm$  7 days will apply to PRO visit assessment.
- g. For women of reproductive potential, a urine or serum pregnancy test should be performed within 72 hours prior to Day 1 of each treatment cycle and 30 days post treatment. A serum test can be done if urine is not appropriate. Additionally, if urine test is positive or is not evaluable, a serum test is required. Subjects must be excluded/discontinued in the event of positive test results. Pregnancy tests (serum and/or urine tests) should be repeated if required by local guidelines.
- h. Urinalysis and Thyroid function tests are performed Day 1 of every other cycle (more testing is allowed if required per local guidance/regulation). CBC (Hematology) and Chemistry to be performed on Day 1 of every cycle (excluding Cycle 1 Day 1) (more testing is allowed if required per local guidance/regulation).
- i. Detailed instructions for the collection and management of specimens are provided in the central laboratory manual and in Section 7.1.3 Laboratory Procedure/Assessments.
- j. Whole blood samples for correlative studies (DNA and RNA) should be collected pre-dose on Day 1 of Cycle 1, Cycle 2, and Cycle 3, and again at treatment discontinuation. Whole blood for correlative studies (plasma and serum) to be collected pre-dose on Day 1 of Cycle 1 only. Leftover samples will be stored for FBR if the subject signs the FBR consent
- k. Newly-obtained tissue is preferred (no intervening treatment [local or systemic] involving the site of tissue biopsy once tissue biopsy is obtained and time of study enrollment). Formalin-fixed, paraffin-embedded (FFPE) block specimens are preferred to slides.
- l. Archival tumor tissue will also be requested (where available) to assess the clinical utility of immune-related GEP assessment in newly obtained vs. archived tissue samples.
- m. Screening tumor imaging will be performed within 14 days prior to randomization. At sites where the local regulatory body and/or IRB/ERC will not permit a second tumor imaging within a 28-day period, an already available imaging scan obtained within 28 days prior to first dose may be used with the approval of the Sponsor Clinical Director. For all subjects, already available imaging scans performed as part of routine clinical management are acceptable if they are of diagnostic quality and performed within the acceptable timeframe.
- n. The first on-study imaging time point will be performed at 9 weeks (63 days  $\pm$  7 days) calculated from the date of allocation and will continue to be performed Q9W (63 days  $\pm$  7 days), or earlier if clinically indicated. Imaging timing should follow calendar days and should not be adjusted for delays in cycle starts.

### 6.3 Trial Flow Chart –Treatment Phase for Docetaxel

Trial Period:	Screening Phase	Treatment Cycles							End of Treatment	Post-treatment		
		1	2	3	4	5	6	7		Safety Follow-up	Follow Up Visits	Survival Follow-Up <sup>a</sup>
Treatment Cycle/Title:	Screening (Visit 1)								Discon	30 Days Post-discon	Every 9 Weeks Post-discon	Every 9 Weeks
Scheduling Window (Days) <sup>b</sup>	-28 to -1		+3	± 3	± 3	± 3	± 3	± 3	At time of Discon	± 7	± 7	± 7
<b>Administrative Procedures</b>												
Informed Consent	X											
Informed Consent for Future Biomedical Research (optional)	X											
Inclusion/Exclusion Criteria	X											
Subject Identification Card	X											
Demographics and Medical History	X											
Prior and Concomitant Medication Review	X	X	X	X	X	X	X	X	X	X		
Post-study Anticancer Therapy Status											X	X
<b>Clinical Procedures/Assessments</b>												
Review Adverse Events	X	X	X	X	X	X	X	X	X	X	X	X <sup>c</sup>
Full Physical Examination	X									X		
Directed Physical Examination		X	X	X	X	X	X	X				
Height, Weight, and Vital Signs (T,P,RR,BP) <sup>d</sup>	X	X	X	X	X	X	X	X	X			
12-Lead Electrocardiogram (Local)	X											
ECOG Performance Status	X <sup>e</sup>	X	X	X	X	X	X	X	X			
PROs (HRQoL Measures) <sup>f</sup>		X	X	X	X	X		X	X	X		
Survival Status												X
									<----->			

Trial Period:	Screening Phase	Treatment Cycles							End of Treatment	Post-treatment		
		1	2	3	4	5	6	7		Safety Follow-up	Follow Up Visits	Survival Follow-Up <sup>a</sup>
Treatment Cycle/Title:	Screening (Visit 1)								Discon	At time of Discon	30 Days Post-discon	Every 9 Weeks Post-discon
Scheduling Window (Days) <sup>b</sup>	-28 to -1		<u>±3</u>	3	3	3	3	3	± 3	± 3	± 7	± 7
<b>Trial Treatment Administration</b>												
Docetaxel Administration		X <sup>b</sup>	X	X	X	X	X	X	X			
<b>Laboratory Procedures/Assessments: Analysis performed by LOCAL laboratory</b>												
Pregnancy Test <sup>g</sup>	X	X	X	X	X	X	X	X	X		X	
PT/INR and aPTT	X <sup>e</sup>											
CBC with Differential <sup>h</sup>	X <sup>e</sup>		X	X	X	X	X	X	X <sup>h</sup>	X	X	
Chemistry Panel <sup>h</sup>	X <sup>e</sup>		X	X	X	X	X	X	X <sup>h</sup>	X	X	
Urinalysis <sup>h</sup>	X <sup>e</sup>		X		X		X		X <sup>h</sup>	X		
T3, FT4, and TSH <sup>h</sup>	X <sup>e</sup>		X		X		X		X <sup>h</sup>	X	X	
<b>Laboratory Procedures/Assessments: Analysis performed by CENTRAL laboratory</b>												
Blood for Genetics <sup>i</sup>		X										
Whole Blood for Correlative Studies (DNA and RNA) <sup>j</sup>		X	X	X					X			
Whole Blood for Biomarkers Studies (plasma and serum) <sup>j</sup>		X										
<b>Tumor Tissue Collection</b>												
Newly-Obtained Tumor Tissue <sup>k</sup>	X											
Archival Tumor Tissue <sup>l</sup>	X											
<b>Efficacy Measurements</b>												
Tumor Imaging	X <sup>m</sup>	<-----X <sup>n</sup> ----->						X		X		

- a. After centrally verified PD, or the start of new anticancer treatment; contacts are approximately every 9 weeks by telephone. Updated survival status may be requested by the Sponsor at any time during the course of the study. Upon Sponsor notification, all participants who do not/will not have a scheduled study visit or study contact during the Sponsor defined time period will be contacted for their survival status (excluding participants that have a death event previously recorded).
- b. Cycle 1 treatment must be given within 3 days of allocation. Trial treatment of docetaxel (administered on Days 1 of every 21-day [3-week] cycle) may be administered up to 3 days after randomization for Cycle 1 Day 1 due to administrative reasons or if the subject requires premedications. The required premedication should be administered as close to randomization as possible. After Cycle 1 there is a 3 day window for all trial treatment. The window for each visit is  $\pm$  3 days unless otherwise noted.
- c. SAEs will be followed through 90 days following cessation of treatment, or 30 days following cessation of treatment if the subject initiates new anticancer therapy, whichever is earlier.
- d. Height will be measured at Visit 1 only.
- e. Laboratory tests for screening and ECOG performance status are to be performed within 3 days prior to the first dose of trial treatment.
- f. See Section 7.1.2.6 for details regarding administration of Patient Reported Outcomes (PROs). All PROs are to be performed at Cycle 1, Cycle 2, Cycle 3, Cycle 4, Cycle 5, and Cycle 7. After Cycle 7 (Week 18), PROs are to be performed every 3 cycles (e.g., Week 27, Week 36, Week 45). PROs are to be performed up to a year or End of Treatment, whichever comes first, and the 30-day post-treatment discontinuation follow-up visit. A visit window of  $\pm$  7 days will apply to PRO visit assessment.
- g. For women of reproductive potential, a urine or serum pregnancy test should be performed within 72 hours prior to Day 1 of each treatment cycle and 30 days post treatment. A serum test can be done if urine is not appropriate. Additionally, if urine test is positive or is not evaluable, a serum test is required. Subjects must be excluded/discontinued in the event of positive test results. Pregnancy tests (serum and/or urine tests) should be repeated if required by local guidelines.
- h. Urinalysis and thyroid function tests to be performed every other cycle. CBC (Hematology) and Chemistry to be performed every cycle (excluding Cycle 1 Day 1).
- i. Detailed instructions for the collection and management of specimens are provided in the central laboratory manual and in Section 7.1.3 Laboratory Procedure/Assessments.
- j. Whole blood samples for biomarker studies (DNA and RNA) should be collected pre-dose on Day 1 of Cycle 1, Cycle 2, and Cycle 3, and again at treatment discontinuation. Whole blood for correlative studies (plasma and serum) to be collected pre-dose on Day 1 of Cycle 1 only. Leftover samples will be stored for FBR if the subject signs the FBR consent.
- k. Newly-obtained tissue is preferred (no intervening treatment [local or systemic] involving the site of tissue biopsy once tissue biopsy is obtained and time of study enrollment). Formalin-fixed, paraffin-embedded (FFPE) block specimens are preferred to slides.
- l. Archival tumor tissue will also be requested (where available) to assess the clinical utility of immune-related GEP assessment in newly obtained vs. archived tissue samples.
- m. Screening tumor imaging will be performed within 14 days prior to randomization. At sites where the local regulatory body and/or IRB/ERC will not permit a second tumor imaging within a 28-day period, an already available imaging scan obtained within 28 days prior to first dose may be used with the approval of the Sponsor Clinical Director. For all subjects, already available imaging scans performed as part of routine clinical management are acceptable if they are of diagnostic quality and performed within the acceptable timeframe for each cohort.
- n. The first on-study imaging time point will be performed at 9 weeks (63 days  $\pm$  7 days) calculated from the date of allocation and will continue to be performed Q9W (63 days  $\pm$  7 days), or earlier if clinically indicated. Imaging timing should follow calendar days and should not be adjusted for delays in cycle starts.

## 6.4 Trial Flow Chart –Treatment Phase for Irinotecan

Trial Period:	Screening Phase	Treatment Cycles							End of Treatment	Post-treatment			
		1	2	3	4	5	6	7		Discon	Safety Follow-up	Follow Up Visits	Survival Follow-Up <sup>a</sup>
Treatment Cycle/Title:	Screening (Visit 1)									At time of Discon	30 Days Post-discon	Every 9 Weeks Post-discon	Every 9 Weeks
<b>Scheduling Window (Days)<sup>b</sup></b>	-28 to -1		± 3	± 3	± 3	± 3	± 3	± 3	± 3	± 3	± 7	± 7	± 7
<b>Administrative Procedures</b>													
Informed Consent	X												
Informed Consent for Future Biomedical Research (optional)	X												
Inclusion/Exclusion Criteria	X												
Subject Identification Card	X												
Demographics and Medical History	X												
Prior and Concomitant Medication Review	X	X	X	X	X	X	X	X	X	X	X		
Post-study Anticancer Therapy Status												X	X
<b>Clinical Procedures/Assessments</b>													
Review Adverse Events	X	X	X	X	X	X	X	X	X	X	X	X <sup>c</sup>	
Full Physical Examination	X									X			
Directed Physical Examination		X	X	X	X	X	X	X	X				
Height, Weight, and Vital Signs (T,P,RR,BP) <sup>d</sup>	X	X	X	X	X	X	X	X	X	X			
12-Lead Electrocardiogram (Local)	X												
ECOG Performance Status	X <sup>e</sup>	X	X	X	X	X	X	X	X	X			
PROs (HRQoL Measures) <sup>f</sup>		<-----X <sup>f</sup> ----->							X	X			
Survival Status		<----->											X

Trial Period:	Screening Phase	Treatment Cycles							End of Treatment	Post-treatment			
		1	2	3	4	5	6	7		Discon	Safety Follow-up	Follow Up Visits	Survival Follow-Up <sup>a</sup>
Treatment Cycle/Title:	Screening (Visit 1)								At time of Discon	30 Days Post-discon	Every 9 Weeks Post-discon	Every 9 Weeks	
<b>Scheduling Window (Days)<sup>b</sup></b>	-28 to -1		± 3	± 3	± 3	± 3	± 3	± 3	± 3	± 3	± 7	± 7	± 7
<b>Trial Treatment Administration</b>													
Irinotecan Administration		X <sup>b</sup>	X	X	X	X	X	X	X				
<b>Laboratory Procedures/Assessments: Analysis performed by LOCAL laboratory</b>													
Pregnancy Test <sup>g</sup>	X	X	X	X	X	X	X	X	X		X		
PT/INR and aPTT	X <sup>e</sup>												
CBC with Differential <sup>h</sup>	X <sup>e</sup>		X	X	X	X	X	X	X <sup>h</sup>	X	X		
Chemistry Panel <sup>h</sup>	X <sup>e</sup>		X	X	X	X	X	X	X <sup>h</sup>	X	X		
Urinalysis <sup>h</sup>	X <sup>e</sup>		X		X		X		X <sup>h</sup>	X			
T3, FT4, and TSH <sup>h</sup>	X <sup>e</sup>		X		X		X		X <sup>h</sup>	X	X		
UGT1A1*28 allele	X												
<b>Laboratory Procedures/Assessments: Analysis performed by CENTRAL laboratory</b>													
Blood for Genetics <sup>i</sup>		X											
Whole Blood for Correlative Studies (DNA and RNA) <sup>j</sup>		X	X	X					X				
Whole Blood for Biomarkers Studies (plasma and serum) <sup>j</sup>		X											

Trial Period:	Screening Phase	Treatment Cycles							End of Treatment	Post-treatment			
		1	2	3	4	5	6	7		Discon	Safety Follow-up	Follow Up Visits	Survival Follow-Up <sup>a</sup>
Treatment Cycle/Title:	Screening (Visit 1)									At time of Discon	30 Days Post-discon	Every 9 Weeks Post-discon	Every 9 Weeks
<b>Scheduling Window (Days)<sup>b</sup></b>	-28 to -1		± 3	± 3	± 3	± 3	± 3	± 3	± 3	± 3	± 7	± 7	± 7
<b>Tumor Tissue Collection</b>													
Newly-Obtained Tumor Tissue <sup>k</sup>	X												
Archival Tumor Tissue <sup>l</sup>	X												
<b>Efficacy Measurements</b>													
Tumor Imaging	X <sup>m</sup>	<-----X <sup>n</sup> ----->							X		X		

- a. After centrally verified PD, or the start of new anticancer treatment; contacts are approximately every 9 weeks by telephone. Updated survival status may be requested by the Sponsor at any time during the course of the study. Upon Sponsor notification, all participants who do not/will not have a scheduled study visit or study contact during the Sponsor defined time period will be contacted for their survival status (excluding participants that have a death event previously recorded).
- b. Cycle 1 treatment must be given within 3 days of allocation. Trial treatment of irinotecan (administered on Days 1 of every 14-day [2-week] cycle) may be administered up to 3 days after randomization for Cycle 1 Day 1 due to administrative reasons or if the subject requires premedications. The required premedications should be administered as close to randomization as possible. After Cycle 1 there is a 3 day window for all trial treatment. The window for each visit is  $\pm$  3 days unless otherwise noted.
- c. SAEs will be followed through 90 days following cessation of treatment, or 30 days following cessation of treatment if the subject initiates new anticancer therapy, whichever is earlier.
- d. Height will be measured at Visit 1 only.
- e. Laboratory tests for screening and ECOG performance status are to be performed within 3 days prior to the first dose of trial treatment.
- f. See Section 7.1.2.6 for details regarding administration of Patient Reported Outcomes (PROs). All PROs are to be performed prior to Cycle 1-Day 1, Cycle 2-Day 1, Cycle 4-Day 1, Cycle 5-Day 8, Cycle 7-Day 1, Cycle 10-Day 1, Cycle 14-Day 8, Cycle 19-Day 1, and Cycle 23-Day 8. PROs are to be performed up to a year or End of Treatment, whichever comes first, and the 30-day post-treatment discontinuation follow-up visit. A visit window of  $\pm$  7 days will apply to PRO visit assessment.
- g. For women of reproductive potential, a urine or serum pregnancy test should be performed within 72 hours prior to Day 1 of each treatment cycle and 30 days post treatment. A serum test can be done if urine is not appropriate. Additionally, if urine test is positive or is not evaluable, a serum test is required. Subjects must be excluded/discontinued in the event of positive test results. Pregnancy tests (serum and/or urine tests) should be repeated if required by local guidelines.
- h. Urinalysis and thyroid function tests to be performed every other cycle. CBC (Hematology) and Chemistry to be performed every cycle (excluding Cycle 1 Day 1).
- i. Detailed instructions for the collection and management of specimens are provided in the central laboratory manual and in Section 7.1.3 Laboratory Procedure/Assessments.
- j. Whole blood samples for biomarkers studies (DNA and RNA) should be collected pre-dose on Day 1 of Cycle 1, Cycle 2, and Cycle 3, and again at treatment discontinuation. Whole blood for correlative studies (plasma and serum) to be collected pre-dose on Day 1 of Cycle 1 only. Leftover samples will be stored for FBR if the subject signs the FBR consent.
- k. Newly-obtained tissue is preferred (no intervening treatment [local or systemic] involving the site of tissue biopsy once tissue biopsy is obtained and time of study enrollment). Formalin-fixed, paraffin-embedded (FFPE) block specimens are preferred to slides.
- l. Archival tumor tissue will also be requested (where available) to assess the clinical utility of immune-related GEP assessment in newly obtained vs. archived tissue samples.
- m. Screening tumor imaging will be performed within 14 days prior to randomization. At sites where the local regulatory body and/or IRB/ERC will not permit a second tumor imaging within a 28-day period, an already available imaging scan obtained within 28 days prior to first dose may be used with the approval of the Sponsor Clinical Director. For all subjects, already available imaging scans performed as part of routine clinical management are acceptable if they are of diagnostic quality and performed within the acceptable timeframe for each cohort.
- n. The first on-study imaging time point will be performed at 9 weeks (63 days  $\pm$  7 days) calculated from the date of allocation and will continue to be performed Q9W (63 days  $\pm$  7 days), or earlier if clinically indicated. Imaging timing should follow calendar days and should not be adjusted for delays in cycle starts.

## 6.5 Second Course Phase (Retreatment with Pembrolizumab)

Trial Period:	Treatment Cycles								End of Treatment	Post-treatment		
	1	2	3	4	5	6	7	8 - 17		Safety Follow-up	Follow Up Visits	Survival Follow-Up <sup>a</sup>
Treatment Cycle/Title:									At time of Discon	30 Days Post-discon	Every 9 Weeks Post-discon	Every 9 Weeks
Scheduling Window (Days) <sup>b</sup>		± 3	± 3	± 3	± 3	± 3	± 3	± 3	± 3	± 7	± 7	± 7
<b>Administrative Procedures</b>												
Eligibility Criteria	X											
Concomitant Medication Review	X	X	X	X	X	X	X	X	X	X		
Post-study anticancer Therapy Status											X	X
<b>Clinical Procedures/Assessments</b>												
Review Adverse Events	X	X	X	X	X	X	X	X	X	X	X <sup>c</sup>	
Full Physical Examination	X								X			
Directed Physical Examination		X	X	X	X	X	X	X				
Weight, and Vital Signs (T,P,RR,BP)	X	X	X	X	X	X	X	X	X			
ECOG Performance Status	X	X	X	X	X	X	X	X	X			
Survival Status		<----->									X	
<b>Trial Treatment Administration</b>												
Pembrolizumab	X	X	X	X	X	X	X	X				
<b>LOCAL Laboratory Assessments</b>												
Pregnancy Test <sup>d</sup>	X	X	X	X	X	X	X	X		X		
PT/INR and aPTT	X <sup>e</sup>											
CBC with Differential <sup>f</sup>	X <sup>e</sup>	X	X	X	X	X	X	X <sup>f</sup>	X	X		
Chemistry Panel <sup>f</sup>	X <sup>e</sup>	X	X	X	X	X	X	X <sup>f</sup>	X	X		
Urinalysis <sup>f</sup>	X <sup>e</sup>		X		X		X	X <sup>f</sup>		X		
T3, FT4, and TSH <sup>f</sup>	X <sup>e</sup>		X		X		X	X <sup>f</sup>	X	X		

Trial Period:	Treatment Cycles							End of Treatment	Post-treatment		
	1	2	3	4	5	6	7		Safety Follow-up	Follow Up Visits	Survival Follow-Up <sup>a</sup>
Treatment Cycle/Title:								Discon	30 Days Post-discon	Every 9 Weeks Post-discon	Every 9 Weeks
Scheduling Window (Days) <sup>b</sup>	± 3	± 3	± 3	± 3	± 3	± 3	± 3	± 3	± 7	± 7	± 7
<b>Efficacy Measurements</b>											
Tumor Imaging	<----- X <sup>g</sup> ----->							X <sup>h</sup>		X	
<p>a. After the start of new anti-cancer treatment or PD contacts are approximately every 9 weeks by telephone. Updated survival status may be requested by the Sponsor at any time during the course of the study. Upon Sponsor notification, all participants who do not/will not have a scheduled study visit or study contact during the Sponsor defined time period will be contacted for their survival status (excluding participants that have a death event previously recorded).</p> <p>b. In general, the window for each visit is ± 3 days unless otherwise noted.</p> <p>c. SAEs will be followed through 90 days following cessation of treatment, or 30 days following cessation of treatment if the subject initiates new anticancer therapy, whichever is earlier.</p> <p>d. For women of reproductive potential, a urine or serum pregnancy test should be performed within 72 hours prior to Day 1 of each treatment cycle and 30 days post treatment. A serum test can be done if urine is not appropriate. Additionally, if urine test is positive or is not evaluable, a serum test is required. Subjects must be excluded/discontinued in the event of positive test results. Pregnancy tests (serum and/or urine tests) should be repeated if required by local guidelines.</p> <p>e. Laboratory tests for determining eligibility are to be performed within 3 days prior to the first retreatment dose of pembrolizumab.</p> <p>f. Urinalysis and thyroid function tests to be performed every other cycle. CBC (Hematology) and Chemistry to be performed every cycle (excluding Cycle 1 Day 1).</p> <p>g. Tumor imaging should be performed within 14 days prior to restarting treatment with pembrolizumab and continue to be performed every 9 weeks (63 ± 7 days) after the first dose of retreatment, or more frequently if clinically indicated. Imaging timing should follow calendar days and should not be adjusted for delays in cycle starts. At sites where the local regulatory body and/or IRB/ERC will not permit a second tumor imaging within a 28-day period, an already available imaging scan obtained within 28 days prior to first dose may be used with the approval of the Sponsor Clinical Director. For all subjects, already available imaging scans performed as part of routine clinical management are acceptable if they are of diagnostic quality and performed within the acceptable timeframe for each cohort.</p> <p>h. Tumor imaging should be performed at the time of treatment discontinuation (i.e., date of discontinuation ± 4 week window). If previous tumor imaging was obtained within 4 weeks prior to the date of discontinuation, then additional tumor imaging at treatment discontinuation isn't mandatory.</p>											

## **7.0 TRIAL PROCEDURES**

### **7.1 Trial Procedures**

The Trial Flow Chart - Section 6.0 summarizes the trial procedures to be performed at each visit. Individual trial procedures are described in detail below. It may be necessary to perform these procedures at unscheduled time points if deemed clinically necessary by the investigator.

Furthermore, additional evaluations/testing may be deemed necessary by the investigator and or the Sponsor for reasons related to subject safety. In some cases, such evaluation/testing may be potentially sensitive in nature (e.g., HIV, Hepatitis C, etc.), and thus local regulations may require that additional informed consent be obtained from the subject. In these cases, such evaluations/testing will be performed in accordance with those regulations.

#### **7.1.1 Administrative Procedures**

##### **7.1.1.1 Informed Consent**

The investigator or qualified designee must obtain documented consent from each potential subject or each subject's legally acceptable representative prior to participating in a clinical trial or Future Biomedical Research.

###### **7.1.1.1.1 General Informed Consent**

Consent must be documented by the subject's dated signature or by the subject's legally acceptable representative's dated signature on a consent form along with the dated signature of the person conducting the consent discussion.

A copy of the signed and dated consent form should be given to the subject before participation in the trial.

The initial informed consent form, any subsequent revised written informed consent form and any written information provided to the subject must receive the IRB/ERC's approval/favorable opinion in advance of use. The subject or his/her legally acceptable representative should be informed in a timely manner if new information becomes available that may be relevant to the subject's willingness to continue participation in the trial. The communication of this information will be provided and documented via a revised consent form or addendum to the original consent form that captures the subject's dated signature or by the subject's legally acceptable representative's dated signature.

Specifics about a trial and the trial population will be added to the consent form template at the protocol level.

The informed consent will adhere to IRB/ERC requirements, applicable laws and regulations and Sponsor requirements.

#### **7.1.1.1.2 Consent and Collection of Specimens for Future Biomedical Research**

The investigator or qualified designee will explain the Future Biomedical Research consent to the subject, answer all of his/her questions, and obtain documented informed consent before performing any procedure related to the Future Biomedical Research sub-trial. A copy of the informed consent will be given to the subject.

#### **7.1.1.2 Inclusion/Exclusion Criteria**

All inclusion and exclusion criteria will be reviewed by the investigator or qualified designee to ensure that the subject qualifies for the trial.

#### **7.1.1.3 Subject Identification Card**

All subjects will be given a Subject Identification Card identifying them as participants in a research trial. The card will contain trial site contact information (including direct telephone numbers) to be utilized in the event of an emergency. The investigator or qualified designee will provide the subject with a Subject Identification Card immediately after the subject provides documented informed consent.

The subject identification card also contains contact information for the emergency unblinding call center so that a health care provider can obtain information about trial medication/vaccination in emergency situations where the investigator is not available.

#### **7.1.1.4 Medical History**

A medical history will be obtained by the investigator or qualified designee. Medical history will include all active conditions, and any condition diagnosed within the prior 10 years that are considered to be clinically significant by the investigator. Disease details regarding the subject's esophageal cancer will be recorded separately and not listed as medical history.

If the subject has lost at least 15 lbs. (6.8 kg.) over the three months prior to screening, "weight loss" should be entered as an active condition on the Medical History. As well, any autoimmune disorders, regardless of onset date, should be recorded.

#### **7.1.1.5 Disease Details**

The investigator or qualified designee will obtain prior and current details regarding the subject's esophageal carcinoma.

#### **7.1.1.6 Prior and Concomitant Medications Review**

##### **7.1.1.6.1 Prior Medications**

The investigator or qualified designee will review prior medication use, including any protocol-specified washout requirement, and record prior medication taken by the subject within 30 days of the first dose of trial treatment.

Prior treatment for esophageal carcinoma will be recorded separately and not listed as a prior medication.

#### **7.1.1.6.1.1 Prior Treatment Details for Esophageal or EGJ Carcinoma**

The investigator or qualified designee will review all prior anti-cancer treatments including systemic treatments, radiation and surgeries.

#### **7.1.1.6.2 Concomitant Medications**

The investigator or qualified designee will record medication, if any, taken by the subject during the trial from the time of signing the informed consent form until the Safety Follow-up Visit. In addition, new medications started during the Second Course Phase through the Second Course Safety Follow-up Visit should be recorded.

All medications related to reportable SAEs and ECIs should be recorded as defined in Section 7.2

#### **7.1.1.6.3 Subsequent Anti-Cancer Therapy Status**

The investigator or qualified designee will review all new anti-cancer therapy initiated after the last dose of trial treatment. If a subject initiates a new anti-cancer therapy within 30 days after the last dose of trial treatment, the 30 day Safety Follow-up visit must occur before the first dose of the new therapy.

Once new anti-cancer therapy has been initiated the subject will move into survival follow-up. Details regarding survival status follow-up are outlined in Section 7.1.6.3.3 – Survival Follow Up.

#### **7.1.1.7 Assignment of Screening Number**

All consented subjects will be given a unique screening number that will be used to identify the subject for all procedures that occur prior to randomization or treatment allocation. Each subject will be assigned only one screening number. Screening numbers must not be re-used for different subjects.

#### **7.1.1.8 Assignment of Treatment/Randomization Number**

All eligible subjects will be randomly allocated and will receive a treatment/randomization number. The treatment/randomization number identifies the subject for all procedures occurring after treatment allocation/randomization. Once a treatment/randomization number is assigned to a subject, it can never be re-assigned to another subject.

A single subject cannot be assigned more than 1 treatment/randomization number.

Subjects who undergo Second Course Therapy with pembrolizumab will maintain the treatment/randomization number assigned at the beginning of First Course Therapy.

In a situation where rerandomization of the subjects is planned (eg, study extension periods), the rerandomization will be based on a new randomization schedule; however, each subject will retain his/her original treatment/randomization number. Only the study intervention regimen associated with the rerandomization period or phase may change.

### **7.1.1.9 Trial Compliance (Medication/Diet/Activity/Other)**

Interruptions from the protocol specified treatment plan for greater than 12 weeks between pembrolizumab, docetaxel, paclitaxel or irinotecan doses for non-drug-related or administrative reasons require consultation between the investigator and the Sponsor and written documentation of the collaborative decision on subject management.

The total volume of pembrolizumab infused will be compared to the total volume prepared to determine compliance with each dose of pembrolizumab administered. The instructions for preparing and administering pembrolizumab are provided in the Pharmacy Manual. Preparation and administration of paclitaxel, docetaxel, or irinotecan should be completed as per the approved product label.

Administration of trial medication will be witnessed by the investigator and/or trial staff.

## **7.1.2 Clinical Procedures/Assessments**

### **7.1.2.1 Adverse Event Monitoring**

The investigator or qualified designee will assess each subject to evaluate for potential new or worsening AEs as specified in the Trial Flow Chart and more frequently if clinically indicated. Adverse events will be graded and recorded throughout the trial and during the follow-up period according to NCI CTCAE Version 4.0 (see Section 12.6). Toxicities will be characterized for seriousness, causality, toxicity grading, and action taken with regard to trial treatment.

All AEs of unknown etiology associated with pembrolizumab exposure should be evaluated to determine if it is possibly an event of a potentially immunologic etiology; see Section 5.6.1.

Refer to Section 7.2 for detailed information regarding the assessment and recording of AEs.

### **7.1.2.2 Physical Exam**

#### **7.1.2.2.1 Full Physical Exam**

The investigator or clinical designee will perform a complete physical exam (PE) during the screening period. A complete physical examination is a comprehensive inspection of a patient's general appearance, HEENT, neck, chest and lungs, cardiovascular system, abdomen, genitourinary system, musculoskeletal system, lymph nodes, extremities, and neurological system by reviewing history, palpation, percussion, and auscultation. Clinically significant abnormal findings should be recorded as medical history. Additional full physical exams should be performed as specified in the Trial Flow Chart-Section 6. After the first

dose of trial treatment new clinically significant abnormal findings should be recorded as AEs.

#### **7.1.2.2.2 Directed Physical Exam**

For cycles that do not require a full physical exam per the Trial Flow Chart-Section 6, the investigator or qualified designee will perform a directed physical exam as clinically indicated prior to dosing on Day 1 of each treatment cycle. New clinically significant abnormal findings should be recorded as AEs.

#### **7.1.2.3 Height, Weight, and Vital Signs**

The investigator or qualified designee will take vital signs at screening, prior to the administration of each dose of trial treatment, and at treatment discontinuation as specified in the Trial Flow Chart- Section 6. Height will be measured at Visit 1 only.

Vital signs should include temperature, pulse, respiratory rate, blood pressure, height, and weight.

#### **7.1.2.4 12-Lead Electrocardiogram**

A standard 12-lead electrocardiogram (ECG) will be performed one time during screening using local standard procedures. Clinically significant abnormal findings should be recorded as medical history. Additional time points may be performed as clinically necessary.

#### **7.1.2.5 Eastern Cooperative Oncology Group Performance Status**

The investigator or qualified designee will assess ECOG Performance Status (see Section 12.5) within 3 days prior to dosing Cycle 1 and prior to dosing on Day 1 of each subsequent treatment cycle and at discontinuation of trial treatment as specified in the Trial Flow Chart – Section 6.

#### **7.1.2.6 Patient Reported Outcome**

It is strongly recommended that Patient Reported Outcomes (PROs) are administered prior to drug administration, adverse event evaluation and disease status notification starting with the EQ-5D, followed by EORTC QLQ-C30, and EORTC QLQ-OES18; an exception to this recommendation may occur at the treatment discontinuation visit where patients may have already been notified of their disease status or an AE evaluation is Known prior to them arriving to the clinic. All PROs are to be performed as specified in the Trial Flow Chart – Section 6. If the subject does not complete the PROs, the MISS\_MODE form must be completed to capture the reason the assessment was not performed. A visit window of  $\pm$  7 days will apply to PRO visit assessment.

If at the time of the enrollment of a subject, the translated version of the OES-18, one of the PRO measures, is not available for that language/country, and therefore cannot be completed by the subject at Cycle 1 Day 1, then the OES-18 will not be required for this subject at any point during the study. The other study PRO measures must be completed as scheduled.

NOTE: For some sites, the translated OES-18 might become available after study startup and should be administered to subjects at their time of enrollment; for some sites the OES-18 translation might not be available for the entire duration of the study.

### 7.1.3 Laboratory Procedures/Assessments

Details regarding specific laboratory procedures/assessments to be performed in this trial are provided below.

Refer to the Trial Flow Chart - Section 6 for the schedule of laboratory assessments.

#### 7.1.3.1 Laboratory Safety Evaluations

Laboratory tests for hematology, chemistry and urinalysis are specified in [Table 5](#).

Table 5 Laboratory Tests

Hematology	Chemistry	Urinalysis	Other
Hematocrit	Alkaline phosphatase	Specific gravity	Thyroid-Stimulating Hormone (TSH)
Hemoglobin	Blood urea nitrogen/Urea <sup>a</sup>	Microscopic exam, if abnormal results are noted	Pregnancy test (serum or urine) <sup>b</sup>
Platelet count	Lactate dehydrogenase (LDH)	Protein	Free thyroxine (FT4)
Red blood count	Alanine aminotransferase (ALT)	Glucose	Total triiodothyronine (T3) or Free T3 <sup>c</sup>
White blood cell count (total and differential) <sup>d</sup>	Aspartate aminotransferase (AST)	Blood	aPTT
Absolute neutrophil count <sup>e</sup>	Bicarbonate or Carbon dioxide <sup>f</sup>		PT
Absolute lymphocyte count <sup>e</sup>	Calcium		(INR)
	Chloride		
	Creatinine		
	Glucose		
	Potassium		
	Sodium		
	Total bilirubin		
	Direct bilirubin, if total bilirubin is elevated above the upper limit of normal		
	Total protein		
	Albumin <sup>g</sup>		

a. Blood Urea Nitrogen is preferred; if not available urea may be tested.

b. Perform on women of childbearing potential only, 72 hours prior to Day 1 of each cycle and 30 days post treatment.

c. T3 is preferred; if not available free T3 may be tested. If the local laboratory is unable to perform either of these tests the site should submit the sample to the central laboratory for testing; details are provided in the procedure manual.

d. Report % or absolute results per standard of practice. Report the results in the same manner throughout the study.

e. Results should be calculated per local standard of practice.

f. If these tests are not done as part of standard of care in your region, then these test do not need to be performed.

g. Screening only

Laboratory tests for screening should be performed within 3 days prior to the first dose of trial treatment. Subjects eligible for retreatment with pembrolizumab should have lab tests performed within 3 days prior to the first dose of trial treatment in the Second Course Phase. After Cycle 1, in both the Initial Treatment Phase and the Second Course Phase, pre-dose laboratory safety tests can be conducted up to 72 hours prior to dosing.

Laboratory test results must be reviewed by the investigator or qualified designee and found to be acceptable prior to administration of each dose of trial treatment. Unresolved abnormal labs that are drug related AEs should be followed until resolution. Laboratory tests do not need to be repeated after the end of treatment if laboratory results are within normal range.

#### **7.1.3.1.1 Pregnancy Tests**

All women who are being considered for participation in the trial, and who are not surgically sterilized or postmenopausal, must be tested for pregnancy within 72 hours of each cycle of trial treatment and 30 days post treatment. If a urine test is positive or not evaluable, a serum test will be required. Subjects must be excluded/discontinued from the study in the event of a positive or borderline-positive test result.

#### **7.1.3.2 Central Laboratory Assessments**

Sample collection timing, storage, and shipment instructions for the central laboratory assessments are provided the central laboratory manual.

#### **7.1.3.3 Pharmacokinetic/Pharmacodynamic Evaluations**

To evaluate the immunogenicity and exposure of pembrolizumab in this indication, sample collections for analysis of anti-pembrolizumab antibodies (ADA) and PK are currently planned as shown in the Trial Flowchart. Blood samples for PK and ADA collected may be stored at this time. Further analysis may be performed if required. If ongoing PK and/or ADA sampling is deemed to be unnecessary by the Sponsor, it may be reduced or discontinued.

##### **7.1.3.3.1 Blood Collection for Serum MK-3475**

Sample collection, storage and shipment instructions for serum samples will be provided in the laboratory manual. PK samples should be drawn according to the PK collection schedule for subjects who receive pembrolizumab.

##### **7.1.3.3.2 Blood Collection for Anti-pembrolizumab (MK-3475) Antibodies**

Sample collection, storage and shipment instructions for serum samples will be provided in the laboratory manual. Anti- pembrolizumab antibody samples should be drawn according to the ADA collection schedule for subjects who receive pembrolizumab. Simultaneous PK sampling is required for interpretation of ADA analysis.

### **7.1.3.3.3 Correlative and Biomarker Blood Samples**

Additional biomarker research to identify factors important for pembrolizumab therapy may also be pursued. Analysis to be inclusive of all testing is in Section 4.2.3.5. If the samples are collected, any leftovers will be stored for future biomedical research if the subject signs the FBR consent.

### **7.1.3.4 Planned Genetic Analysis Sample Collection**

Sample collection, storage and shipment instructions for Planned Genetic Analysis samples will be provided in the central laboratory manual. This sample should be drawn for planned analysis of the association between genetic variants in DNA and drug response. If there is either a documented law or regulation prohibiting collection, or if the IRB/IEC does not approve the collection of the sample for these purposes, then this sample will not be collected at that site. If the sample is collected, leftover extracted DNA will be stored for future biomedical research if the subject signs the FBR consent. If the planned genetic analysis is not approved, but FBR is approved and consent is given, this sample will be collected for the purpose of FBR.

### **7.1.3.5 Future Biomedical Research Sample Collection**

The following specimens are to be obtained as part of Future Biomedical Research:

- (DNA) for future research.
- Leftover archival or newly obtained tumor tissue
- Leftover DNA and RNA from correlative studies
- Leftover plasma and serum from biomarker studies

### **7.1.3.6 Tumor Tissue**

Eligibility for this study is dependent upon supplying tumor tissue for biomarker analysis as described under eligibility criteria. Repeat samples may be required if adequate tissue is not provided. If the subject signs the FBR consent, any leftover tissue that would ordinarily be discarded at the end of the main study will be retained for FBR.

Newly-obtained tissue is preferred (no intervening treatment [local or systemic] involving the site of tissue biopsy once tissue biopsy is obtained and time of study enrollment). Formalin-fixed, paraffin-embedded (FFPE) block specimens are preferred to slides.

Detailed instructions for tissue collection, processing and shipment are provided in the laboratory manual.

### **7.1.4 Efficacy Measurements**

#### **7.1.4.1 Tumor Imaging and Assessment of Disease**

The process for image collection and transmission to the central imaging vendor can be found in the Site Imaging Manual (SIM). Tumor imaging is strongly preferred to be acquired

by computed tomography (CT). Magnetic resonance imaging (MRI) should be used only when CT is contraindicated or for imaging of the brain. The same imaging technique regarding modality and the use of contrast should be used in a subject throughout the trial to optimize the visualization of existing and new tumor burden.

Local site investigator/radiology assessment based on RECIST 1.1 will be used to determine subject eligibility. Although RECIST 1.1 references to maximum of 5 target lesions in total and 2 per organ, Merck allows maximum of 10 target lesions in total and 5 per organ. All scheduled images for all study subjects from the sites will be submitted to the central imaging vendor. In addition, additional imaging (including other modalities) that are obtained at an unscheduled time point to determine disease progression, as well as imaging obtained for other reasons but captures radiologic progression, should be submitted to the central imaging vendor as well.

The central imaging vendor will verify progressive disease (PD) following local site investigator-assessed 1st radiologic evidence of PD. Expedited verification of radiologic PD by the central imaging vendor will be communicated to the study site and sponsor (See Section 7.1.4.1.2).

#### **7.1.4.1.1 Initial Tumor Imaging**

Initial tumor imaging (baseline scans) of the chest, abdomen and pelvis at screening must be performed within 14 days prior to the date of randomization. The site study team must review baseline images to confirm the subject has measurable disease per RECIST 1.1. The baseline images must be submitted to the central imaging vendor for retrospective review.

Scans performed as part of routine clinical management are acceptable for use as baseline tumor imaging if they are of diagnostic quality and performed within 14 days prior to the date of randomization and can be assessed by the central imaging vendor.

A scan performed outside 14 days but within 28 days prior to the first dose of study medication may be acceptable as the baseline scan if (1) it was performed as part of routine clinical management, (2) the subject is participating at a site where the local regulatory body and/or IRB/ERC would not permit a repeat scan to be performed to meet the 14 day criteria, and (3) permission is given by the Sponsor.

#### **7.1.4.1.2 Tumor Imaging During the Trial**

The first on study imaging assessment should be performed at 9 weeks (63 days  $\pm$  7 days) from the date of randomization. Subsequent tumor imaging should be performed every 9 weeks (63 days  $\pm$  7 days) or more frequently if clinically indicated. Imaging timing should follow calendar days and should not be adjusted for delays in cycle starts. Imaging should continue to be performed until disease progression verified by central imaging vendor (unless site PI elects to continue treatment and follow irRECIST), the start of new anti-cancer treatment, withdrawal of consent, or death, whichever occurs first. All supplemental imaging must be submitted to the central imaging vendor.

Per RECIST 1.1, partial and complete response should be confirmed by a repeat tumor imaging assessment not less than 4 weeks from the date the response was first documented.

The tumor imaging for confirmation of response may be performed at the earliest 4 weeks after the first indication of response, or at the next scheduled scan (i.e. 9 weeks later), whichever is clinically indicated. Subjects will then return to regular scheduled imaging every 9 weeks, starting with the next scheduled imaging time point. Subjects who obtain a confirmation scan do not need to undergo the next scheduled tumor imaging if it is < 4 weeks later; tumor imaging may resume at the subsequent scheduled imaging time point.

For subjects in the pembrolizumab arm and per irRECIST (Section 4.2.3.4.1), disease progression should be confirmed by the site at least 4 weeks after central verification of site-assessed 1<sup>st</sup> radiologic evidence of PD in clinically stable subjects. Subjects who have unconfirmed disease progression may continue on treatment at the discretion of the site investigator until progression is confirmed by the site provided they have met the conditions detailed in Section 4.2.3.4.1. Subjects who obtain a confirmation scan do not need to undergo the next scheduled tumor imaging if it is < 4 weeks later; tumor imaging may resume at the subsequent scheduled imaging time point if clinically stable. Subjects who have confirmed disease progression as assessed by the site will discontinue the treatment. Exception is detailed in Section 7.1.4.1.6.

#### **7.1.4.1.3 End of Treatment and Follow-up Tumor Imaging**

In subjects who discontinue trial treatment, tumor imaging should be performed at the time of treatment discontinuation ( $\pm$  4 week window). If a previous scan was obtained within 4 weeks prior to the date of discontinuation, then a scan at treatment discontinuation isn't mandatory. In subjects who discontinue trial treatment due to documented disease progression, this is the final required tumor imaging.

In subjects who discontinue trial treatment without documented disease progression, every effort should be made to continue monitoring their disease status by tumor imaging using the same imaging schedule used while on treatment to monitor disease status until (1) the start of new anti-cancer treatment, (2) disease progression, (3) death, or (4) the end of the study, whichever occurs first.

#### **7.1.4.1.4 Second Course (Retreatment) Tumor Imaging**

A scan must be performed within 14 days prior to restarting treatment with pembrolizumab. Local reading (investigator assessment with site radiology reading) will be used to determine eligibility. Imaging should be submitted to the central imaging vendor for retrospective review.

The first on study imaging assessment should be performed at 9 weeks (63 days  $\pm$  7 days) after the restart of treatment. Subsequent tumor imaging should be performed every 9 weeks (63 days  $\pm$  7 days) or more frequently if clinically indicated.

Per irRECIST (Section 4.2.3.4.1), if tumor imaging shows initial PD, tumor assessment should be repeated  $\geq$  4 weeks later in order to confirm PD with the option of continuing treatment while awaiting radiologic confirmation of progression. Subjects who obtain a confirmation scan do not need to undergo scheduled tumor imaging if it is < 4 weeks later and may wait until the next scheduled imaging time point if clinically stable.

Imaging should continue to be performed until disease progression, the start of new anti-cancer treatment, withdrawal of consent, death, or notification by the Sponsor, whichever occurs first. Disease progression may be confirmed at least 4 weeks after the first tumor imaging, indicating progressive disease in clinically stable subjects.

In subjects who discontinue trial treatment, tumor imaging should be performed at the time of treatment discontinuation ( $\pm$  4 week window). If a previous scan was obtained within 4 weeks prior to the date of discontinuation, then a scan at treatment discontinuation isn't mandatory. In subjects who discontinue trial treatment due to documented disease progression, this is the final required tumor imaging.

In subjects who discontinue trial treatment without documented disease progression, every effort should be made to continue monitoring their disease status by radiologic imaging every 9 weeks (63 days  $\pm$  7 days) until (1) the start of new anti-cancer treatment, (2) disease progression, (3) death, or (4) the end of the study, whichever occurs first.

#### **7.1.4.1.5 RECIST 1.1 Assessment of Disease**

RECIST 1.1 will be applied by the central imaging vendor as the primary measure for assessment of tumor response, date of disease progression, and as a basis for all protocol guidelines related to disease status (e.g., discontinuation of study therapy). Initial tumor imaging showing site-assessed PD should be submitted to the central imaging vendor immediately. The site will be notified if the central imaging vendor verifies progressive disease (PD) using RECIST 1.1. [Figure 3](#) illustrates the imaging flow involving verification of PD for clinically stable subjects.

#### **7.1.4.1.6 irRECIST Assessment of Disease**

irRECIST is RECIST 1.1 adapted as described below to account for the unique tumor response seen with immunotherapeutic drugs. irRECIST will be used by site investigator/local radiology review to assess tumor response and progression, and make treatment decisions. These data will be collected in the clinical database. Treatment efficacy based on irRECIST as assessed by central imaging vendor review will be evaluated retrospectively.

When feasible, subjects should not be discontinued until progression is confirmed by the local site investigator/radiology assessment. This allowance to continue treatment despite initial radiologic progressive disease (PD) takes into account the observation that some subjects can have a transient tumor flare in the first few months after the start of immunotherapy, and then experience subsequent disease response. Subjects that are deemed clinically unstable are not required to have repeat tumor imaging for confirmation of PD. Tumor flare includes any of the following scenarios:

- Worsening of existing target lesion(s)
- Worsening of existing non-target lesion(s)
- Development of new lesion(s)

In subjects who have shown initial evidence of radiological PD by RECIST 1.1, it is at the discretion of the investigator whether to continue a subject on study treatment until repeat imaging is obtained (using irRECIST for subject management, see [Table 6](#) and [Figure 3](#)). This clinical judgment decision by the site investigator should be based on the subject's overall clinical condition, including performance status, clinical symptoms, and laboratory data. Subjects may receive study treatment and tumor assessment should be repeated  $\geq$  4 weeks later in order to confirm PD by irRECIST per site assessment. Clinical stability is defined as the following:

- 1) Absence of symptoms and signs indicating clinically significant progression of disease, including worsening of laboratory values
- 2) No decline in ECOG performance status
- 3) Absence of rapid progression of disease
- 4) Absence of progressive tumor at critical anatomical sites (e.g., cord compression) requiring urgent alternative medical intervention

Any subject deemed **clinically unstable** should be discontinued from trial treatment at central verification of site-assessed 1st radiologic evidence of PD and is not required to have repeat imaging for PD confirmation.

In determining whether or not the tumor burden has increased or decreased per irRECIST, the local site investigator should consider all target and non-target lesions as well as any incremental new lesion(s).

Scenarios where PD is not confirmed at repeat imaging if ALL of the following occur by irRECIST:

- Target lesion sum of diameters is  $< 20\%$  or  $< 5$  mm absolute increase compared to nadir
- Non-target disease resulting in initial PD is stable or qualitatively improved
- New lesion resulting in initial PD is stable or qualitatively improved
- No incremental new lesion(s) since last evaluation
- No incremental new non-target lesion progression since last evaluation

If repeat imaging does not confirm PD per irRECIST as assessed by the local site investigator and the subject continues to be clinically stable, treatment may continue and follow the regular imaging schedule.

Scenarios where PD is confirmed at repeat imaging if ANY of the following occur by irRECIST:

- Target lesion sum of diameters remains  $\geq 20\%$  and at least 5 mm absolute increase compared to nadir
- Non-target disease resulting in initial PD is qualitatively worse
- New lesion resulting in initial PD is qualitatively worse

- Additional new lesion(s) since last evaluation
- Additional new non-target lesion progression since last evaluation

If repeat imaging confirms PD due to any of the scenarios listed above, subjects will be discontinued from study therapy.

**NOTE:** If a subject has confirmed radiographic progression (i.e. 2 scans at least 4 weeks apart demonstrating progressive disease) per irRECIST, but the subject is achieving a clinically meaningful benefit, and there is no further increase in the tumor burden at the confirmatory tumor imaging, an exception to continue treatment may be considered following consultation with the Sponsor. In this case, if treatment is continued, tumor imaging should continue to be performed following the intervals as outlined in Section 6.0 Study Flow Chart and be submitted to the central imaging vendor.

Additional details about irRECIST are referenced in Merck TIP Sheet for RECIST 1.1 and irRECIST.

Table 6 Imaging and Treatment after First Radiologic Evidence of PD

	Clinically Stable		Clinically Unstable	
	Imaging	Treatment	Imaging	Treatment
1st radiologic evidence of PD by RECIST 1.1 which has been verified by the central imaging vendor	Repeat imaging at $\geq$ 4 weeks at site to confirm PD	May continue study treatment at the local site Investigator's discretion while awaiting confirmatory tumor imaging by site by irRECIST.	Repeat imaging at $\geq$ 4 weeks to confirm PD per physician discretion only	Discontinue treatment
Repeat tumor imaging confirms PD by irRECIST at the local site	No additional imaging required	Discontinue treatment (exception is possible upon consultation with sponsor)	No additional imaging required	N/A
Repeat tumor imaging shows SD, PR or CR by irRECIST at the local site	Continue regularly scheduled imaging assessments	Continue study treatment at the local site Investigator's discretion	Continue regularly scheduled imaging assessments	May restart study treatment if condition has improved and/or clinically stable per Investigator's discretion. Next tumor image should occur according to the regular imaging schedule outlined in the protocol




Figure 3 Imaging and Treatment for Clinically Stable Subjects after First Radiologic Evidence of PD Assessed by the Site

### 7.1.5 Other Procedures

#### 7.1.5.1 Withdrawal/Discontinuation

Subjects who discontinue/withdraw from treatment prior to completion of the treatment period should be encouraged to continue to be followed for all remaining study visits, and encouraged to participate in the Survival Follow-Up Phase (as outlined in the Trial Flow Chart and Section 7.1.6.3).

When a subject discontinues/withdraws from participation in the trial, all applicable activities scheduled for the end of treatment visit should be performed at the time of discontinuation. Any adverse events which are present at the time of discontinuation/withdrawal should be followed in accordance with the safety requirements outlined in Section 7.2 - Assessing and Recording Adverse Events. Subjects who attain a CR or complete 35 trial treatments (approximately 2 years) may discontinue treatment with the option of restarting treatment if they meet the criteria specified in Section 7.1.6.2. After discontinuing treatment following assessment of a CR or the 35 trial treatments, subjects should return to the site for a Safety Follow-up visit (Section 7.1.6.3.1) and then proceed to the Follow-up Period of the study (Section 7.1.6.3.2).

#### **7.1.5.1.1 Withdrawal From Future Biomedical Research**

Subjects may withdraw their consent for Future Biomedical Research and have their specimens and all derivatives destroyed. Subjects may withdraw consent at any time by contacting the principal investigator for the main trial. If medical records for the main trial are still available, the investigator will contact the Sponsor using the designated mailbox (clinical.specimen.management@merck.com), and a form will be provided by the Sponsor to obtain appropriate information to complete specimen withdrawal. Subsequently, the subject's specimens will be removed from the biorepository and be destroyed. A letter will be sent from the Sponsor to the investigator confirming the destruction. It is the responsibility of the investigator to inform the subject of completion of destruction. Any analyses in progress at the time of request for destruction or already performed prior to the request being received by the Sponsor will continue to be used as part of the overall research trial data and results. No new analyses would be generated after the request is received.

In the event that the medical records for the main trial are no longer available (e.g., if the investigator is no longer required by regulatory authorities to retain the main trial records) or the specimens have been completely anonymized, there will no longer be a link between the subject's personal information and their specimens. In this situation, the request for specimen destruction cannot be processed.

#### **7.1.5.1.2 Lost to Follow-up**

If a subject fails to return to the clinic for a required study visit and/or if the site is unable to contact the subject, the following procedures are to be performed:

- The site must attempt to contact the subject and reschedule the missed visit. If the subject is contacted, the subject should be counseled on the importance of maintaining the protocol-specified visit schedule.
- The investigator or designee must make every effort to regain contact with the subject at each missed visit (e.g. phone calls and/or a certified letter to the subject's last known mailing address or locally equivalent methods). These contact attempts should be documented in the subject's medical record.

Note: A subject is not considered lost to follow up until the last scheduled visit for the individual subject. The amount of missing data for the subject will be managed via the pre-specified data handling and analysis guidelines

#### **7.1.5.2 Blinding/Unblinding**

This is an open label trial; there is no blinding for this trial.

#### **7.1.5.3 Calibration of Equipment**

The investigator or qualified designee has the responsibility to ensure that any device or instrument used for a clinical evaluation/test during a clinical trial that provides information about inclusion/exclusion criteria and/or safety or efficacy parameters shall be suitably calibrated and/or maintained to ensure that the data obtained is reliable and/or reproducible. Documentation of equipment calibration must be retained as source documentation at the trial site.

### **7.1.6 Visit Requirements**

Visit requirements are outlined in Section 6.0 - Trial Flow Chart. Specific procedure-related details are provided above in Section 7.1 - Trial Procedures.

#### **7.1.6.1 Screening**

Approximately 28 days prior to treatment allocation, potential subjects will be evaluated to determine that they fulfill the entry requirements as set forth in Section 5.1. Screening procedures may be repeated.

Results of a test performed prior to the subject signing consent as part of routine clinical management are acceptable in lieu of a screening test if performed within the specified time frame. Screening procedures are to be completed within 28 days prior to the first dose of trial treatment except for the following:

- Laboratory tests and ECOG PS are to be performed within 3 days prior to the first dose of trial treatment.
- Initial tumor imaging for First Course Treatment will be performed within 14 days of randomization and initial tumor imaging for Second Course Treatment will be performed prior to the first dose of second course treatment.
- For women of reproductive potential, a serum pregnancy test will be performed within 72 hours prior to the first dose of trial treatment. A urine test may be considered if serum test is not appropriate.
- For subjects who are to receive therapy with irinotecan, subjects should be tested locally for the UGT1A1\*28 allele at investigator discretion. The starting dose for irinotecan can be adjusted as outlined in the prescribing information or according to local guidelines.

An allele test performed prior to the subject signing consent can be used to support subject eligibility as long as that test was performed as part of standard of care and not specifically for this study.

Subjects will not be allowed to rescreen in this study.

### **7.1.6.2 Treatment Period**

Visit requirements are outlined in the Trial Flow Chart (Section 6.0). Specific procedure-related details are provided above in the Trial Procedures.

Subjects who stop pembrolizumab with SD or better may be eligible for up to 17 additional trial treatments (approximately 1 year) if they progress after stopping study treatments. Retreatment with pembrolizumab is termed the Second Course Phase and is only available if the trial remains open and the subject meets the following conditions:

- **Either**
  - Stopped initial treatment with pembrolizumab after attaining an investigator-determined confirmed CR according to RECIST 1.1
    - Was treated with at least 8 trial treatments (approximately 6 months) with pembrolizumab before discontinuing therapy
    - Received at least two treatments with pembrolizumab beyond the date when the initial CR was declared
- **OR**
  - Had SD, PR or CR and stopped pembrolizumab after 35 trial treatments (approximately 2 years) for reasons other than disease progression or intolerance
- **AND**
  - Experienced an investigator-determined confirmed radiographic disease progression after stopping their initial treatment with pembrolizumab
  - Did not receive any anti-cancer treatment since the last dose of pembrolizumab
  - Has a performance status of 0 or 1 on the ECOG Performance Scale
  - Demonstrates adequate organ function as detailed in Section 5.1.2
  - Female subject of childbearing potential should have a negative serum or urine pregnancy test within 72 hours prior to receiving retreatment with study medication. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required.
  - Female subjects of childbearing potential (Section 5.7.2) must be willing to use an adequate method of contraception as outlined in Section 5.7.2 – Contraception, for the course of the study through 120 days after the last dose of pembrolizumab or through 180 days after the last dose of paclitaxel, docetaxel, or irinotecan.
    - *Note: Abstinence is acceptable if this is the usual lifestyle and preferred contraception for the subject.*

- Male subjects of childbearing potential (Section 5.7.2) must agree to use an adequate method of contraception as outlined in Section 5.7.2- Contraception and not to donate sperm, starting with the first dose of study therapy through 120 days after the last dose of pembrolizumab or through 180 days after the last dose of paclitaxel, docetaxel, or irinotecan.
  - *Note: Abstinence is acceptable if this is the usual lifestyle and preferred contraception for the subject.*
- Does not have a history or current evidence of any condition, therapy, or laboratory abnormality that might interfere with the subject's participation for the full duration of the trial or is not in the best interest of the subject to participate, in the opinion of the treating investigator.

Subjects who enter the Second Course Phase will be retreated at the same dose frequency as when they last received pembrolizumab. Pembrolizumab will be administered for up to an additional 17 trial treatments (approximately 1 year).

Visit requirements for the second course phase are outlined in the Second Course Phase Trial Flow Chart (Section 6.5).

### **7.1.6.3 Post-Trial Visits**

#### **7.1.6.3.1 Safety Follow-up Visits**

The mandatory Safety Follow-up Visit should be conducted approximately 30 days after the last dose of trial treatment or before the initiation of a new anti-cancer treatment, whichever comes first.

All AEs that occur prior to the Safety Follow-Up Visit should be recorded. Subjects with an AE of Grade > 1 will be followed until the resolution of the AE to Grade 0-1 or until the beginning of a new anti-cancer therapy, whichever occurs first. SAEs that occur within 90 days of the end of treatment or before initiation of a new anti-cancer treatment should also be followed and recorded.

Subjects who are eligible for retreatment with pembrolizumab may have up to two safety follow-up visits, one after the Initial Treatment Period and one after the Second Course Treatment Phase.

#### **7.1.6.3.2 Follow-up Visits**

Subjects who discontinue trial treatment for reasons other than disease progression will move into the Follow-up Phase and should be assessed Q9W by radiologic imaging to monitor disease status. Every effort should be made to collect information regarding disease status until the start of a new anti-cancer therapy, disease progression, death, or the end of the study.

Information regarding post-study anti-cancer treatment will be collected if new treatment is initiated.

Subjects who are eligible to receive retreatment with pembrolizumab according to the criteria in Section 7.1.6.2 will move from the Follow-up Phase to the Second Course Phase when they experience disease progression. Details are provided in the Trial Flow Chart (Section 6) for retreatment with pembrolizumab.

### **7.1.6.3.3 Survival Follow-up**

Subjects, who have had centrally verified disease progression or start a new anti-cancer therapy, will move into the Survival Follow-Up Phase. Subjects should be contacted by telephone approximately every 9 weeks to assess for survival status until death, withdrawal of consent, or the end of the study, whichever occurs first.

#### **7.1.6.3.3.1 Survival Status**

To ensure current and complete survival data is available at the time of database locks, updated survival status may be requested during the course of the study by the Sponsor. For example, these additional time points may be requested prior to; an eDMC safety review, efficacy interim analysis, and/or final analysis. Upon Sponsor notification, all subjects who do not/will not have a scheduled study visit or study contact during the Sponsor defined time period will be contacted for their survival status.

## **7.2 Assessing and Recording Adverse Events**

An adverse event is defined as any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An adverse event can therefore be any unfavourable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition that is temporally associated with the use of the Sponsor's product, is also an adverse event.

Changes resulting from normal growth and development that do not vary significantly in frequency or severity from expected levels are not to be considered adverse events. Examples of this may include, but are not limited to, teething, typical crying in infants and children and onset of menses or menopause occurring at a physiologically appropriate time.

Sponsor's product includes any pharmaceutical product, biological product, device, diagnostic agent or protocol-specified procedure, whether investigational (including placebo or active comparator medication) or marketed, manufactured by, licensed by, provided by or distributed by the Sponsor for human use.

Adverse events may occur during clinical trials, or as prescribed in clinical practice, from overdose (whether accidental or intentional), from abuse and from withdrawal.

Progression of the cancer under study is not considered an adverse event.

All adverse events that occur after the consent form is signed but before treatment allocation/randomization must be reported by the investigator if they cause the subject to be excluded from the trial, or are the result of a protocol-specified intervention, including but not limited to washout or discontinuation of usual therapy, diet, placebo treatment or a procedure. From the time of treatment allocation/randomization through 30 days following cessation of treatment, all adverse events must be reported by the investigator. Such events will be recorded at each examination on the Adverse Event case report forms/worksheets. The reporting timeframe for adverse events meeting any serious criteria is described in section 7.2.3.1. The investigator will make every attempt to follow all subjects with non-serious adverse events for outcome.

Electronic reporting procedures can be found in the EDC data entry guidelines. Paper reporting procedures can be found in the Investigator Trial File Binder (or equivalent).

### **7.2.1 Definition of an Overdose for This Protocol and Reporting of Overdose to the Sponsor**

In this trial, an overdose is any dose higher than  $\geq 1000$  mg (5 times the protocol defined dose) of pembrolizumab. No specific information is available on the treatment of over dose of pembrolizumab. In the event of overdose, study treatment should be discontinued and the subject should be observed closely for signs of toxicity. Appropriate supportive treatment should be provided if clinically indicated.

If an adverse event(s) is associated with (“results from”) the overdose of Sponsor's product or vaccine, the adverse event(s) is reported as a serious adverse event, even if no other seriousness criteria are met.

If a dose of Sponsor's product or vaccine meeting the protocol definition of overdose is taken without any associated clinical symptoms or abnormal laboratory results, the overdose is reported as a non-serious Event of Clinical Interest (ECI), using the terminology “accidental or intentional overdose without adverse effect.”

All reports of overdose with and without an adverse event must be reported by the investigator within 24 hours to the Sponsor either by electronic media or paper. Electronic reporting procedures can be found in the EDC data entry guidelines. Paper reporting procedures can be found in the Investigator Trial File Binder (or equivalent).

### **7.2.2 Reporting of Pregnancy and Lactation to the Sponsor**

Although pregnancy and lactation are not considered adverse events, it is the responsibility of investigators or their designees to report any pregnancy or lactation in a subject (spontaneously reported to them) that occurs during the trial.

Pregnancies and lactations that occur after the consent form is signed but before treatment allocation/randomization must be reported by the investigator if they cause the subject to be excluded from the trial, or are the result of a protocol-specified intervention, including but not limited to washout or discontinuation of usual therapy, diet, placebo treatment or a

procedure. Pregnancies and lactations that occur from the time of treatment allocation/randomization through 120 days after the last dose of pembrolizumab or through 180 days after the last dose of paclitaxel, docetaxel or irinotecan or 30 days following cessation of treatment if the subject initiates new anticancer therapy, whichever is earlier, must be reported by the investigator. All reported pregnancies must be followed to the completion/termination of the pregnancy. Pregnancy outcomes of spontaneous abortion, missed abortion, benign hydatidiform mole, blighted ovum, fetal death, intrauterine death, miscarriage and stillbirth must be reported as serious events (Important Medical Events). If the pregnancy continues to term, the outcome (health of infant) must also be reported.

Such events must be reported within 24 hours to the Sponsor either by electronic media or paper. Electronic reporting procedures can be found in the EDC data entry guidelines. Paper reporting procedures can be found in the Investigator Trial File Binder (or equivalent).

### **7.2.3 Immediate Reporting of Adverse Events to the Sponsor**

#### **7.2.3.1 Serious Adverse Events**

A serious adverse event is any adverse event occurring at any dose or during any use of Sponsor's product that:

- Results in death;
- Is life threatening;
- Results in persistent or significant disability/incapacity;
- Results in or prolongs an existing inpatient hospitalization;
- Is a congenital anomaly/birth defect;
- Is an other important medical event.

**Note:** In addition to the above criteria, adverse events meeting either of the below criteria, although not serious per ICH definition, are reportable to the Sponsor in the same timeframe as SAEs to meet certain local requirements. Therefore, these events are considered serious by the Sponsor for collection purposes.

- Is a new cancer (that is not a condition of the study);
- Is associated with an overdose.

Refer to [Table 7](#) for additional details regarding each of the above criteria.

For the time period beginning when the consent form is signed until treatment allocation/randomization, any serious adverse event, or follow up to a serious adverse event, including death due to any cause other than progression of the cancer under study (reference Section 7.2.3.3 for additional details), that occurs to any subject must be reported within 24 hours to the Sponsor if it causes the subject to be excluded from the trial, or is the result of a protocol-specified intervention, including but not limited to washout or discontinuation of usual therapy, diet, placebo treatment or a procedure.

For the time period beginning at treatment allocation/randomization through 90 days following cessation of treatment, or 30 days following cessation of treatment if the subject initiates new anticancer therapy, whichever is earlier, any serious adverse event, or follow up to a serious adverse event, including death due to any cause other than progression of the

cancer under study (reference Section 7.2.3.3 for additional details), whether or not related to the Sponsor's product, must be reported within 24 hours to the Sponsor either by electronic media or paper. Electronic reporting procedures can be found in the EDC data entry guidelines. Paper reporting procedures can be found in the Investigator Trial File Binder (or equivalent).

Additionally, any serious adverse event, considered by an investigator who is a qualified physician to be related to the Sponsor's product that is brought to the attention of the investigator at any time following consent through the end of the specified safety follow-up period specified in the paragraph above, or at any time outside of the time period specified in the previous paragraph also must be reported immediately to the Sponsor.

All subjects with serious adverse events must be followed up for outcome.

### **7.2.3.2 Events of Clinical Interest**

Selected non-serious and serious adverse events are also known as Events of Clinical Interest (ECI) and must be reported to the Sponsor.

For the time period beginning when the consent form is signed until treatment allocation/randomization, any ECI, or follow up to an ECI, that occurs to any subject must be reported within 24 hours to the Sponsor if it causes the subject to be excluded from the trial, or is the result of a protocol-specified intervention, including but not limited to washout or discontinuation of usual therapy, diet, placebo treatment or a procedure.

For the time period beginning at treatment allocation/randomization through 30 days following cessation of treatment, or 30 days following cessation of treatment if the subject initiates new anticancer therapy, whichever is earlier, any ECI, or follow up to an ECI, whether or not related to the Sponsor's product, must be reported within 24 hours to the Sponsor, either by electronic media or paper. Electronic reporting procedures can be found in the EDC data entry guidelines. Paper reporting procedures can be found in the Investigator Trial File Binder (or equivalent).

Events of clinical interest for this trial include:

- 1) an overdose of Sponsor's product, as defined in Section 7.2.1 - Definition of an Overdose for This Protocol and Reporting of Overdose to the Sponsor, that is not associated with clinical symptoms or abnormal laboratory results.
- 2) an elevated AST or ALT lab value that is greater than or equal to 3X the upper limit of normal and an elevated total bilirubin lab value that is greater than or equal to 2X the upper limit of normal and, at the same time, an alkaline phosphatase lab value that is less than 2X the upper limit of normal, as determined by way of protocol-specified laboratory testing or unscheduled laboratory testing.\*

\*Note: These criteria are based upon available regulatory guidance documents. The purpose of the criteria is to specify a threshold of abnormal hepatic tests that may require an additional evaluation for an underlying etiology. The trial site guidance for assessment

and follow up of these criteria can be found in the Investigator Trial File Binder (or equivalent).

### **7.2.3.3 Protocol-Specific Exceptions to Serious Adverse Event Reporting**

Efficacy endpoints as outlined in this section will not be reported to the Sponsor as described in Section 7.2.3 - Immediate Reporting of Adverse Events to the Sponsor.

Specifically, the suspected/actual events covered in this exception include any event that is disease progression of the cancer under study.

The Sponsor will monitor safety data to ensure the safety of the subjects in the trial. Any suspected endpoint which upon review is not progression of the cancer under study will be forwarded to global safety as a SAE within 24 hours of determination that the event is not progression of the cancer under study

### **7.2.4 Evaluating Adverse Events**

An investigator who is a qualified physician will evaluate all adverse events according to the NCI Common Terminology for Adverse Events (CTCAE), version 4.0. Any adverse event which changes CTCAE grade over the course of a given episode will have each change of grade recorded on the adverse event case report forms/worksheets.

All adverse events regardless of CTCAE grade must also be evaluated for seriousness.

Table 7 Evaluating Adverse Events

An investigator who is a qualified physician, will evaluate all adverse events as to:

<b>V4.0 CTCAE Grading</b>	<b>Grade 1</b>	<b>Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated.</b>
	<b>Grade 2</b>	<b>Moderate; minimal, local or noninvasive intervention indicated; limiting age-appropriate instrumental ADL.</b>
	<b>Grade 3</b>	<b>Severe or medically significant but not immediately life-threatening; hospitalization or prolongation or hospitalization indicated; disabling; limiting self-care ADL.</b>
	<b>Grade 4</b>	<b>Life threatening consequences; urgent intervention indicated.</b>
	<b>Grade 5</b>	<b>Death related to AE</b>
<b>Seriousness</b>	A serious adverse event is any adverse event occurring at any dose or during any use of Sponsor's product that:	
	† <b>Results in death;</b> or	
	† <b>Is life threatening;</b> or places the subject, in the view of the investigator, at immediate risk of death from the event as it occurred (Note: This does not include an adverse event that, had it occurred in a more severe form, might have caused death.); or	
	† <b>Results in a persistent or significant disability/incapacity</b> (substantial disruption of one's ability to conduct normal life functions); or	
	† <b>Results in or prolongs an existing inpatient hospitalization</b> (hospitalization is defined as an inpatient admission, regardless of length of stay, even if the hospitalization is a precautionary measure for continued observation. (Note: Hospitalization for an elective procedure to treat a pre-existing condition that has not worsened is not a serious adverse event. A pre-existing condition is a clinical condition that is diagnosed prior to the use of a Merck product and is documented in the patient's medical history.); or	
	† <b>Is a congenital anomaly/birth defect</b> (in offspring of subject taking the product regardless of time to diagnosis); or	
	<b>Is a new cancer</b> (that is not a condition of the study) (although not serious per ICH definition, is reportable to the Sponsor within 24 hours to meet certain local requirements); or	
	<b>Is an overdose</b> (whether accidental or intentional). Any adverse event associated with an overdose is considered a serious adverse event for collection purposes. An overdose that is not associated with an adverse event is considered a non-serious event of clinical interest and must be reported within 24 hours.	
	<b>Other important medical events</b> that may not result in death, not be life threatening, or not require hospitalization may be considered a serious adverse event when, based upon appropriate medical judgment, the event may jeopardize the subject and may require medical or surgical intervention to prevent one of the outcomes listed previously (designated above by a †).	
<b>Duration</b>	Record the start and stop dates of the adverse event. If less than 1 day, indicate the appropriate length of time and units	
<b>Action taken</b>	Did the adverse event cause the Sponsor's product to be discontinued?	
<b>Relationship to Sponsor's Product</b>	Did the Sponsor's product cause the adverse event? The determination of the likelihood that the Sponsor's product caused the adverse event will be provided by an investigator who is a qualified physician. The investigator's signed/dated initials on the source document or worksheet that supports the causality noted on the AE form, ensures that a medically qualified assessment of causality was done. This initialed document must be retained for the required regulatory time frame. The criteria below are intended as reference guidelines to assist the investigator in assessing the likelihood of a relationship between the test drug and the adverse event based upon the available information.  <b>The following components are to be used to assess the relationship between the Sponsor's product and the AE;</b> the greater the correlation with the components and their respective elements (in number and/or intensity), the more likely the Sponsor's product caused the adverse event (AE):	
	<b>Exposure</b>	Is there evidence that the subject was actually exposed to the Sponsor's product such as: reliable history, acceptable compliance assessment (pill count, diary, etc.), expected pharmacologic effect, or measurement of drug/metabolite in bodily specimen?
	<b>Time Course</b>	Did the AE follow in a reasonable temporal sequence from administration of the Sponsor's product? Is the time of onset of the AE compatible with a drug-induced effect (applies to trials with investigational medicinal product)?
	<b>Likely Cause</b>	Is the AE not reasonably explained by another etiology such as underlying disease, other drug(s)/vaccine(s), or other host or environmental factors

Relationship to Sponsor's Product (continued)	The following components are to be used to assess the relationship between the test drug and the AE: (continued)	
	Dechallenge	<p>Was the Sponsor's product discontinued or dose/exposure/frequency reduced?</p> <p>If yes, did the AE resolve or improve?</p> <p>If yes, this is a positive dechallenge. If no, this is a negative dechallenge.</p> <p>(Note: This criterion is not applicable if: (1) the AE resulted in death or permanent disability; (2) the AE resolved/improved despite continuation of the Sponsor's product; or (3) the trial is a single-dose drug trial); or (4) Sponsor's product(s) is/are only used one time.)</p>
	Rechallenge	<p>Was the subject re-exposed to the Sponsor's product in this study?</p> <p>If yes, did the AE recur or worsen?</p> <p>If yes, this is a positive rechallenge. If no, this is a negative rechallenge.</p> <p>(Note: This criterion is not applicable if: (1) the initial AE resulted in death or permanent disability, or (2) the trial is a single-dose drug trial); or (3) Sponsor's product(s) is/are used only one time).</p> <p>NOTE: IF A RECHALLENGE IS PLANNED FOR AN ADVERSE EVENT WHICH WAS SERIOUS AND WHICH MAY HAVE BEEN CAUSED BY THE SPONSOR'S PRODUCT, OR IF REEXPOSURE TO THE SPONSOR'S PRODUCT POSES ADDITIONAL POTENTIAL SIGNIFICANT RISK TO THE SUBJECT, THEN THE RECHALLENGE MUST BE APPROVED IN ADVANCE BY THE SPONSOR CLINICAL DIRECTOR AS PER DOSE MODIFICATION GUIDELINES IN THE PROTOCOL.</p>
		The assessment of relationship will be reported on the case report forms /worksheets by an investigator who is a qualified physician according to his/her best clinical judgment, including consideration of the above elements.
Record one of the following		Use the following scale of criteria as guidance (not all criteria must be present to be indicative of a Sponsor's product relationship).
Yes, there is a reasonable possibility of Sponsor's product relationship.		There is evidence of exposure to the Sponsor's product. The temporal sequence of the AE onset relative to the administration of the Sponsor's product is reasonable. The AE is more likely explained by the Sponsor's product than by another cause.
No, there is not a reasonable possibility of Sponsor's product relationship		Subject did not receive the Sponsor's product OR temporal sequence of the AE onset relative to administration of the Sponsor's product is not reasonable OR the AE is more likely explained by another cause than the Sponsor's product. (Also entered for a subject with overdose without an associated AE.)

## **7.2.5 Sponsor Responsibility for Reporting Adverse Events**

All Adverse Events will be reported to regulatory authorities, IRB/IECs and investigators in accordance with all applicable global laws and regulations, i.e., per ICH Topic E6 (R1) Guidelines for Good Clinical Practice.

# **7.3 TRIAL GOVERNANCE AND OVERSIGHT**

## **7.3.1 Scientific Advisory Committee**

This trial was developed in collaboration with a Scientific Advisory Committee (SAC). The SAC comprises both Sponsor and non-Sponsor scientific experts who provide input with respect to trial design, interpretation of trial results and subsequent peer-reviewed scientific publications.

## **7.3.2 Executive Oversight Committee**

The Executive Oversight Committee (EOC) comprises members of Sponsor Senior Management. The EOC will receive and decide upon any recommendations made by the external Data Monitoring Committee (eDMC) regarding the trial.

## **7.3.3 Data Monitoring Committee**

To supplement the routine trial monitoring outlined in this protocol, an external Data Monitoring Committee (DMC) will monitor the interim data from this trial. The voting members of the committee are external to the Sponsor. The members of the DMC must not be involved with the trial in any other way (e.g., they cannot be trial investigators) and must have no competing interests that could affect their roles with respect to the trial.

The DMC will make recommendations to the EOC regarding steps to ensure both subject safety and the continued ethical integrity of the trial. Also, the DMC will review interim trial results, consider the overall risk and benefit to trial participants (see Section 8.7 - Interim Analyses) and recommend to the EOC if the trial should continue in accordance with the protocol.

Specific details regarding composition, responsibilities, and governance, including the roles and responsibilities of the various members and the Sponsor protocol team; meeting facilitation; the trial governance structure; and requirements for and proper documentation of DMC reports, minutes, and recommendations will be described in the DMC charter that is reviewed and approved by all the DMC members.

## 8.0 STATISTICAL ANALYSIS PLAN

This section outlines the statistical analysis strategy and procedures for the study. If, after the study has begun, changes made to primary and/or key secondary hypotheses, or the statistical methods related to those hypotheses, then the protocol will be amended (consistent with ICH Guideline E-9). Changes to exploratory or other non-confirmatory analyses made after the protocol has been finalized, but prior to the conduct of any analysis, will be documented in a supplemental SAP (sSAP) and referenced in the Clinical Study Report (CSR) for the study. There will be a separate PK analysis plan as well as biomarker analysis plan. Post hoc exploratory analyses will be clearly identified in the CSR. The PRO analysis plan will be included in the sSAP.

### 8.1 Statistical Analysis Plan Summary

The key elements of the statistical analysis plan that are summarized in [Table 8](#) below are applicable to the Global Cohort; the comprehensive plan is provided in Sections 8.2 through 8.12. Statistical analysis plan for the China Cohort will be provided in a supplemental SAP.

Table 8 Statistical Plan Analysis Summary

<b>Study Overview</b>	A Phase III Randomized Open-Label Study of Single Agent Pembrolizumab vs. Physicians' Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)
<b>Treatment Assignment</b>	Subjects will be randomized in a 1:1 ratio to receive pembrolizumab or investigator's choice of paclitaxel, docetaxel, or irinotecan (Control Arm). Stratification factors are in Section 5.4. This is an open-label study.
<b>Analysis Populations</b>	Efficacy: Intention to Treat (ITT) Safety: All Subjects as Treated (ASaT)
<b>Primary Endpoints/Hypotheses</b>	1. Overall Survival (OS) in subjects with squamous cell carcinoma of the Esophagus. 2. Overall Survival (OS) in subjects with PD-L1 CPS $\geq$ 10 3. Overall Survival (OS) in all subjects.
<b>Statistical Methods for Key Efficacy Analyses</b>	The primary hypotheses will be evaluated by comparing pembrolizumab to the control on OS in subjects with squamous cell carcinoma of the esophagus and OS in subjects with PD-L1 CPS $\geq$ 10 using a stratified Log-rank test. The primary hypotheses on OS in all subjects will be evaluated using a stratified maximum weighted log-rank test (max-combo test) [51], [52]. Estimation of the hazard ratio will be done using a stratified Cox regression model. Event rates over time will be estimated within each treatment group using the Kaplan-Meier method.
<b>Statistical Methods for Key Safety Analyses</b>	The analysis of safety results will follow a tiered approach. The tiers differ with respect to the analyses that will be performed. "Tier 1" safety endpoints will be subject to inferential testing for statistical significance with p-values and 95% confidence intervals provided for between-group comparisons. Other safety parameters will be considered Tier 2 or Tier 3. Tier 2 parameters will be assessed via point estimates with 95% confidence intervals provided for between-group comparisons; only point estimates by treatment group are provided for Tier 3 safety parameters. There are no Tier 1 events in this trial. The between-treatment difference will be analyzed using the Miettinen and Nurminen method [53].

<b>Interim Analyses</b>	<p>One interim efficacy analysis will be performed in this study. Results will be reviewed by an external data monitoring committee. Details are provided in Section 8.7.</p> <ul style="list-style-type: none"> <li>• <b>Interim Efficacy Analysis</b> <ul style="list-style-type: none"> <li>◦ <b>Timing:</b> To be performed after (1) enrollment is completed, (2) approximately 251 OS events and 385 OS events have been observed among subjects with squamous cell carcinoma of the esophagus and all subjects, respectively, and (3) 8 months after last subject randomized. In addition, if there are fewer than 172 OS events among subjects with PD-L1 CPS<math>\geq</math>10 at the time, the interim efficacy analysis may be delayed for up to 2 months or when the target number of OS events in subjects with PD-L1 CPS<math>\geq</math>10 is reached, whichever occurs first.</li> <li>◦ <b>Primary purpose:</b> Interim efficacy analysis for OS</li> </ul> </li> <li>• <b>Final Analysis</b> <ul style="list-style-type: none"> <li>◦ <b>Timing:</b> after approximately 310 OS events and 473 OS events have been observed among subjects with squamous cell carcinoma of the esophagus and all subjects, respectively , and 16 months after last subject randomized.</li> </ul> </li> </ul>
<b>Multiplicity</b>	<p>The multiplicity strategy specified in this section will be applied to the three primary hypotheses (superiority of pembrolizumab on OS in subjects with squamous cell carcinoma of the esophagus, or subjects with PD-L1 CPS<math>\geq</math>10 or in all subjects) and two secondary hypotheses (superiority of pembrolizumab on PFS in all subjects or ORR in all subjects).</p> <p>The overall Type-I error is strongly controlled at 2.5% (one-sided), with initially 0.8% allocated to OS hypothesis in subjects with squamous cell carcinoma of the esophagus, 0.9% allocated to OS hypothesis in subjects with PD-L1 CPS<math>\geq</math>10 and 0.8% allocated to the OS hypotheses in all subjects, and 0% to the PFS and ORR hypotheses. By using the graphical approach of Maurer and Bretz [54], if OS hypothesis in subjects with squamous cell carcinoma of the esophagus is rejected, the corresponding alpha level can be shifted to OS hypothesis in all subjects. If OS hypothesis in subjects with PD-L1 CPS<math>\geq</math>10 is rejected, the corresponding alpha level can also be shifted to OS hypotheses in all subjects.</p> <p>The secondary hypotheses of PFS and ORR will be tested only if pembrolizumab arm is superior to the control in OS in all subjects. If OS hypothesis in all subjects is rejected, the corresponding alpha level can be shifted by half to PFS in all subjects and by half to ORR in all subjects, respectively.</p>
<b>Sample Size and Power</b>	<p>For the hypotheses in all subjects, the sample size is approximately 600.</p> <p>Among all subjects, it is expected that about 400 subjects with squamous cell carcinoma of the esophagus will be enrolled. For the hypotheses in subjects with PD-L1 CPS<math>\geq</math>10, the sample size is approximately 280 (based on an observed prevalence rate of ~47% from KN180).</p> <p>For the primary endpoint, OS in subjects with squamous cell carcinoma of the esophagus, with 310 OS events, the trial has 91.3% power to demonstrate that pembrolizumab is superior to the control at a one-sided 0.8% alpha-level, if the underlying hazard ratio of OS is 0.65.</p> <p>For the primary endpoint, OS in subjects with PD-L1 CPS<math>\geq</math>10, with 213 OS events, the trial has 90.9% power to demonstrate that pembrolizumab is superior to the control at a one-sided 0.9% alpha-level, if the underlying hazard ratio of OS is 0.6.</p> <p>For the primary endpoint, OS in all subjects, with 473 OS events, the trial has 92.6% power to demonstrate that pembrolizumab is superior to the control at a one-sided 0.8% alpha-level, if the underlying hazard ratio of OS is 0.7.</p>

## **8.2 Responsibility for Analyses/In-House Blinding**

The statistical analysis of the data obtained from this study will be the responsibility of the Clinical Biostatistics department of the SPONSOR.

The SPONSOR will generate the randomized allocation schedule(s) for study treatment assignment for this protocol, and the randomization will be implemented in IVRS/IWRS.

Although the trial is open label, analyses or summaries generated by randomized treatment assignment, actual treatment received will be limited and documented. In addition, the central imaging vendor will perform the central imaging review without knowledge of treatment group assignment.

The eDMC will serve as the primary reviewer of the unblinded results of the interim analyses and will make recommendations for discontinuation of the study or modification to an executive oversight committee of the Sponsor. Depending on the recommendation of the eDMC, the Sponsor may prepare a regulatory submission. If the eDMC recommends modifications to the design of the protocol or discontinuation of the study, this executive oversight committee and limited additional Sponsor personnel may be unblinded to results at the treatment level in order to act on these recommendations. The extent to which individuals are unblinded with respect to results of interim analyses will be documented. Additional logistical details, revisions to the above plan and data monitoring guidance will be provided in the eDMC Charter.

## **8.3 Hypotheses/Estimation**

Objectives and hypotheses of the study are stated in Section 3.0.

## **8.4 Analysis Endpoints**

### **8.4.1 Efficacy Endpoints**

#### **Primary**

#### **Overall Survival**

Overall Survival (OS) is defined as the time from randomization to death due to any cause. Subjects without documented death at the time of the final analysis will be censored at the date of the last follow-up.

#### **Secondary**

Progression-free survival (PFS) – RECIST 1.1 by central imaging vendor review in all subjects;

Progression-free-survival (PFS) is defined as the time from randomization to the first documented disease progression per RECIST 1.1 based on central imaging vendor review or death due to any cause, whichever occurs first. See Section 8.6.1 for definition of censoring;

Objective Response Rate (ORR) – RECIST 1.1 by central imaging vendor review in all subjects;

Objective response rate is defined as the proportion of the subjects in the analysis population who have a complete response (CR) or partial response (PR).

#### **8.4.2 Safety Endpoints**

Safety measurements are described in Section 7.

### **8.5 Analysis Populations**

#### **8.5.1 Efficacy Analysis Populations**

The Intention-to-Treat (ITT) population will serve as the population for primary efficacy analysis. All randomized subjects will be included in this population. Subjects will be included in the treatment group to which they are randomized.

Details on the approach to handling missing data are provided in Section 8.6 Statistical Methods.

#### The China Cohort

After the sample size required for the Global Cohort is reached, the study will continue to randomize subjects in China until the sample size for the Chinese subjects meets the target for China. The Chinese subjects randomized after the enrollment of the Global Cohort is closed will not be included in the above primary efficacy analysis population which is based on the Global Cohort. The China Cohort will also be analyzed separately per local regulatory requirement.

#### **8.5.2 Safety Analysis Populations**

The All Subjects as Treated (ASaT) population will be used for the analysis of safety data in this study. The ASaT population consists of all randomized subjects who received at least one dose of study treatment. Subjects will be included in the treatment group corresponding to the study treatment they actually received for the analysis of safety data using the ASaT population. For most subjects this will be the treatment group to which they are randomized. Subjects who take incorrect study treatment for the entire treatment period will be included in the treatment group corresponding to the study treatment actually received. Any subject who receives the incorrect study medication for one cycle but receives the correct treatment for all other cycles will be analyzed according to the correct treatment group and a narrative will be provided for any events that occur during the cycle for which the subject is incorrectly dosed.

At least one laboratory or vital sign measurement obtained subsequent to at least one dose of study treatment is required for inclusion in the analysis of each specific parameter. To assess change from baseline, a baseline measurement is also required.

### The China Cohort

The Chinese subjects randomized and treated in the China extension enrollment period will not be included in the above primary safety analysis population. The China Cohort will also be analyzed separately per local regulatory requirement.

## **8.6 Statistical Methods**

### **8.6.1 Statistical Methods for Efficacy Analyses**

This section describes the statistical methods that address the primary and secondary objectives. Methods related to exploratory objectives will be described in the supplemental SAP.

Efficacy results that will be deemed to be statistically significant after consideration of the Type I error control strategy are described in Section 8.8, Multiplicity. Nominal p-values may be computed for other efficacy analyses, but should be interpreted with caution due to potential issues of multiplicity.

#### **8.6.1.1 Overall Survival (OS)**

The non-parametric Kaplan-Meier method will be used to estimate the survival curves. A stratified Cox proportional hazard model with Efron's method of tie handling will be used to estimate the magnitude of the treatment difference (i.e., the hazard ratio). The hazard ratio and its 95% confidence interval from the stratified Cox model with a single treatment covariate will be reported. The hypotheses of treatment difference for OS curves in subjects with squamous cell carcinoma of the esophagus and OS in subjects with PD-L1 CPS $\geq$ 10 will be tested using the stratified log-rank test. The hypotheses of treatment difference for OS curves in all subjects will be tested using the stratified max-combo test. The stratification factors used for randomization (See Section 5.4) will be applied to both the stratified log-rank test, stratified max-combo test, and the stratified Cox model if applicable.

The max-combo test statistic is the maximum of the log-rank test statistic and a weighted log-rank variation of the Fleming-Harrington test statistic;  $Z_m = \max (Z_1, Z_2)$ , where  $Z_1$  and  $Z_2$  are the test statistics from the FH (0, 0) and FH (0, 1) family of test statistics, respectively. FH (0, 0) corresponds to the log-rank test, while FH (0, 1) is more sensitive to late-difference alternatives.

A sensitivity analysis, which tests the hypothesis of treatment difference for OS in all subjects using the stratified log-rank test, will be conducted.

Subjects in the control arm are expected to discontinue treatment earlier compared to subjects in the pembrolizumab arm, and may switch to another anti PD-1 treatment. Exploratory analyses to adjust for the effect of crossover to other PD-1 therapies on OS may be performed based on recognized methods, e.g. the Rank Preserving Structural Failure Time (RPSFT) model proposed by Robins and Tsiatis (1989) [55], two stage model, etc., based on an examination of the appropriateness of the data to the assumptions required by the methods.

### 8.6.1.2 Progression-Free Survival (PFS)

The non-parametric Kaplan-Meier method will be used to estimate the PFS curve in each treatment group. A stratified Cox proportional hazard model with Efron's method of tie handling will be used to estimate the magnitude of the treatment difference (i.e., hazard ratio) between the treatment arms. The hazard ratio and its 95% confidence interval from the stratified Cox model with Efron's method of tie handling and with a single treatment covariate will be reported. The hypotheses of treatment difference for PFS curves in subjects with squamous cell carcinoma of the esophagus and PFS in subjects with PD-L1 CPS $\geq$ 10 will be tested using the stratified log-rank test. The hypotheses of treatment difference for PFS curves in all subjects will be tested using the stratified max-combo test. The stratification factors used for randomization (See Section 5.4) will be applied to both the stratified log-rank test, stratified max-combo test, and the stratified Cox model if applicable.

Since disease progression is assessed periodically, progressive disease (PD) can occur any time in the time interval between the last assessment where PD was not documented and the assessment when PD is documented. For the primary analysis, for the subjects who have PD, the true date of disease progression will be approximated by the date of the first assessment at which PD is objectively documented per RECIST 1.1 by central imaging vendor review, regardless of discontinuation of study drug. Death is always considered as a confirmed PD event. Sensitivity analyses will be performed for comparison of PFS based on investigator's assessment.

In order to evaluate the robustness of the PFS endpoint per RECIST 1.1 by central imaging vendor review, we will perform two sensitivity analyses with a different set of censoring rules. The first sensitivity analysis is the same as the primary analysis except that it censors at the last disease assessment without PD when PD or death is documented after more than one missed disease assessment. The second sensitivity analysis is the same as the primary analysis except that it considers discontinuation of treatment or initiation of an anticancer treatment subsequent to discontinuation of study-specified treatments, whichever occurs later, to be a PD event for subjects without documented PD or death. If a subject meets multiple criteria for censoring, the censoring criterion that occurs earliest will be applied. The censoring rules for primary and sensitivity analyses are summarized in [Table 9](#).

Table 9 Censoring rules for Primary and Sensitivity Analyses of PFS

Situation	Primary Analysis	Sensitivity Analysis 1	Sensitivity Analysis 2
No PD and no death; new anticancer treatment is not initiated	Censored at last disease assessment	Censored at last disease assessment	Censored at last disease assessment if still on study therapy; progressed at treatment discontinuation
No PD and no death; new anticancer treatment is initiated	Censored at last disease assessment before new anticancer treatment	Censored at last disease assessment before new anticancer treatment	Progressed at date of new anticancer treatment
No PD and no death; $\geq 2$ consecutive missed disease assessments	Censored at last disease assessment	Censored at last disease assessment prior to $\geq 2$ consecutive missed visits	Censored at last disease assessment
PD or death documented after $\leq 1$ missed disease assessment	Progressed at date of documented PD or death	Progressed at date of documented PD or death	Progressed at date of documented PD or death
PD or death documented at any time after $\geq 2$ consecutive missed	Progressed at date of documented PD or death	Censored at last disease assessment prior to the $\geq 2$ consecutive missed disease	Progressed at date of documented PD or death

The proportional hazards assumption on PFS will be examined using both graphical and analytical methods if warranted. The log[-log] of the survival function vs. time for PFS will be plotted for the comparison between pembrolizumab and the control arm. If the curves are not parallel, indicating that hazards are not proportional, supportive analyses may be conducted to account for the possible non-proportional hazards effect associated with immunotherapies: for example, using Restricted Mean Survival Time (RMST) method [56], parametric method [57], etc. Further details of sensitivity analyses will be described in supplemental SAP.

#### 8.6.1.3 Objective Response Rate (ORR)

Stratified Miettinen and Nurminen's method [53] will be used for comparison of the objective response rates between the treatment arms. The difference in ORR and its 95% confidence interval from the stratified Miettinen and Nurminen's method with strata weighting by sample size will be reported. The stratification factors used for randomization (See Section 5.4) will be applied to the analysis if applicable.

**Table 10** summarizes the primary analysis approach for primary and secondary efficacy endpoints. Sensitivity analysis methods are described above for each endpoint.

The strategy to address multiplicity issues with regard to multiple efficacy endpoints, multiple populations, and interim analyses is described in Section 8.7 Interim Analyses and in Section 8.8 Multiplicity.

Table 10 Analysis Strategy for Key Efficacy Endpoints

Endpoint/Variable (Description, Time Point)	†Statistical Method	Analysis Population	Missing Data Approach
<b>Primary Hypothesis #1</b>			
OS in subjects with squamous cell carcinoma of the Esophagus.	Test: Stratified Log-rank test Estimation: Stratified Cox model with Efron's tie handling method	ITT in subjects with squamous cell carcinoma of the Esophagus.	Censored at last known alive date
<b>Primary Hypothesis #2</b>			
OS in subjects with PD-L1 CPS $\geq$ 10.	Test: Stratified Log-rank test Estimation: Stratified Cox model with Efron's tie handling method	ITT in subjects with PD-L1 CPS $\geq$ 10	Censored at last known alive date
<b>Primary Hypothesis #3</b>			
OS in all subjects	Test: Max-combo test Estimation: Stratified Cox model with Efron's tie handling method	ITT in all subjects	Censored at last known alive date
<b>Key Secondary Endpoints</b>			
PFS per RECIST 1.1 by central imaging vendor review in all subjects	Test: Max-combo test Estimation: Stratified Cox model with Efron's tie handling method	ITT in all subjects	<ul style="list-style-type: none"> <li>• Primary censoring rule</li> <li>• Sensitivity analysis 1</li> <li>• Sensitivity analysis 2 (More details are in <a href="#">Table 9</a>)</li> </ul>
ORR per RECIST 1.1 by central imaging vendor review in all subjects	Test: Stratified M & N method <sup>‡</sup>	ITT in all subjects	Subjects with missing data are considered non-responders
† Statistical models are described in further detail in the text. For stratified analyses, the stratification factors used for randomization (See Section 5.4) will be applied to the analysis model if applicable.			
‡ Miettinen and Nurminen method [53]			

### 8.6.2 Statistical Methods for Safety Analyses

Safety and tolerability will be assessed by clinical review of all relevant parameters including adverse events (AEs), laboratory tests, vital signs, etc.

#### Tiered Approach

The analysis of safety results will follow a tiered approach ([Table 11](#)). The tiers differ with respect to the analyses that will be performed. “Tier 1” safety endpoints that will be subject to inferential testing for statistical significance with p-values and 95% confidence intervals provided for between-group comparisons. Other safety parameters will be considered Tier 2 or Tier 3. Tier 2 parameters will be assessed via point estimates with 95% confidence intervals provided for between-group comparisons; only point estimates by treatment group are provided for Tier 3 safety parameters.

AEs (specific terms as well as system organ class terms) that are not pre-specified as Tier 1 endpoints will be classified as belonging to "Tier 2" or "Tier 3", based on the number of events observed. Membership in Tier 2 requires that at least 4 subjects in any treatment group exhibit the event; all other AEs and predefined limits of change will belong to Tier 3.

The threshold of at least 4 events was chosen because the 95% confidence interval for the between-group difference in percent incidence will always include zero when treatment groups of equal size each have less than 4 events and thus would add little to the interpretation of potentially meaningful differences. Because many 95% confidence intervals may be provided without adjustment for multiplicity, the confidence intervals should be regarded as a helpful descriptive measure to be used in review, not a formal method for assessing the statistical significance of the between-group differences in AEs and predefined limits of change.

Continuous measures such as changes from baseline in laboratory, vital signs, that are not pre-specified as Tier 1 endpoints will be considered Tier 3 safety parameters. Summary statistics for baseline, on-treatment, and change from baseline values will be provided by treatment group in table format.

Based on the mechanism of action of pembrolizumab and safety data observed in historic pembrolizumab trials to date, there are no events of interest that warrant classification as Tier 1 events for this protocol. In addition, the broad clinical and laboratory AE categories consisting of the percentage of subjects with any AE, any drug related AE, any Grade 3-5 AE, any serious AE, any AE which is both drug-related and Grade 3-5, any AE which is both serious and drug-related, dose modification due to AE, and who discontinued due to an AE, and death will be considered Tier 2 endpoints. 95% confidence intervals (Tier 2) will be provided for between-treatment differences in the percentage of subjects with events; these analyses will be performed using the Miettinen and Nurminen method (1985) [53], an unconditional, asymptotic method.

Table 11 Analysis Strategy for Safety Parameters

<b>Safety Tier</b>	<b>Safety Endpoint<sup>†</sup></b>	<b>95% CI for Treatment Comparison</b>	<b>Descriptive Statistics</b>
Tier 2	Any AE Any Serious AE Any Grade 3-5 AE Any Drug-Related AE Any Serious and Drug-Related AE Any Grade 3-5 and Drug-Related AE Dose Modification due to AE Discontinuation due to AE Death Specific AEs, SOCs, or PDLCs <sup>‡</sup> (incidence $\geq 4$ of subjects in one of the treatment groups)	X X X X X X X X X	X X X X X X X X
Tier 3	Specific AEs, SOCs or PDLCs <sup>‡</sup> (incidence $< 4$ of subjects in all of the treatment groups) Change from Baseline Results (Labs, ECGs, Vital Signs)		X X

### 8.6.3 Summaries of Demographic and Baseline Characteristics

The comparability of the treatment groups for each relevant characteristic will be assessed by the use of tables and/or graphs. No statistical hypothesis tests will be performed on these characteristics. The number and percentage of subjects screened, randomized, the primary reasons for screening failure, and the primary reason for discontinuation will be displayed. Demographic variables (e.g., age), baseline characteristics, primary and secondary diagnoses, and prior and concomitant therapies will be summarized by treatment either by descriptive statistics or categorical tables.

### 8.7 Interim Analyses

There is one planned interim efficacy analysis in this trial. Results will be reviewed by an external data monitoring committee (eDMC).

The primary purpose of the interim efficacy analysis is to evaluate superiority of pembrolizumab in OS. In order to account for potential delayed treatment effects that have been observed with immunotherapy, the interim efficacy analysis will be performed after: (1) enrollment is completed, (2) approximately 251 OS events and 385 OS events have been observed among subjects with squamous cell carcinoma of the Esophagus and all subjects, respectively, and (3) 8 months after last subject randomized. In addition, if there are fewer than 172 OS events among subjects with PD-L1 CPS $\geq 10$  at the time, the interim efficacy analysis may be delayed for up to 2 months or when the target number of OS events in subjects with PD-L1 CPS $\geq 10$  is reached, whichever occurs first. Thus, adequate follow-up time is incorporated into the trial to ensure that the interim efficacy analysis is conducted at an appropriate time to characterize the potential benefit of immunotherapy. The boundary for

the final analysis will be adjusted according to the actual alpha spent at IA and the actual number of events at IA and FA.

For the OS hypotheses, Lan-DeMets O'Brien-Fleming alpha spending function with specified calendar time fraction (0.76)[58] will be used to construct group sequential boundaries to control the Type-I error.

$$\text{Calendar Time Fraction} = \frac{\text{Interim Analysis Time} (\sim 25 \text{ months after first subject randomized})}{\text{Final Analysis Time} (\sim 33 \text{ months after first subject randomized})} = 0.76$$

The actual boundaries for interim analysis will be determined from the number of OS events observed at the time of the interim efficacy analysis using the alpha spending function. The actual boundaries for final analysis will be determined from the number of OS events observed at the time of the interim efficacy analysis and final analysis using the alpha spending function.

**Table 12** summarizes the timing, sample size and decision guidance of the interim efficacy analysis and final analysis. Bounds are based on estimated number of events and will be updated at times of analyses using spending functions as noted above.

**Table 12 Summary of Timing, Sample Size and Decision Guidance of Interim Efficacy Analysis and Final Analysis**

	<b>Criteria for Conduct of Analysis</b>	<b>Endpoint</b>	<b>Value</b>	<b>Efficacy</b>
Interim Efficacy Analysis	~ 25 months after first subject randomized	OS in subjects with squamous cell carcinoma of the esophagus	p value (1-sided) at boundary ~ HR at boundary	≤0.0023 0.70
	Approximately 251 OS events and 385 OS events have been observed among subjects with squamous cell carcinoma of the esophagus and all subjects, respectively, and 8 months after last subject randomized. If there are fewer than 172 OS events among subjects with PD-L1 CPS≥10 at the time, the interim efficacy analysis may be delayed for up to 2 months or when the target number of OS events in subjects with PD-L1 CPS≥10 is reached, whichever occurs first. OS events among subjects with squamous cell carcinoma of the esophagus: ~251	OS in subjects with PD-L1 CPS≥10	p value (1-sided) at boundary ~ HR at boundary	≤0.0027 0.65
	OS events among subjects with PD-L1 CPS≥10: ~172 OS events among all subjects: 385	OS in all subjects	p value (1-sided) at boundary ~ HR at boundary	≤0.0023 0.75
Final Analysis	~ 33 months after first subject randomized	OS in subjects with squamous cell carcinoma of the esophagus	p value (1-sided) at boundary ~ HR at boundary	≤0.0075 0.76
	Approximately 310 OS events and 473 OS events have been observed among subjects with squamous cell carcinoma of the esophagus and all subjects, respectively, and 16 months after last subject randomized. OS events among subjects with squamous cell carcinoma of the esophagus: ~310 OS events among subjects with PD-L1 CPS≥10: ~213 OS events among all subjects: 473	OS in subjects with PD-L1 CPS≥10	p value (1-sided) at boundary ~ HR at boundary	≤0.0084 0.72
		OS in all subjects	p value (1-sided) at boundary ~ HR at boundary	≤0.0075 0.80

## 8.8 Multiplicity

The multiplicity strategy specified in this section will be applied to the three primary hypotheses (superiority of pembrolizumab on OS in subjects with squamous cell carcinoma of the esophagus or subjects with PD-L1 CPS $\geq$ 10 or all subjects) and two secondary hypotheses (superiority of pembrolizumab on PFS in all subjects and ORR in all subjects).

The overall Type-I error is strongly controlled at 2.5% (one-sided), with initially 0.8% allocated to OS hypothesis in subjects with squamous cell carcinoma of the esophagus, 0.9% allocated to OS hypothesis in subjects with PD-L1 CPS $\geq$ 10 and 0.8% allocated to OS hypothesis in all subjects, and 0% to PFS and ORR hypotheses.

Within each hypothesis, the Type-I error rate for the interim efficacy analysis and final analysis is controlled through alpha spending functions as described in Section 8.7 Interim Analyses.

By using the graphical approach of Maurer and Bretz [54], if OS hypothesis in subjects with squamous cell carcinoma of the esophagus is rejected, the corresponding alpha level can be shifted to OS hypothesis in all subjects. If the OS hypothesis in subjects with PD-L1 CPS $\geq$ 10 is rejected, the corresponding alpha level can also be shifted to the OS hypothesis in all subjects.

The secondary hypotheses of PFS and ORR will be tested only if pembrolizumab arm is superior to the control on OS in all subjects. If the OS hypothesis in all subjects is rejected, the corresponding alpha level can be shifted by half to PFS in all subjects and half to ORR in all subjects.

See [Figure 4](#) for the multiplicity strategy diagram of the study.




Figure 4 Multiplicity Strategy

## 8.9 Sample Size and Power Calculations

The study will randomize subjects in a 1:1 ratio into pembrolizumab arm and the control arm. The enrollment is driven by all subjects. The total sample size in the Global Cohort is approximately 600. It is expected that approximately 400 subjects with squamous cell carcinoma of the esophagus will be enrolled. Based on the observed preliminary prevalence of PD-L1 CPS $\geq$ 10 in subjects with esophageal carcinoma of ~47% from MK-3475 KN180, for the hypotheses in subjects with PD-L1 CPS $\geq$ 10, the sample size is approximately 280.

The final analysis of the study will complete after approximately 310 OS events and 473 OS events have been observed among subjects with squamous cell carcinoma of the esophagus and all subjects, respectively, and 16 months after last subject randomized.

### OS analysis

The sample size and power calculations are based on the following assumptions: 1) OS follows an exponential distribution with a median of 8 months in the control arm; 2) an enrollment period of 17 months and a minimum of 16 months follow-up after enrollment completion; 3) a yearly dropout rate of 2%.

The final OS analysis will be carried out after approximately 310 OS events and 473 OS events have been observed among subjects with squamous cell carcinoma of the esophagus and all subjects, respectively, and 16 months after last subject randomized. It is expected that approximately 213 OS events would have been observed in subjects with PD-L1 CPS $\geq$ 10. With 310/213/473 OS events in subjects with squamous cell carcinoma of the esophagus/subjects with PD-L1 CPS $\geq$ 10/all subjects, respectively, the trial has at least 91.3%/90.9%/92.6% power to demonstrate that pembrolizumab is superior to the control at a one-sided 0.8%/0.9%/0.8% alpha-level, if the underlying hazard ratio of OS is 0.65/0.6/0.7. Success for OS at the final analysis approximately corresponds to an observed hazard ratio of < 0.76 for subjects with squamous cell carcinoma of the esophagus, 0.72 for subjects with PD-L1 CPS $\geq$ 10, and < 0.80 for all subjects. To further investigate the impact of the delayed separation of OS curve on the actual power in all subjects, a simulation was carried out using the current study design parameters described above but with a piece-wise time varying hazard ratio: the hazard ratio was specified as 1 and 0.6 at the beginning of time intervals of Month 0 and 5 since randomization respectively. With 1,000 simulations the overall study power with 473 events at the final analysis given the hazard ratio assumption above is approximately 74.7% using log-rank test statistics and 86% using max-combo test statistics.

### The China Cohort

After the enrollment for the Global Cohort has completed, the study will continue to randomize subjects in a 1:1 ratio into the pembrolizumab arm and the SOC arm in China until the sample size for the Chinese subjects overall reaches approximately 120. Chinese subjects randomized after completion of enrollment in the Global Cohort will not be included in the analyses of the Global Cohort.

## **8.10 Subgroup Analyses and Effect of Baseline Factors**

To determine whether the treatment effect is consistent across various subgroups, the estimate of the between-group treatment effect (with a nominal 95% CI) for the three primary endpoints will be estimated and plotted within each category of the following classification variables:

- Age category (<65 vs.  $\geq$ 65 years)
- Sex (Female vs. Male)
- Geographic region (Asia vs. Rest of the World)
- ECOG Performance Scale (0 vs. 1)
- Histological subtype (Squamous cell carcinoma vs. adenocarcinoma/Siewert type 1 adenocarcinoma of the EGJ)

Country specific population (e.g. Chinese, Japanese, etc.) may also be analyzed per local regulatory requirements.

## **8.11 Compliance (Medication Adherence)**

Drug accountability data for trial treatment will be collected during the study. Any deviation from protocol-directed administration will be reported.

## **8.12 Extent of Exposure**

The extent of exposure will be summarized as duration of treatment in cycles.

## 9.0 LABELING, PACKAGING, STORAGE AND RETURN OF CLINICAL SUPPLIES

### 9.1 Investigational Product

The investigator shall take responsibility for and shall take all steps to maintain appropriate records and ensure appropriate supply, storage, handling, distribution and usage of investigational product in accordance with the protocol and any applicable laws and regulations.

Clinical Supplies will be provided by the Sponsor as summarized in [Table 13](#).

Clinical supplies will be packaged to support enrollment and replacement subjects as required. When a replacement subject is required, the Sponsor or designee needs to be contacted prior to dosing the replacement supplies.

Table 13 Product Descriptions

Product Name & Potency	Dosage Form	Source/Additional Information
MK-3475	Injection	Provided centrally by the Sponsor
Paclitaxel, 6 mg/mL *	Injection	Provided centrally by the Sponsor or locally by the trial site, subsidiary, or designee.
Docetaxel, 20 mg/mL *	Injection	Provided centrally by the Sponsor or locally by the trial site, subsidiary, or designee.
Irinopecan, 20 mg/mL *	Injection	Provided centrally by the Sponsor or locally by the trial site, subsidiary, or designee.

\* NOTE: Concentration may be different for products sourced in China.

All other supplies not indicated in [Table 13](#) above will be provided centrally by the Sponsor or locally by the trial site, subsidiary or designee, depending on local country operational or regulatory requirements.

For any commercially available product that is provided by the trial site, subsidiary or designee every attempt will be made to source these supplies from a single lot/batch number. The trial site is responsible to record the lot number, manufacturer and expiry date for any locally purchased product as per local guidelines unless otherwise instructed by the Sponsor.

### 9.2 Packaging and Labeling Information

Clinical supplies will be affixed with a clinical label in accordance with regulatory requirements.

Subjects will receive open label vials and/or kits for each treatment cycle. The MK-3475 will not be kitted. The standard of care drugs will be kitted. Each kit will contain 1 vial.

### **9.3 Clinical Supplies Disclosure**

The trial is open-label; therefore, the subject, the trial site personnel, the Sponsor and/or designee are not blinded. Treatment (name, strength or potency) is included in the label text; random code/disclosure envelopes or lists are not provided.

### **9.4 Storage and Handling Requirements**

Clinical supplies must be stored in a secure, limited-access location under the storage conditions specified on the label.

Receipt and dispensing of trial medication must be recorded by an authorized person at the trial site.

Clinical supplies may not be used for any purpose other than that stated in the protocol.

### **9.5 Discard/Destruction>Returns and Reconciliation**

The investigator is responsible for keeping accurate records of the clinical supplies received from the Sponsor or designee, the amount dispensed to and returned by the subjects and the amount remaining at the conclusion of the trial. For all trial sites, the local country Sponsor personnel or designee will provide appropriate documentation that must be completed for drug accountability and return, or local discard and destruction if appropriate. Where local discard and destruction is appropriate, the investigator is responsible for ensuring that a local discard/destruction procedure is documented.

### **9.6 Standard Policies**

Trial site personnel will have access to a central electronic treatment allocation/randomization system (IVRS/IWRS system) to allocate subjects, to assign treatment to subjects and to manage the distribution of clinical supplies. Each person accessing the IVRS system must be assigned an individual unique PIN. They must use only their assigned PIN to access the system, and they must not share their assigned PIN with anyone.

## **10.0 ADMINISTRATIVE AND REGULATORY DETAILS**

### **10.1 Confidentiality**

#### **10.1.1 Confidentiality of Data**

By signing this protocol, the investigator affirms to the Sponsor that information furnished to the investigator by the Sponsor will be maintained in confidence, and such information will be divulged to the institutional review board, ethics review committee (IRB/ERC) or similar or expert committee; affiliated institution and employees, only under an appropriate understanding of confidentiality with such board or committee, affiliated institution and employees. Data generated by this trial will be considered confidential by the investigator, except to the extent that it is included in a publication as provided in the Publications section of this protocol.

#### **10.1.2 Confidentiality of Subject Records**

By signing this protocol, the investigator agrees that the Sponsor (or Sponsor representative), IRB/ERC, or regulatory authority representatives may consult and/or copy trial documents in order to verify worksheet/case report form data. By signing the consent form, the subject agrees to this process. If trial documents will be photocopied during the process of verifying worksheet/case report form information, the subject will be identified by unique code only; full names/initials will be masked prior to transmission to the Sponsor.

By signing this protocol, the investigator agrees to treat all subject data used and disclosed in connection with this trial in accordance with all applicable privacy laws, rules and regulations.

#### **10.1.3 Confidentiality of Investigator Information**

By signing this protocol, the investigator recognizes that certain personal identifying information with respect to the investigator, and all subinvestigators and trial site personnel, may be used and disclosed for trial management purposes, as part of a regulatory submissions, and as required by law. This information may include:

1. name, address, telephone number and e-mail address;
2. hospital or clinic address and telephone number;
3. curriculum vitae or other summary of qualifications and credentials; and
4. other professional documentation.

Consistent with the purposes described above, this information may be transmitted to the Sponsor, and subsidiaries, affiliates and agents of the Sponsor, in your country and other countries, including countries that do not have laws protecting such information. Additionally, the investigator's name and business contact information may be included when reporting certain serious adverse events to regulatory authorities or to other

investigators. By signing this protocol, the investigator expressly consents to these uses and disclosures.

If this is a multicenter trial, in order to facilitate contact between investigators, the Sponsor may share an investigator's name and contact information with other participating investigators upon request.

#### **10.1.4 Confidentiality of IRB/IEC Information**

The Sponsor is required to record the name and address of each IRB/IEC member that reviews and approves this trial. The Sponsor is also required to document that each IRB/IEC meets regulatory and ICH GCP requirements by requesting and maintaining records of the names and qualifications of the IRB/IEC members and to make these records available for regulatory agency review upon request by those agencies.

### **10.2 Compliance with Financial Disclosure Requirements**

Financial Disclosure requirements are outlined in the US Food and Drug Administration Regulations, Financial Disclosure by Clinical Investigators (21 CFR Part 54). It is the Sponsor's responsibility to determine, based on these regulations, whether a request for Financial Disclosure information is required. It is the investigator's/subinvestigator's responsibility to comply with any such request.

The investigator/subinvestigator(s) agree, if requested by the Sponsor in accordance with 21 CFR Part 54, to provide his/her financial interests in and/or arrangements with the Sponsor to allow for the submission of complete and accurate certification and disclosure statements. The investigator/subinvestigator(s) further agree to provide this information on a Certification/Disclosure Form, commonly known as a financial disclosure form, provided by the Sponsor. The investigator/subinvestigator(s) also consent to the transmission of this information to the Sponsor in the United States for these purposes. This may involve the transmission of information to countries that do not have laws protecting personal data.

### **10.3 Compliance with Law, Audit and Debarment**

By signing this protocol, the investigator agrees to conduct the trial in an efficient and diligent manner and in conformance with this protocol; generally accepted standards of Good Clinical Practice (e.g., International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use Good Clinical Practice: Consolidated Guideline and other generally accepted standards of good clinical practice); and all applicable federal, state and local laws, rules and regulations relating to the conduct of the clinical trial.

The Code of Conduct, a collection of goals and considerations that govern the ethical and scientific conduct of clinical investigations sponsored by Merck, is provided in Section 12.1 - Merck Code of Conduct for Clinical Trials.

The investigator also agrees to allow monitoring, audits, IRB/ERC review and regulatory authority inspection of trial-related documents and procedures and provide for direct access to all trial-related source data and documents.

The investigator agrees not to seek reimbursement from subjects, their insurance providers or from government programs for procedures included as part of the trial reimbursed to the investigator by the Sponsor.

The investigator shall prepare and maintain complete and accurate trial documentation in compliance with Good Clinical Practice standards and applicable federal, state and local laws, rules and regulations; and, for each subject participating in the trial, provide all data, and, upon completion or termination of the clinical trial, submit any other reports to the Sponsor as required by this protocol or as otherwise required pursuant to any agreement with the Sponsor.

Trial documentation will be promptly and fully disclosed to the Sponsor by the investigator upon request and also shall be made available at the trial site upon request for inspection, copying, review and audit at reasonable times by representatives of the Sponsor or any regulatory authorities. The investigator agrees to promptly take any reasonable steps that are requested by the Sponsor as a result of an audit to cure deficiencies in the trial documentation and worksheets/case report forms.

The investigator must maintain copies of all documentation and records relating to the conduct of the trial in compliance with all applicable legal and regulatory requirements. This documentation includes, but is not limited to, the protocol, worksheets/case report forms, advertising for subject participation, adverse event reports, subject source data, correspondence with regulatory authorities and IRBs/ERCs, consent forms, investigator's curricula vitae, monitor visit logs, laboratory reference ranges, laboratory certification or quality control procedures and laboratory director curriculum vitae. By signing this protocol, the investigator agrees that documentation shall be retained until at least 2 years after the last approval of a marketing application in an ICH region or until there are no pending or contemplated marketing applications in an ICH region or until at least 2 years have elapsed since the formal discontinuation of clinical development of the investigational product. Because the clinical development and marketing application process is variable, it is anticipated that the retention period can be up to 15 years or longer after protocol database lock. The Sponsor will determine the minimum retention period and notify the investigator when documents may be destroyed. The Sponsor will determine the minimum retention period and upon request, will provide guidance to the investigator when documents no longer need to be retained. The sponsor also recognizes that documents may need to be retained for a longer period if required by local regulatory requirements. All trial documents shall be made available if required by relevant regulatory authorities. The investigator must consult with and obtain written approval by the Sponsor prior to destroying trial and/or subject files.

ICH Good Clinical Practice guidelines recommend that the investigator inform the subject's primary physician about the subject's participation in the trial if the subject has a primary physician and if the subject agrees to the primary physician being informed.

The investigator will promptly inform the Sponsor of any regulatory authority inspection conducted for this trial.

Persons debarred from conducting or working on clinical trials by any court or regulatory authority will not be allowed to conduct or work on this Sponsor's trials. The investigator will immediately disclose in writing to the Sponsor if any person who is involved in conducting the trial is debarred or if any proceeding for debarment is pending or, to the best of the investigator's knowledge, threatened.

In the event the Sponsor prematurely terminates a particular trial site, the Sponsor will promptly notify that trial site's IRB/IEC.

According to European legislation, a Sponsor must designate an overall coordinating investigator for a multi-center trial (including multinational). When more than one trial site is open in an EU country, Merck, as the Sponsor, will designate, per country, a national principal coordinator (Protocol CI), responsible for coordinating the work of the principal investigators at the different trial sites in that Member State, according to national regulations. For a single-center trial, the Protocol CI is the principal investigator. In addition, the Sponsor must designate a principal or coordinating investigator to review the trial report that summarizes the trial results and confirm that, to the best of his/her knowledge, the report accurately describes the conduct and results of the trial [Clinical Study Report (CSR) CI]. The Sponsor may consider one or more factors in the selection of the individual to serve as the Protocol CI and or CSR CI (e.g., availability of the CI during the anticipated review process, thorough understanding of clinical trial methods, appropriate enrollment of subject cohort, timely achievement of trial milestones). The Protocol CI must be a participating trial investigator.

#### **10.4 Compliance with Trial Registration and Results Posting Requirements**

Under the terms of the Food and Drug Administration Modernization Act (FDAMA) and the Food and Drug Administration Amendments Act (FDAAA), the Sponsor of the trial is solely responsible for determining whether the trial and its results are subject to the requirements for submission to the Clinical Trials Data Bank, <http://www.clinicaltrials.gov>. Merck, as Sponsor of this trial, will review this protocol and submit the information necessary to fulfill these requirements. Merck entries are not limited to FDAMA/FDAAA mandated trials. Information posted will allow subjects to identify potentially appropriate trials for their disease conditions and pursue participation by calling a central contact number for further information on appropriate trial locations and trial site contact information.

By signing this protocol, the investigator acknowledges that the statutory obligations under FDAMA/FDAAA are that of the Sponsor and agrees not to submit any information about this trial or its results to the Clinical Trials Data Bank.

#### **10.5 Quality Management System**

By signing this protocol, the Sponsor agrees to be responsible for implementing and maintaining a quality management system with written development procedures and

functional area standard operating procedures (SOPs) to ensure that trials are conducted and data are generated, documented, and reported in compliance with the protocol, accepted standards of Good Clinical Practice, and all applicable federal, state, and local laws, rules and regulations relating to the conduct of the clinical trial.

## **10.6 Data Management**

The investigator or qualified designee is responsible for recording and verifying the accuracy of subject data. By signing this protocol, the investigator acknowledges that his/her electronic signature is the legally binding equivalent of a written signature. By entering his/her electronic signature, the investigator confirms that all recorded data have been verified as accurate.

Detailed information regarding Data Management procedures for this protocol will be provided separately.

## **10.7 Publications**

This trial is intended for publication, even if terminated prematurely. Publication may include any or all of the following: posting of a synopsis online, abstract and/or presentation at a scientific conference, or publication of a full manuscript. The Sponsor will work with the authors to submit a manuscript describing trial results within 12 months after the last data become available, which may take up to several months after the last subject visit in some cases such as vaccine trials. However, manuscript submission timelines may be extended on OTC trials. For trials intended for pediatric-related regulatory filings, the investigator agrees to delay publication of the trial results until the Sponsor notifies the investigator that all relevant regulatory authority decisions on the trial drug have been made with regard to pediatric-related regulatory filings. Merck will post a synopsis of trial results for approved products on [www.clinicaltrials.gov](http://www.clinicaltrials.gov) by 12 months after the last subject's last visit for the primary outcome, 12 months after the decision to discontinue development, or product marketing (dispensed, administered, delivered or promoted), whichever is later.

These timelines may be extended for products that are not yet marketed, if additional time is needed for analysis, to protect intellectual property, or to comply with confidentiality agreements with other parties. Authors of the primary results manuscript will be provided the complete results from the Clinical Study Report, subject to the confidentiality agreement. When a manuscript is submitted to a biomedical journal, the Sponsor's policy is to also include the protocol and statistical analysis plan to facilitate the peer and editorial review of the manuscript. If the manuscript is subsequently accepted for publication, the Sponsor will allow the journal, if it so desires, to post on its website the key sections of the protocol that are relevant to evaluating the trial, specifically those sections describing the trial objectives and hypotheses, the subject inclusion and exclusion criteria, the trial design and procedures, the efficacy and safety measures, the statistical analysis plan, and any amendments relating to those sections. The Sponsor reserves the right to redact proprietary information.

For multicenter trials, subsequent to the multicenter publication (or after public disclosure of the results online at [www.clinicaltrials.gov](http://www.clinicaltrials.gov) if a multicenter manuscript is not planned), an

investigator and his/her colleagues may publish their data independently. In most cases, publication of individual trial site data does not add value to complete multicenter results, due to statistical concerns. In rare cases, publication of single trial site data prior to the main paper may be of value. Limitations of single trial site observations in a multicenter trial should always be described in such a manuscript.

Authorship credit should be based on 1) substantial contributions to conception and design, or acquisition of data, or analysis and interpretation of data; 2) drafting the article or revising it critically for important intellectual content; and 3) final approval of the version to be published. Authors must meet conditions 1, 2 and 3. Significant contributions to trial execution may also be taken into account to determine authorship, provided that contributions have also been made to all three of the preceding authorship criteria. Although publication planning may begin before conducting the trial, final decisions on authorship and the order of authors' names will be made based on participation and actual contributions to the trial and writing, as discussed above. The first author is responsible for defending the integrity of the data, method(s) of data analysis and the scientific content of the manuscript.

The Sponsor must have the opportunity to review all proposed abstracts, manuscripts or presentations regarding this trial 45 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission; this confidentiality does not include efficacy and safety results. Sponsor review can be expedited to meet publication timelines.

## 11.0 LIST OF REFERENCES

- [1] Nishino M, Giobbie-Hurder A, Gargano M, Suda M, Ramaiya NH, Hodi FS. Developing a common language for tumor response to immunotherapy: immune-related response criteria using unidimensional measurements. *Clin Cancer Res.* 2013 Jul 15;19(14):3936-43.
- [2] Disis ML. Immune regulation of cancer. *J Clin Oncol* 2010;28(29):4531-8.
- [3] Greenwald RJ, Freeman GJ, Sharpe AH. The B7 family revisited. *Annu Rev Immunol* 2005;23:515-48.
- [4] Okazaki T, Maeda A, Nishimura H, Kurosaki T, Honjo T. PD-1 immunoreceptor inhibits B cell receptor-mediated signaling by recruiting src homology 2-domain-containing tyrosine phosphatase 2 to phosphotyrosine. *Proc Natl Acad Sci U S A* 2001;98(24):13866-71.
- [5] Zhang X, Schwartz J-CD, Guo X, Bhatia S, Cao E, Chen L, et al. Structural and functional analysis of the costimulatory receptor programmed death-1. *Immunity* 2004;20:337-47.
- [6] Chemnitz JM, Parry RV, Nichols KE, June CH, Riley JL. SHP-1 and SHP-2 associate with immunoreceptor tyrosine-based switch motif of programmed death 1 upon primary human T cell stimulation, but only receptor ligation prevents T cell activation. *J Immunol* 2004;173:945-54.
- [7] Sheppard K-A, Fitz LJ, Lee JM, Benander C, George JA, Wooters J, et al. PD-1 inhibits T-cell receptor induced phosphorylation of the ZAP70/CD3zeta signalosome and downstream signaling to PKCtheta. *FEBS Lett.* 2004;574:37-41.
- [8] Riley JL. PD-1 signaling in primary T cells. *Immunol Rev* 2009;229:114-25.
- [9] Parry RV, Chemnitz JM, Frauwirth KA, Lanfranco AR, Braunstein I, Kobayashi SV, et al. CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms. *Mol Cell Biol* 2005;25(21):9543-53.
- [10] Francisco LM, Sage PT, Sharpe AH. The PD-1 pathway in tolerance and autoimmunity. *Immunol Rev* 2010;236:219-42.
- [11] Kloor M. Lymphocyte infiltration and prognosis in colorectal cancer. *Lancet Oncol.* 2009 Sep;10(9):840-1.
- [12] Hillen F, Baeten CIM, van de Winkel A, Creytens D, van der Schaft DWJ, Winnepernincx V, et al. Leukocyte infiltration and tumor cell plasticity are parameters of aggressiveness in primary cutaneous melanoma. *Cancer Immunol Immunother* 2008;57(1):97-106.

[13] Lee HE, Chae SW, Lee YJ, Kim MA, Lee HS, Lee BL, et al. Prognostic implications of type and density of tumour-infiltrating lymphocytes in gastric cancer. *Br J Cancer* 2008;99(10):1704-11.

[14] Leffers N, Gooden MJM, de Jong RA, Hoogeboom B-N, ten Hoor KA, Hollema H, et al. Prognostic significance of tumor-infiltrating T-lymphocytes in primary and metastatic lesions of advanced stage ovarian cancer. *Cancer Immunol Immunother* 2009;58(3):449-59.

[15] Nishimura H, Honjo T, Minato N. Facilitation of beta selection and modification of positive selection in the thymus of PD-1-deficient mice. *J Exp Med.* 2000 Mar 6;191(5):891-8.

[16] Hiraoka N. Tumor-infiltrating lymphocytes and hepatocellular carcinoma: molecular biology. *Int J Clin Oncol* 2010;15(6):544-51.

[17] Liotta F, Gacci M, Frosali F, Querci V, Vittori G, Lapini A, et al. Frequency of regulatory T cells in peripheral blood and in tumour-infiltrating lymphocytes correlates with poor prognosis in renal cell carcinoma. *BJU Int* 2011;107(9):1500-6.

[18] Ropponen KM, Eskelinen MJ, Lippinen PK, Alhava E, Kosma V-M. Prognostic value of tumour-infiltrating lymphocytes (TILs) in colorectal cancer. *J Pathol* 1997;182(3):318-24.

[19] Dudley ME, Wunderlich JR, Yang JC, Sherry RM, Topalian SL, Restifo NP, et al. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. *J Clin Oncol* 2005;23(10):2346-57.

[20] Hunder NN, Wallen H, Cao J, Hendricks DW, Reilly JZ, Rodmyre R, et al. Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1. *N Engl J Med* 2008;358(25):2698-703.

[21] Pölcher M, Braun M, Friedrichs N, Rudlowski C, Bercht E, Fimmers R, et al. Foxp3(+) cell infiltration and granzyme B(+)/Foxp3(+) cell ratio are associated with outcome in neoadjuvant chemotherapy-treated ovarian carcinoma. *Cancer Immunol Immunother* 2010;59(6):909-19.

[22] Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. *CA Cancer J Clin* 2011;61:69-90.

[23] Bosetti C, Levi F, Ferlay J, Garavello W, Lucchini F, Bertuccio P, et al. Trends in oesophageal cancer incidence and mortality in Europe. *Int J Cancer.* 2008 Mar 1;122(5):1118-29.

[24] Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015 Jan;65(1):5-29.

[25] Kuwano H, Nishimura Y, Oyama T, Kato H, Kitagawa Y, Kusano M, et al. Guidelines for Diagnosis and Treatment of Carcinoma of the Esophagus April 2012 edited by the Japan Esophageal Society. Esophagus. 2015;12:1-30.

[26] Corley DA, Buffler PA. Oesophageal and gastric cardia adenocarcinomas: analysis of regional variation using the Cancer Incidence in Five Continents database. Int J Epidemiol. 2001 Dec;30(6):1415-25.

[27] Brown LM, Devesa SS, Chow WH. Incidence of adenocarcinoma of the esophagus among white Americans by sex, stage, and age. J Natl Cancer Inst. 2008 Aug 20;100(16):1184-7.

[28] Trivers KF, Sabatino SA, Stewart SL. Trends in esophageal cancer incidence by histology, United States, 1998-2003. Int J Cancer. 2008 Sep 15;123(6):1422-8.

[29] Pickens A, Orringer MB. Geographical distribution and racial disparity in esophageal cancer. Ann Thorac Surg. 2003 Oct;76(4):S1367-9.

[30] Siewert JR, Ott K. Are squamous and adenocarcinomas of the esophagus the same disease? Semin Radiat Oncol. 2007 Jan;17(1):38-44.

[31] Siewert JR, Stein HJ, Feith M, Bruecher BL, Bartels H, Fink U. Histologic tumor type is an independent prognostic parameter in esophageal cancer: lessons from more than 1,000 consecutive resections at a single center in the Western world. Ann Surg. 2001 Sep;234(3):360-7; discussion 368-9.

[32] Dutton SJ, Ferry DR, Blazeby JM, Abbas H, Dahle-Smith A, Mansoor W, et al. Gefitinib for oesophageal cancer progressing after chemotherapy (COG): a phase 3, multicentre, double-blind, placebo-controlled randomised trial. Lancet Oncol. 2014 Jul;15(8):894-904.

[33] Grunberger B, Raderer M, Schmidinger M, Hejna M. Palliative chemotherapy for recurrent and metastatic esophageal cancer. Anticancer Res. 2007 Jul-Aug;27(4C):2705-14.

[34] Cunningham D, Starling N, Rao S, Iveson T, Nicolson M, Coxon F, et al. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med. 2008 Jan 3;358(1):36-46.

[35] Thuss-Patience PC, Kretzschmar A, Bichev D, Deist T, Hinke A, Breithaupt K, et al. Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer--a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). Eur J Cancer. 2011 Oct;47(15):2306-14.

[36] Ford HER, Marshall A, Bridgewater JA, Janowitz T, Coxon FY, Wadsley J, et al. Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial. *Lancet Oncol.* 2014 Jan;15(1):78-86.

[37] Ilson DH, Wadleigh RG, Leichman LP, Kelsen DP. Paclitaxel given by a weekly 1-h infusion in advanced esophageal cancer. *Ann Oncol.* 2007 May;18(5):898-902.

[38] Fenchel K, Karthaus M, Steffens C, Dreher K, Boehme V, Pralle H, et al. Taxanes: An effective 2nd line treatment of advanced esophageal cancer - A randomised trial [abstract]. Abstracts of the 1999 ASCO Annual Meeting; 1999 May 15 - 18; Atlanta, Georgia. ASCO; 1999. p. 283a.

[39] Anderson SE, O'Reilly EM, Kelsen DP, Ilson DH. Phase II trial of 96-hour paclitaxel in previously treated patients with advanced esophageal cancer. *Cancer Invest.* 2003;21(4):512-6.

[40] Heath EI, Urba S, Marshall J, Piantadosi S, Forastiere AA. Phase II trial of docetaxel chemotherapy in patients with incurable adenocarcinoma of the esophagus. *Invest New Drugs.* 2002 Feb;20(1):95-9.

[41] Muro K, Hamaguchi T, Ohtsu A, Boku N, Chin K, Hyodo I, et al. A phase II study of single-agent docetaxel in patients with metastatic esophageal cancer. *Ann Oncol.* 2004 Jun;15(6):955-9.

[42] Metges J, Hennequin C, Ychou M, Malhaire J, Gouerou H, Maylin C, et al. Docetaxel (DOC) as a second line chemotherapy in metastatic esophageal cancer (MEC): a french study [abstract]. Abstracts of the 2001 ASCO Annual Meeting; 2001 May 12 - 15; San Francisco, California. ASCO; 2001. p. 160a.

[43] Shim HJ, Cho SH, Hwang JE, Bae WK, Song SY, Cho SB, et al. Phase II study of docetaxel and cisplatin chemotherapy in 5-fluorouracil/cisplatin pretreated esophageal cancer. *Am J Clin Oncol.* 2010 Dec;33(6):624-8.

[44] Ribas A, Robert C, Hodi FS, Wolchok JD, Joshua AM, Hwu WJ, et al. Association of response to programmed death receptor 1 (PD-1) blockade with pembrolizumab (MK-3475) with an interferon-inflammatory immune gene signature. 2015 ASCO (American Society of Clinical Oncology) Annual Meeting; 2015 May 29-June 2; Chicago, IL.

[45] Seiwert TY, Burtness B, Weiss J, Eder JP, Yearley J, Murphy E, et al. Inflamed-phenotype gene expression signatures to predict benefit from the anti-PD-1 antibody pembrolizumab in PD-L1+ head and neck cancer patients. 2015 ASCO (American Society of Clinical Oncology) Annual Meeting; 2015 May 29-June 2; Chicago, IL.

[46] Shankaran V, Muro K, Bang YJ, Geva R, Catenacci DV, et al. Correlation of gene expression signatures and clinical outcomes in patients with advanced gastric cancer treated with pembrolizumab (MK-3475). 2015 ASCO (American Society of Clinical Oncology) Annual Meeting; 2015 May 29-June 2; Chicago, IL.

[47] Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. *J Natl Cancer Inst* 1993;85(5):365-76.

[48] Blazeby JM, Conroy T, Hammerlid E, Fayers P, Sezer O, Koller M, et al. Clinical and psychometric validation of an EORTC questionnaire module, the EORTC QLQ-OES18, to assess quality of life in patients with oesophageal cancer. *Eur J Cancer*. 2003 Jul;39(10):1384-94.

[49] The EuroQol Group. EuroQol - a new facility for the measurement of health-related quality of life. *Health Policy* 1990;16(3):199-208.

[50] Johnson DB, Rieth MJ, Horn L. Immune checkpoint inhibitors in NSCLC. *Curr Treat Options Oncol*. 2014 Dec;15(4):658-69.

[51] Seung-Hwan L. On the versatility of the combination of the weighted log-rank statistics. *Comput Stat Data Anal*. 2007 Mar;51(12):6057-64.

[52] Garrison TG. Versatile tests for comparing survival curves based on weighted log-rank statistics. *The Stata Journal*. 2016;16(3):678-90.

[53] Miettinen O, Nurminen M. Comparative analysis of two rates. *Stat Med* 1985;4:213-26.

[54] Maurer W, Bretz F. Multiple testing in group sequential trials using graphical approaches. *Stat Biopharm Res* 2013;5(4):311-20.

[55] Robins JM, Tsiatis AA. Correcting for non-compliance in randomized trials using rank preserving structural failure time models. *Commun Stat Theory Methods* 1991;20(8):2609-31.

[56] Uno H, Claggett B, Tian L, Inoue E, Gallo P, Miyata T, et al. Moving beyond the hazard ratio in quantifying the between-group difference in survival analysis. *J Clin Oncol*. 2014 Aug 1;32(22):2380-5.

[57] Odell PM, Anderson KM, Kannel WB. New models for predicting cardiovascular events. *J Clin Epidemiol*. 1994 Jun;47(6):583-92.

[58] Lan KKG, DeMets DL. Group sequential procedures: calendar versus information time: biostatistics technical report. Madison (WI): University of Wisconsin Clinical Cancer Center (US); 1988 May. 16 p. Report No.:44.

## 12.0 APPENDICES

### 12.1 Merck Code of Conduct for Clinical Trials

**Merck\***  
**Code of Conduct for Clinical Trials**

#### **I. Introduction**

##### **A. Purpose**

Merck, through its subsidiaries, conducts clinical trials worldwide to evaluate the safety and effectiveness of our products. As such, we are committed to designing, implementing, conducting, analyzing and reporting these trials in compliance with the highest ethical and scientific standards. Protection of subject safety is the overriding concern in the design of clinical trials. In all cases, Merck clinical trials will be conducted in compliance with local and/or national regulations and in accordance with the ethical principles that have their origin in the Declaration of Helsinki.

##### **B. Scope**

Such standards shall be endorsed for all clinical interventional investigations sponsored by Merck irrespective of the party (parties) employed for their execution (e.g., contract research organizations, collaborative research efforts). This Code is not intended to apply to trials which are observational in nature, or which are retrospective. Further, this Code does not apply to investigator-initiated trials which are not under the control of Merck.

#### **II. Scientific Issues**

##### **A. Trial Conduct**

###### **1. Trial Design**

Except for pilot or estimation trials, clinical trial protocols will be hypothesis-driven to assess safety, efficacy and/or pharmacokinetic or pharmacodynamic indices of Merck or comparator products. Alternatively, Merck may conduct outcomes research trials, trials to assess or validate various endpoint measures, or trials to determine subject preferences, etc.

The design (i.e., subject population, duration, statistical power) must be adequate to address the specific purpose of the trial. Research subjects must meet protocol entry criteria to be enrolled in the trial.

###### **2. Site Selection**

Merck selects investigative sites based on medical expertise, access to appropriate subjects, adequacy of facilities and staff, previous performance in Merck trials, as well as budgetary considerations. Prior to trial initiation, sites are evaluated by Merck personnel to assess the ability to successfully conduct the trial.

###### **3. Site Monitoring/Scientific Integrity**

Trial sites are monitored to assess compliance with the trial protocol and general principles of Good Clinical Practice. Merck reviews clinical data for accuracy, completeness and consistency. Data are verified versus source documentation according to standard operating procedures. Per Merck policies and procedures, if fraud, misconduct or serious GCP-non-Compliance are suspected, the issues are promptly investigated. When necessary, the clinical site will be closed, the responsible regulatory authorities and ethics review committees notified and data disclosed accordingly.

##### **B. Publication and Authorship**

To the extent scientifically appropriate, Merck seeks to publish the results of trials it conducts. Some early phase or pilot trials are intended to be hypothesis-generating rather than hypothesis testing. In such cases, publication of results may not be appropriate since the trial may be underpowered and the analyses complicated by statistical issues of multiplicity.

Merck's policy on authorship is consistent with the requirements outlined in the ICH-Good Clinical Practice guidelines. In summary, authorship should reflect significant contribution to the design and conduct of the trial, performance or interpretation of the analysis, and/or writing of the manuscript. All named authors must be able to defend the trial results and conclusions. Merck funding of a trial will be acknowledged in publications.

**III. Subject Protection**

**A. IRB/ERC review**

All clinical trials will be reviewed and approved by an independent IRB/ERC before being initiated at each site. Significant changes or revisions to the protocol will be approved by the IRB/ERC prior to implementation, except that changes required urgently to protect subject safety and well-being may be enacted in anticipation of IRB/ERC approval. For each site, the IRB/ERC and Merck will approve the subject informed consent form.

**B. Safety**

The guiding principle in decision-making in clinical trials is that subject welfare is of primary importance. Potential subjects will be informed of the risks and benefits of, as well as alternatives to, trial participation. At a minimum, trial designs will take into account the local standard of care. Subjects are never denied access to appropriate medical care based on participation in a Merck clinical trial.

All participation in Merck clinical trials is voluntary. Subjects are enrolled only after providing informed consent for participation. Subjects may withdraw from a Merck trial at any time, without any influence on their access to, or receipt of, medical care that may otherwise be available to them.

**C. Confidentiality**

Merck is committed to safeguarding subject confidentiality, to the greatest extent possible. Unless required by law, only the investigator, sponsor (or representative) and/or regulatory authorities will have access to confidential medical records that might identify the research subject by name.

**D. Genomic Research**

Genomic Research will only be conducted in accordance with informed consent and/or as specifically authorized by an Ethics Committee.

**IV. Financial Considerations**

**A. Payments to Investigators**

Clinical trials are time- and labor-intensive. It is Merck's policy to compensate investigators (or the sponsoring institution) in a fair manner for the work performed in support of Merck trials. Merck does not pay incentives to enroll subjects in its trials. However, when enrollment is particularly challenging, additional payments may be made to compensate for the time spent in extra recruiting efforts.

Merck does not pay for subject referrals. However, Merck may compensate referring physicians for time spent on chart review to identify potentially eligible subjects.

**B. Clinical Research Funding**

Informed consent forms will disclose that the trial is sponsored by Merck, and that the investigator or sponsoring institution is being paid or provided a grant for performing the trial. However, the local IRB/ERC may wish to alter the wording of the disclosure statement to be consistent with financial practices at that institution. As noted above, publications resulting from Merck trials will indicate Merck as a source of funding.

**C. Funding for Travel and Other Requests**

Funding of travel by investigators and support staff (e.g., to scientific meetings, investigator meetings, etc.) will be consistent with local guidelines and practices including, in the U.S., those established by the American Medical Association (AMA).

**V. Investigator Commitment**

Investigators will be expected to review Merck's Code of Conduct as an appendix to the trial protocol, and in signing the protocol, agree to support these ethical and scientific standards.

\* In this document, "Merck" refers to Merck Sharp & Dohme Corp. and Schering Corporation, each of which is a subsidiary of Merck & Co., Inc. Merck is known as MSD outside of the United States and Canada. As warranted by context, Merck also includes affiliates and subsidiaries of Merck & Co., Inc."

## 12.2 Collection and Management of Specimens for Future Biomedical Research

### 1. Definitions

- a. Biomarker: A biological molecule found in blood, other body fluids, or tissues that is a sign of a normal or abnormal process or of a condition or disease. A biomarker may be used to see how well the body responds to a treatment for a disease or condition.<sup>1</sup>
- b. Pharmacogenomics: The investigation of variations of DNA and RNA characteristics as related to drug/vaccine response.<sup>2</sup>
- c. Pharmacogenetics: A subset of pharmacogenomics, pharmacogenetics is the influence of variations in DNA sequence on drug/vaccine response.<sup>2</sup>
- d. DNA: Deoxyribonucleic acid.
- e. RNA: Ribonucleic acid.

### 2. Scope of Future Biomedical Research

The specimens collected in this trial as outlined in Section 7.1.3.5 – Future Biomedical Research Sample Collection will be used to study various causes for how subjects may respond to a drug/vaccine. Future biomedical research specimen(s) will be stored to provide a resource for future trials conducted by the Sponsor focused on the study of biomarkers responsible for how a drug/vaccine enters and is removed by the body, how a drug/vaccine works, other pathways a drug/vaccine may interact with, or other aspects of disease. The specimen(s) may be used for future assay development and/or drug/vaccine development.

It is now well recognized that information obtained from studying and testing clinical specimens offers unique opportunities to enhance our understanding of how individuals respond to drugs/vaccines, enhance our understanding of human disease and ultimately improve public health through development of novel treatments targeted to populations with the greatest need. All specimens will be used by the Sponsor or those working for or with the Sponsor.

### 3. Summary of Procedures for Future Biomedical Research

#### a. Subjects for Enrollment

All subjects enrolled in the clinical trial will be considered for enrollment in the Future Biomedical Research sub-trial.

#### b. Informed Consent

Informed consent for specimens (i.e., DNA, RNA, protein, etc.) will be obtained during screening for protocol enrollment from all subjects or legal guardians, at a trial visit by the investigator or his or her designate. Informed consent for Future Biomedical Research should be presented to the subjects on Visit 1. If delayed, present consent at next possible Subject Visit. Informed consent must be obtained prior to collection of all Future Biomedical Research specimens. Consent forms signed by the subject will be kept at the clinical trial site under secure storage for regulatory reasons.

A template of each trial site's approved informed consent will be stored in the Sponsor's clinical document repository. Each consent will be assessed for appropriate specimen permissions.

c. eCRF Documentation for Future Biomedical Research Specimens

Documentation of patient consent for Future Biomedical Research will be captured in the electronic Case Report Forms (eCRFs). Any specimens for which such an informed consent cannot be verified will be destroyed.

d. Future Biomedical Research Specimen Collections

Collection of specimens for Future Biomedical Research will be performed as outlined in the trial flow chart. In general, if additional blood specimens are being collected for Future Biomedical Research, these will usually be obtained at a time when the subject is having blood drawn for other trial purposes.

**4. Confidential Subject Information for Future Biomedical Research**

In order to optimize the research that can be conducted with Future Biomedical Research specimens, it is critical to link subject' clinical information with future test results. In fact little or no research can be conducted without connecting the clinical trial data to the specimen. The clinical data allow specific analyses to be conducted. Knowing subject characteristics like gender, age, medical history and treatment outcomes are critical to understanding clinical context of analytical results.

To maintain privacy of information collected from specimens obtained for Future Biomedical Research, the Sponsor has developed secure policies and procedures. All specimens will be single-coded per ICH E15 guidelines as described below.

At the clinical trial site, unique codes will be placed on the Future Biomedical Research specimens for transfer to the storage facility. This first code is a random number which does not contain any personally identifying information embedded within it. The link (or key) between subject identifiers and this first unique code will be held at the trial site. No personal identifiers will appear on the specimen tube.

**5. Biorepository Specimen Usage**

Specimens obtained for the Merck Biorepository will be used for analyses using good scientific practices. Analyses utilizing the Future Biomedical Research specimens may be performed by the Sponsor, or an additional third party (e.g., a university investigator) designated by the Sponsor. The investigator conducting the analysis will follow the Sponsor's privacy and confidentiality requirements. Any contracted third party analyses will conform to the specific scope of analysis outlined in this sub-trial. Future Biomedical Research specimens remaining with the third party after specific analysis is performed will be reported to the Sponsor.

**6. Withdrawal From Future Biomedical Research**

Subjects may withdraw their consent for Future Biomedical Research and have their specimens and all derivatives destroyed. Subjects may withdraw consent at any time by contacting the principal investigator for the main trial. If medical records for the main trial are still available, the investigator will contact the Sponsor using the designated

mailbox (clinical.specimen.management@merck.com) and a form will be provided to obtain appropriate information to complete specimen withdrawal. Subsequently, the subject's specimens will be removed from the biorepository and be destroyed. Documentation will be sent to the investigator confirming the destruction. It is the responsibility of the investigator to inform the subject of completion of destruction. Any analyses in progress at the time of request for destruction or already performed prior to the request being received by the Sponsor will continue to be used as part of the overall research trial data and results. No new analyses would be generated after the request is received.

In the event that the medical records for the main trial are no longer available (e.g., if the investigator is no longer required by regulatory authorities to retain the main trial records) or the specimens have been completely anonymized, there will no longer be a link between the subject's personal information and their specimens. In this situation, the request for specimen destruction can not be processed.

## **7. Retention of Specimens**

Future Biomedical Research specimens will be stored in the biorepository for potential analysis for up to 20 years from the end of the main study. Specimens may be stored for longer if a regulatory or governmental authority has active questions that are being answered. In this special circumstance, specimens will be stored until these questions have been adequately addressed.

Specimens from the trial site will be shipped to a central laboratory and then shipped to the Sponsor-designated biorepository. If a central laboratory is not utilized in a particular trial, the trial site will ship directly to the Sponsor-designated biorepository. The specimens will be stored under strict supervision in a limited access facility which operates to assure the integrity of the specimens. Specimens will be destroyed according to Sponsor policies and procedures and this destruction will be documented in the biorepository database.

## **8. Data Security**

Databases containing specimen information and test results are accessible only to the authorized Sponsor representatives and the designated trial administrator research personnel and/or collaborators. Database user authentication is highly secure, and is accomplished using network security policies and practices based on international standards (e.g., ISO17799) to protect against unauthorized access.

## **9. Reporting of Future Biomedical Research Data to Subjects**

No information obtained from exploratory laboratory studies will be reported to the subject, family, or physicians. Principle reasons not to inform or return results to the subject include: Lack of relevance to subject health, limitations of predictive capability, and concerns regarding misinterpretation.

If any exploratory results are definitively associated with clinical significance for subjects while the clinical trial is still ongoing, investigators will be contacted with information. After the clinical trial has completed, if any exploratory results are definitively associated with clinical significance, the Sponsor will endeavor to make such results available

through appropriate mechanisms (e.g., scientific publications and/or presentations). Subjects will not be identified by name in any published reports about this study or in any other scientific publication or presentation.

## **10. Future Biomedical Research Study Population**

Every effort will be made to recruit all subjects diagnosed and treated on Sponsor clinical trials for Future Biomedical Research.

## **11. Risks Versus Benefits of Future Biomedical Research**

For future biomedical research, risks to the subject have been minimized. 'No additional risks to the subject have been identified as no additional specimens are being collected for Future Biomedical Research (i.e., only leftover samples are being retained).'

The Sponsor has developed strict security, policies and procedures to address subject data privacy concerns. Data privacy risks are largely limited to rare situations involving possible breach of confidentiality. In this highly unlikely situation there is risk that the information, like all medical information, may be misused.


## **12. Questions**

Any questions related to the future biomedical research should be e-mailed directly to [clinical.specimen.management@merck.com](mailto:clinical.specimen.management@merck.com).

## **13. References**

1. National Cancer Institute: <http://www.cancer.gov/dictionary/?searchTxt=biomarker>
2. International Conference on Harmonization: DEFINITIONS FOR GENOMIC BIOMARKERS, PHARMACOGENOMICS, PHARMACOGENETICS, GENOMIC DATA AND SAMPLE CODING CATEGORIES - E15; <http://www.ich.org/products/guidelines/efficacy/efficacy-single/article/definitions-for-genomic-biomarkers-pharmacogenomics-pharmacogenetics-genomic-data-and-sample-cod.html>

## 12.3 Understanding the Intent, Scope and Public Health Benefits of Exploratory Biomarker Research: A Guide for IRBs/IECs and Investigational Site Staff



This informational brochure is intended for IRBs/IECs and Investigational Site Staff. The brochure addresses issues relevant to specimen collection for biomarker research in the context of pharmaceutical drug and vaccine development.

Developed by  
The Industry Pharmacogenomics Working Group (I-PWG)  
[www.i-pwg.org](http://www.i-pwg.org)

## 1. What is a Biomarker and What is Biomarker Research?

A biomarker is a "characteristic that is objectively measured and evaluated as an indicator of normal biological processes, pathogenic processes, or pharmacologic responses to a therapeutic intervention".<sup>1</sup>

Biomarker research, including research on pharmacogenomic biomarkers, is a tool used to improve the development of pharmaceuticals and understanding of disease. It involves the analysis of biomolecules (such as DNA, RNA, proteins, and lipids), or other measurements (such as blood pressure or brain images) in relation to clinical endpoints of interest. Biomarker research can be influential across all phases of drug development, from drug discovery and preclinical evaluations to clinical development and post-marketing studies. This brochure focuses on biomarker research involving analysis of biomolecules from biological samples collected in clinical trials. Please refer to I-PWG Pharmacogenomic Informational Brochure<sup>2</sup> and ICH Guidance E15<sup>3</sup> for additional information specific to pharmacogenomic biomarkers.

## 2. Why is Biomarker Research Important?

**Importance to Patients and Public Health**  
Biomarker research is helping to improve our ability to predict, detect, and monitor diseases and improve our understanding of how individuals respond to drugs. This research underlies personalized medicine: a tailored approach to patient treatment based on the molecular analysis of genes, proteins, and metabolites.<sup>4</sup> The goal of biomarker research is to aid clinical decision-making toward safer and more efficacious courses of treatment, improved patient outcomes, and overall cost-savings. It also allows for the continued development and availability of drugs that are effective in certain sub-populations when they otherwise might not have been developed due to insufficient efficacy in the broader population.

Recent advances in biomedical technology, including genetic and molecular medicine, have greatly increased the power and precision of analytical tools used in health research and have accelerated the drive toward personalized medicine. In some countries, highly focused initiatives have been created to promote biomarker research (e.g., in the US: [www.fda.gov/oc/initiatives/criticalpath/](http://www.fda.gov/oc/initiatives/criticalpath/); in the EU: [www.imi.europa.eu/index\\_en.html](http://www.imi.europa.eu/index_en.html)).

**Importance to Drug Development**  
Biomarker research is being used by the pharmaceutical industry to streamline the drug development process. Some biomarkers are used as substitutes or "surrogates" for safety or efficacy endpoints in clinical trials particularly where clinical outcomes or events cannot practically or ethically be measured (e.g., cholesterol as a surrogate for cardiovascular disease).<sup>5</sup> By using biomarkers to assess patient response, ineffective drug candidates may be terminated earlier in the development process in favor of more promising drug candidates. Biomarkers are being used to optimize clinical trial designs and outcomes by identifying patient populations that are more likely to respond to a drug therapy or to avoid specific adverse events.

INDUSTRY  
**I-PWG**  
PHARMACOGENOMICS WORKING GROUP

Biomarker research is also being used to enhance scientific understanding of the mechanisms of both treatment response and disease processes, which can help to identify future targets for drug development. Depending on the clinical endpoints in a clinical trial, biomarker sample collection may either be a required or optional component of the trial. However, both mandatory and optional sample collections are important for drug development.

### 3. Importance of Biomarkers to Regulatory Authorities

Regulatory health authorities are increasingly aware of the benefits of biomarkers and how they may be used for drug approval, clinical trial design, and clinical care. Biomarkers have been used to establish risk:benefit profiles. For example, the FDA has modified the US warfarin (Coumadin®) label to include the analysis of CYP2C9 and VKORC1 genes to guide dosing regimens. Health authorities such as the FDA (USA), EMEA (European Union), MHLW (Japan), and ICH (International) are playing a key role in advancing this scientific field as it applies to pharmaceutical development by creating the regulatory infrastructure to facilitate this research. Numerous regulatory guidances and concept papers have already been issued, many of which are available through [www.i-pwg.org](http://www.i-pwg.org). Global regulatory authorities have highlighted the importance of biomarker research and the need for the pharmaceutical industry to take the lead in this arena.<sup>3,6-24</sup>

### 4. How are Biomarkers Being Used in Drug/Vaccine Development?

Biomarker research is currently being used in drug/vaccine development to:

- Explain variability in response among participants in clinical trials
- Better understand the mechanism of action or metabolism of investigational drugs
- Obtain evidence of pharmacodynamic activity (i.e., how the drug affects the body) at the molecular level
- Address emerging clinical issues such as unexpected adverse events
- Determine eligibility for clinical trials to optimize trial design
- Optimize dosing regimens to minimize adverse reactions and maximize efficacy
- Develop drug-linked diagnostic tests to identify patients who are more likely or less likely to benefit from treatment or who may be at risk of experiencing adverse events
- Provide better understanding of mechanisms of disease
- Monitor clinical trial participant response to medical interventions

Biomarker research, including research on banked samples, should be recognized as an important public health endeavor for the overall benefit of society, whether by means of advancement of medical science or by development of safer and more effective therapies.<sup>7</sup> Since the value of collected samples may increase over time as scientific discoveries are made, investment in long-term sample repositories is a key component of biomarker research.



## 5. Biomarkers are Already a Reality in Health Care

A number of drugs now have biomarker information included in their labels.<sup>25</sup> Biomarker tests are already being used in clinical practice to serve various purposes:

**Predictive biomarkers (efficacy)** – In clinical practice, predictive efficacy biomarkers are used to predict which patients are most likely to respond, or not respond, to a particular drug. Examples include: i) *Her2/neu* overexpression analysis required for prescribing trastuzumab (Herceptin<sup>®</sup>) to breast cancer patients, ii) *c-kit* expression analysis prior to prescribing imatinib mesylate (Gleevec<sup>®</sup>) to gastrointestinal stromal tumor patients, and iii) *KRAS* mutational status testing prior to prescribing panitumumab (Vectibix<sup>®</sup>) or cetuximab (Erbitux<sup>®</sup>) to metastatic colorectal cancer patients.

**Predictive biomarkers (safety)** – In clinical practice, predictive safety biomarkers are used to select the proper drug dose or to evaluate the appropriateness of continued therapy in the event of a safety concern. Examples include: i) monitoring of blood potassium levels in patients receiving drospirenone and ethynodiol estradiol (Yasmin<sup>®</sup>) together with daily long-term drug regimens that may increase serum potassium, and ii) prospective *HL4-B+5701* screening to identify those at increased risk for hypersensitivity to abacavir (Ziagen<sup>®</sup>).

**Surrogate biomarkers** – In clinical practice, surrogate biomarkers may be used as alternatives to measures such as survival or irreversible morbidity. Surrogate biomarkers are measures that are reasonably likely, based on epidemiologic, therapeutic, pathophysiologic, or other evidence, to predict clinical benefit. Examples include: i) LDL level as a surrogate for risk of cardiovascular diseases in patients taking lipid-lowering agents such as atorvastatin calcium (Lipitor<sup>®</sup>), ii) blood glucose as a surrogate for clinical outcomes in patients taking anti-diabetic agents, and iii) HIV plasma viral load and CD4 cell counts as sur-

rogates for time-to-clinical-events and overall survival in patients receiving antiretroviral therapy for HIV disease.

**Prognostic biomarkers** – Biomarkers can also help predict clinical outcomes independent of any treatment modality. Examples of prognostic biomarkers used in clinical practice include: i) CellSearch<sup>TM</sup> to predict progression-free survival in breast cancer, ii) anti-CCP (cyclic citrullinated protein) for the severity of rheumatoid arthritis, iii) estrogen receptor status for breast cancer, and iv) anti-dsDNA for the severity of systemic lupus erythematosus.

## 6. Biomarker Samples from Clinical Trials: An Invaluable Resource

Adequate sample sizes and high-quality data from controlled clinical trials are key to advancements in biomarker research. Samples collected in clinical trials create the opportunity for investigation of biomarkers related to specific drugs, drug classes, and disease areas. Clinical drug development programs are therefore an invaluable resource and a unique opportunity for highly productive biomarker research. In addition to conducting independent research, pharmaceutical companies are increasingly contributing to consortia efforts by pooling samples, data, and expertise in an effort to conduct rigorous and efficient biomarker research and to maximize the probability of success.<sup>26-27</sup>

## 7. Informed Consent for Collection & Banking of Biomarker Samples

Collection of biological samples in clinical trials must be undertaken with voluntary informed consent of the participant (or legally-acceptable representative). Policies



and regulations for legally-appropriate informed consent vary on national, state, and local levels, but are generally based on internationally recognized pillars of ethical conduct for research on human subjects.<sup>28-31</sup>

**Optional vs. Required Subject Participation**  
Depending on the relevance of biomarker research to a clinical development program at the time of protocol development, the biomarker research may be a core required component of a trial (e.g., key to elucidating the drug mechanism of action or confirming that the drug is interacting with the target) or may be optional (e.g., to gain valuable knowledge that enhances the understanding of diseases and drugs). Informed consent for the collection of biomarker samples may be presented either in the main clinical informed consent form or as a separate informed consent form, with approaches varying somewhat across pharmaceutical companies. The relevance of biomarker research to a clinical development program may change over time as the science evolves. The samples may therefore increase in value after a protocol is developed.

**Consent for Future Research Use**  
While it can be a challenge to specify the details of the research that will be conducted in the future, the I-PWG holds the view that future use of samples collected for exploratory biomarker research in clinical trials should be permissible when i) the research is scientifically sound, ii) participants are informed of the scope of the intended future research, even if this is broadly defined (see potential uses in Section 4 above), iii) autonomy is respected by providing the option to consent separately to future use of samples or by providing the option to terminate further use of samples upon request (consent withdrawal / sample destruction), and iv) industry standards for confidentiality protection per Good Clinical Practice guidelines are met.<sup>3, 31</sup> Importantly, any research using banked samples should be consistent with the original informed consent, except where otherwise permitted by local law or regulation.

4


Important elements of informed consent for future use of samples include, but are not limited to:<sup>30</sup>

**The scope of research** – Where the scope of the potential future research is broad, participants should be informed of the boundaries of the research. While it may not be possible to describe the exact analytical techniques that will be used, or specific molecules that will be analyzed, it is possible to clearly articulate in reasonable detail the type of research to be conducted and its purpose. Information regarding whether stored samples may be shared with other parties or utilized for commercialization purposes should also be addressed.

**Withdrawal of consent / sample destruction** – The informed consent form should inform participants of their right to withdraw their consent / request destruction of their samples. This should include the mechanisms for exercising that right and any limitations to exercising that right. For example, participants should be informed that it is not possible to destroy samples that have been anonymized.<sup>3</sup> In addition, according to industry standards and regulatory guidance, participants should be informed that data already generated prior to a consent withdrawal request are to be maintained as part of the study data.<sup>30</sup>

**The duration of storage** – The permissible duration of storage may vary according to the nature and uses of the samples and may also vary on national, state, and local levels. The intended duration of storage, including indefinite storage, should be specified.

INDUSTRY  
**I-PWG**  
PHARMACEUTICAL WORKING GROUP



## 8. Biomarker Sample Collection in Different Countries

Collection of biological samples for biomarker research is straightforward in most jurisdictions. Some countries have specific laws and regulations regarding collection, labeling, storage, export, and/or use of exploratory samples. In addition, some regulations distinguish between DNA and non-DNA samples or between samples used for diagnostic purposes and samples collected for scientific research. Processes for the collection, labeling, storage, export, and/or use of biomarker samples should always adhere to the laws and regulations of the country/region in which those samples are collected.

## 9. Return of Research Results to Study Participants

Policies for the return of biomarker research results to study participants who request them vary among pharmaceutical companies. There are many considerations that pharmaceutical companies weigh when determining their policy regarding the return of biomarker research results to study participants. These include:

- i) the conditions under which biomarker research results were generated (i.e., exploratory research laboratory versus accredited diagnostic laboratory)
- ii) whether the results will have an impact on the medical care of the participant or on a related person, if applicable
- iii) whether genetic counseling is recommended (for genetic results)
- iv) the ability to accurately link the result to the individual from whom the sample was collected
- v) international, national, and local guidelines, policies, legislation, and regulations regarding participants' rights to access data generated on them

Renegar *et al.* 2006 and Article 29 Data Protection Working Party (an advisory committee to the European Commission on the European Data Protection Directive) have addressed these considerations in detail in relation to pharmacogenomic research data and provided a list of documents addressing the general issue of return of research results.<sup>34-36</sup>

## 10. Benefits and Risks Associated with Biomarker Research

### Benefits

While it may not always directly benefit the study participant who is providing the samples, biomarker research can improve overall understanding of disease and treatment of future patients receiving therapies developed from such research. Patients are now benefiting from retrospective biomarker research conducted on samples collected from clinical trials and stored for exploratory research. One example is the recent label update to the EGFR antibody drugs cetuximab (Erbitux<sup>®</sup>) and panitumumab (Vectibix<sup>®</sup>) which highlights the value of KRAS status as a predictive biomarker for treatment of metastatic colorectal cancer with this class of drug.

The humanitarian benefit of human research is recognized by the Nuremberg Code.<sup>28,33</sup> Provided that the degree of risk does not exceed that determined by the humanitarian importance of the problem to be solved, research participants should not be denied the right to contribute to the greater common good.<sup>28,32</sup>

### Risks

Risks associated with biomarker research are primarily related to the physical aspects of obtaining the sample and to patient privacy concerns.

Physical risks associated with biomarker sample collection in clinical trials can be characterized in two ways:

- i) negligible additional risk when the biomarker sample is collected as part of a procedure conducted to support



other core trial objectives, and ii) some added risk where the sampling procedure would otherwise have not been performed as a core component of a trial. Risks are also determined by the invasiveness of the sample collection procedure.

Privacy risks are generally those associated with the inappropriate disclosure and misuse of data. Pharmaceutical companies have policies and procedures for confidentiality protection to minimize this risk for all data collected and generated in clinical trials. These may vary across companies, but are based on industry standards of confidentiality and privacy protection highlighted in the following section. Importantly, privacy risks inherent to biomarker data are no greater than other data collected in a clinical trial.

## 11. Privacy, Confidentiality, and Patient Rights

Maintaining the privacy of study participants and the confidentiality of information relating to them is of paramount concern to industry researchers, regulators, and patients. Good Clinical Practice (GCP), the standard adhered to in pharmaceutical clinical research, is a standard that

*"...provides assurance that the data and reported results are credible and accurate, and that the rights, integrity, and confidentiality of trial subjects are protected,"*

where confidentiality is defined as, *"The prevention of disclosure, to other than authorized individuals, of a sponsor's proprietary information or of a subject's identity."*

This standard dictates that *"the confidentiality of records that could identify subjects should be protected, respecting the privacy and confidentiality rules in accordance with applicable regulatory requirements."*<sup>31</sup>

7


Exploratory biomarker research in pharmaceutical development is commonly conducted in research laboratories that are not accredited to perform diagnostic tests used for healthcare decision-making. Therefore, results from exploratory biomarker research usually are not appropriate for use in making decisions about a trial participant's health. In addition, exploratory research data should not be included as part of a participant's medical record accessible for use by insurance companies. Legislation and policies to protect individuals against discrimination based on genetic information continually evolve based on social, ethical, and legal considerations. Examples of such legislation include the Human Tissue Act 2004 (UK) and the Genetic Information Nondiscrimination Act (GINA) 2008 (USA).<sup>36-37</sup>

## 12. Where to Get More Information?

Educational resources related to biomarker and pharmacogenomic research that caters to health care professionals, IRBs/IECs, scientists, and patients are continually being created and are publicly available. Links to many of these resources are available through the I-PWG website: [www.i-pwg.org](http://www.i-pwg.org).

## 13. What is I-PWG?

The Industry Pharmacogenomics Working Group (I-PWG) (formerly the Pharmacogenetics Working Group) is a voluntary association of pharmaceutical companies engaged in pharmacogenomic research. The Group's activities focus on non-competitive educational, informational, ethical, legal, and regulatory topics. The Group provides information and expert opinions on these topics and sponsors educational/informational programs to promote better understanding of pharmacogenomic and other biomarker research for key stakeholders. The I-PWG interacts with regulatory author-



ities and policy groups to ensure alignment. More information about the I-PWG is available at: [www.i-pwg.org](http://www.i-pwg.org).

#### 14. Contributing authors

Monique A. Franc, Teresa Heesley, Feng Hong, Ronenn Roubenoff, Jasjit Sarang, Andrea Tyukody Renninger, Amelia Warner

#### 15. References

1. Atkinson AJ, Colburn WA, DeGruttola VG, et al. Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework. *Clinical Pharmacology & Therapeutics*. 2001; 69(3): 89-95. (Accessed at: [www.ncbi.nlm.nih.gov/pubmed/11240971](http://www.ncbi.nlm.nih.gov/pubmed/11240971))
2. I-PWG Pharmacogenomics Informational Brochure, 2008. (Accessed at: [http://www.i-pwg.org/cms/index.php?option=com\\_docman&task=doc\\_download&gid=77&Itemid=118](http://www.i-pwg.org/cms/index.php?option=com_docman&task=doc_download&gid=77&Itemid=118))
3. ICH E16 – Definitions for Genomic Biomarkers, Pharmacogenomics, Pharmacogenetics, Genomic Data and Sample Coding Categories. April 2008. (Accessed at: [www.fda.gov/CDER/OfficeofNewDrugs/DOCKETS/98fr/FDA-2008-O-0199-gd1.pdf](http://www.fda.gov/CDER/OfficeofNewDrugs/DOCKETS/98fr/FDA-2008-O-0199-gd1.pdf) and at: <http://www.ich.org/LOBs/media/MEDIA3363.pdf>)
4. Davis JC, Furukenthal L, Desai AA, et al. The microeconomics of personalized medicine: today's challenge and tomorrow's promise. *Nature Reviews Drug Discovery*. 2009; 8: 279. (Accessed at: <http://www.nature.com/nrdd/journal/v8/n4/abs/nrdd2825.html>)
5. Bems B, Demols P, Scheulen ME. How can biomarkers become surrogate endpoints? *European Journal of Cancer Supplements* 2007; 5: 37-40. (Accessed at: [www.journals.elsevierhealth.com/periodicals/ejosp/Issues/contents?issue\\_key=G1359-6349%2807%29X0031-4](http://www.journals.elsevierhealth.com/periodicals/ejosp/Issues/contents?issue_key=G1359-6349%2807%29X0031-4))
6. Lesko LJ, Woodcock J. Translation of pharmacogenomics and pharmacogenetics: a regulatory perspective. *Nature Reviews Drug Discovery*. 2004; 3: 763-769. (Accessed at: [www.nature.com/nrdd/journal/v3/n9/abs/nrdd1489.html](http://www.nature.com/nrdd/journal/v3/n9/abs/nrdd1489.html))
7. Lesko LJ, Woodcock J. Pharmacogenomic-guided drug development: regulatory perspective. *The Pharmacogenomics Journal*, 2002; 2: 20-24. (Accessed at: [www.ncbi.nlm.nih.gov/pubmed/11990376](http://www.ncbi.nlm.nih.gov/pubmed/11990376))
8. Petricoin EF, Hackett JL, Lesko LJ, et al. Medical applications of microarray technologies: a regulatory science perspective. *Nat Genet*, 2002; 32: 474-479. (Accessed at: [www.nature.com/ng/journal/v32/n4/abs/ng1029.html](http://www.nature.com/ng/journal/v32/n4/abs/ng1029.html))
9. Lesko LJ, Salerno RA, Spear BB, et al. Pharmacogenetics and pharmacogenomics in drug development and regulatory decision making: report of the first FDA-PWG-PhRMA-DruSafe Workshop. *J Clin Pharmacol*. 2003; 43: 342-358. (Accessed at: <http://jcp.sagepub.com/cgi/content/abstract/43/4/342>)
10. Salerno RA, Lesko LJ. Pharmacogenomics in Drug Development and Regulatory Decision-making: the Genomic Data Submission (GDS) Proposal. *Pharmacogenomics*. 2004; 5: 25-30. (Accessed at: [www.futuremedicine.com/doi/pdf/10.2217/14622416.5.1.25](http://www.futuremedicine.com/doi/pdf/10.2217/14622416.5.1.25))
11. Frueh FW, Goodale F, Rudman A, et al. The need for education in pharmacogenomics: a regulatory perspective. *The Pharmacogenomics Journal*, 2005; 5: 218-220. (Accessed at: [www.nature.com/tpj/journal/v5/n4/abs/6500316a.html](http://www.nature.com/tpj/journal/v5/n4/abs/6500316a.html))
12. Genomic Biomarkers Related to Drug Response: Context, Structure and Format of Qualification Submissions. ICH E16 Step 3 draft. (Accessed at: [www.emea.europa.eu/pdfs/human/ich/31063609endraft.pdf](http://www.emea.europa.eu/pdfs/human/ich/31063609endraft.pdf))
13. Guiding principles Processing Joint FDA EMEA Voluntary Genome Data Submissions (VGDSs) within the framework of the Confidentiality Arrangement. May 19, 2006. (Accessed at: [www.emea.europa.eu/WorkArea/DrugScienceResearchAndResearchArea/Pharmacogenomics/um/085378.pdf](http://www.emea.europa.eu/WorkArea/DrugScienceResearchAndResearchArea/Pharmacogenomics/um/085378.pdf))
14. Guidance for Industry Pharmacogenomic Data Submissions. FDA. March 2005. (Accessed at: [www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm079649.pdf](http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm079649.pdf))
15. Pharmacogenomic Data Submissions - Companion Guidance. FDA Draft Guidance. August 2007. (Accessed at: [www.fda.gov/ucm/groups/ucm/documents/ucm079685.pdf](http://www.fda.gov/ucm/groups/ucm/documents/ucm079685.pdf))
16. Reflection Paper on Pharmacogenomics In Oncology. EMEA. 2008. (Accessed at: [www.emea.europa.eu/pdfs/human/pharmacogenetics/12843506endraft.pdf](http://www.emea.europa.eu/pdfs/human/pharmacogenetics/12843506endraft.pdf))
17. Position paper on Terminology In Pharmacogenetics. EMEA. 2002. (Accessed at: [www.emea.europa.eu/pdfs/human/press/p/307001en.pdf](http://www.emea.europa.eu/pdfs/human/press/p/307001en.pdf))
18. Concept paper on the development of a Guideline on the use of pharmacogenomic methodologies in the pharmacokinetic evaluation of medicinal products. EMEA. 2009. (Accessed at: [www.emea.europa.eu/pdfs/human/pharmacogenetics/6327009en.pdf](http://www.emea.europa.eu/pdfs/human/pharmacogenetics/6327009en.pdf))
19. Reflection paper on Pharmacogenomic samples, testing and data handling. EMEA. 2007. (Accessed at: [www.emea.europa.eu/pdfs/human/pharmacogenetics/20191406en.pdf](http://www.emea.europa.eu/pdfs/human/pharmacogenetics/20191406en.pdf))
20. Ishiguro A, Toyoshima S, Uyama Y. Current Japanese regulatory situations of pharmacogenomics in drug administration. *Expert Review of Clinical Pharmacology*. 2008;1: 505-514. (Accessed at: [www.ingentaconnect.com/content/btd/ecp/2008/0000001/00000004/art00007](http://www.ingentaconnect.com/content/btd/ecp/2008/0000001/00000004/art00007))
21. Amur S, Frueh FW, Lesko LJ, et al. Integration and use of



biomarkers in drug development, regulation and clinical practice: A US regulatory practice. *Biomarkers Med.* 2008; 2, 305-311. (Accessed at: [www.ingentaconnect.com/content/fm/bmm/2008/00000002/00000003/art00107?crawler=true](http://www.ingentaconnect.com/content/fm/bmm/2008/00000002/00000003/art00107?crawler=true))

22. Mendrick DL, Brazell C, Mansfield EA, et al. Pharmacogenomics and regulatory decision making: an international perspective. *The Pharmacogenomics Journal*. 2006; 6(3), 154-157. (Accessed at: [www.nature.com/tpj/journal/v6n3/abs/6500364a.html](http://www.nature.com/tpj/journal/v6n3/abs/6500364a.html))

23. Pendergast MK. Regulatory agency consideration of pharmacogenomics. *Exp Biol Med (Maywood)*. 2008; 233:1498-503. (Accessed at: [www.ebmonline.org/cgi/content/abstract/233/12/1498](http://www.ebmonline.org/cgi/content/abstract/233/12/1498))

24. Goodlad F, Frueh F. Process map proposal for the validation of genomic biomarkers. *Pharmacogenomics*. 2006; 7(5):773-82 (Accessed at: [www.futuremedicine.com/dol/abs/10.2217/14622416.7.5.773](http://www.futuremedicine.com/dol/abs/10.2217/14622416.7.5.773))

25. FDA Table of Valid Genomic Biomarkers in the Context of Approved Drug Labels. (Accessed at: [www.fda.gov/Drugs/ScienceResearch/ResearchAreas/Pharmacogenetics/ucm063378.htm](http://www.fda.gov/Drugs/ScienceResearch/ResearchAreas/Pharmacogenetics/ucm063378.htm))

26. International Serious Adverse Event Consortium. (Accessed at: [www.saeconsortium.org](http://www.saeconsortium.org))

27. Predictive Safety Testing Consortium. (Accessed at: [www.o-path.org/pstc.cfm](http://www.o-path.org/pstc.cfm))

28. Nuremberg code. (Accessed at: <http://ohsr.od.nih.gov/guidelines/nuremberg.html>)

29. Declaration of Helsinki. (Accessed at: <http://ohsr.od.nih.gov/guidelines/heislnkl.html>)

30. Belmont report. (Accessed at: <http://ohsr.od.nih.gov/guidelines/belmont.html>)

31. ICH E6(R1) – Guideline for Good Clinical Practice. June 1996. (Accessed at: [www.ich.org/LCB/media/MEDIA/482.pdf](http://www.ich.org/LCB/media/MEDIA/482.pdf))

32. Barnes M, Heffernan K. The "Future Uses" Dilemma: Secondary Uses of Data and Materials by Researchers for Commercial Research Sponsors. *Medical Research Law & Policy*. 2004; 3: 440-450.

33. Eriksson S, Helgesson G. Potential harms, anonymization, and the right to withdraw consent to biobank research. *Eur J Hum Genet.* 2005; 13:1071-1076. (Accessed at: [www.nature.com/ejhg/journal/v13n5/pdf/5201458a.pdf](http://www.nature.com/ejhg/journal/v13n5/pdf/5201458a.pdf))

34. Renegar G, Webster CJ, Stuerzebecher S, et al. Returning genetic research results to individuals: points-to-consider. *bioethics* 2006; 20: 24-36. (Accessed at: <http://www3.interscience.wiley.com/cgi-bin/fulltext/118562753/PDFSTART>)

35. Article 29 Data Protection Working Party. (Accessed at: [www.ec.europa.eu/justice\\_home/fsj/privacy/workinggroup/index\\_en.htm](http://www.ec.europa.eu/justice_home/fsj/privacy/workinggroup/index_en.htm))

36. Human Tissue Act 2004 (UK). (Accessed at: [www.opsi.gov.uk/acts/acts2004/en/ukpga/en\\_20040030\\_en\\_1](http://www.opsi.gov.uk/acts/acts2004/en/ukpga/en_20040030_en_1))

37. Genetic Information Nondiscrimination Act. (Accessed at: <http://www.hrsa.hrsa.gov/ehc/ehc.aspx?objid=110>)

[http://www.access.gpo.gov/ogp/sisyphus/doc/GetDocument.asp?docid=110\\_corgi\\_public\\_law&id=1010233.110.pdf](http://www.access.gpo.gov/ogp/sisyphus/doc/GetDocument.asp?docid=110_corgi_public_law&id=1010233.110.pdf))

38. Guidance for Sponsors, Clinical Investigators, and IRBs: Data Retention When Subjects Withdraw from FDA-Regulated Clinical Trials. FDA October 2008 [www.fda.gov/cDRMS/DOCKETs/98th/FDA-2008-0-0576-gd.pdf](http://www.fda.gov/cDRMS/DOCKETs/98th/FDA-2008-0-0576-gd.pdf)

39. Anderson C, Gomez-Mancilla B, Spear BB, Barnes DM, Cheeseman K, Shaw P, Friedman J, McCarthy A, Brazell C, Ray SC, McHale D, Hashimoto L, Sandbrink R, Watson ML, Salemo RA, on behalf of The Pharmacogenetics Working Group. Elements of Informed Consent for Pharmacogenetic Research: Perspective of the Pharmacogenetics Working Group. *Pharmacogenomics Journal* 2002;2:284-92. (Accessed at: [www.nature.com/tpj/journal/v2/n5/abs/6500131a.html](http://www.nature.com/tpj/journal/v2/n5/abs/6500131a.html))



[www.i-pwg.org](http://www.i-pwg.org)

#### **12.4 Response Evaluation Criteria in Solid Tumors**

RECIST 1.1\* will be used in this study for assessment of tumor response. While either CT or MRI may be utilized, as per RECIST 1.1, CT is the preferred imaging technique in this study.

\* As published in the European Journal of Cancer

## 12.5 ECOG Performance Status

Grade	Description
0	Fully active, able to carry on all pre-disease performance without restriction
1	Restricted in physically strenuous activity but ambulatory and able to carry out work of light or sedentary nature, e.g., light housework, office work.
2	Ambulatory and capable of all self-care but unable to carry out any work activities. Up and about more than 50% of waking hours .
3	Capable of only limited self-care, confined to bed or chair more than 50% of waking hours.
4	Completely disabled. Cannot carry on any self-care. Totally confined to bed or chair .
5	Dead.

\* As published in Am. J. Clin. Oncol.: *Oken, M.M., Creech, R.H., Tormey, D.C., Horton, J., Davis, T.E., McFadden, E.T., Carbone, P.P.: Toxicity And Response Criteria Of The Eastern Cooperative Oncology Group. Am J Clin Oncol 5:649-655, 1982.* The Eastern Cooperative Oncology Group, Robert Comis M.D., Group Chair.

## **12.6 Common Terminology Criteria for Adverse Events**

The descriptions and grading scales found in the revised NCI Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 will be utilized for adverse event reporting. (<http://ctep.cancer.gov>).

## 12.7 List of Abbreviations

Abbreviation/Term	Definition
2L	Second Line
AE	Adverse Event
AC	adenocarcinoma
ADA	Anti-Drug Antibodies
ALT	Alanine Aminotransferase
ANC	Absolute Neutrophil Count
aPTT	Activated Partial Thromboplastin Time
ASaT	All Subjects as Treated
ASCO	American Society of Clinical Oncology
AST	Aspartate Aminotransferase
β-HCG	Beta Human Chorionic Gonadotropin
BSA	Body Surface Area
CBC	Complete Blood Count
CI	Confidence Interval
CNS	Central Nervous System
CPS	Combined Positive Score
CR	Complete Response
CrCl	Calculated Creatinine Clearance
CRF	Case Report Form
CSR	Clinical Study Report
CT	Computed Tomography
CTCAE	Common Toxicity Criteria for Adverse Events
CTFG	Clinical Trial Facilitation Group
CTLA-4	Cytotoxic T-Lymphocyte-Associated Antigen-4
DKA	diabetic ketoacidosis
DNA	Deoxyribonucleic acid
DO.R	Duration of Response
DRAE	Drug-related Adverse Events
ECI	Events of Clinical Interest
ECG	Electrocardiogram
ECOG	Eastern Cooperative Oncology Group
eCRF	Electronic Case Report Form
EDC	Electronic Data Capture
eDMC	external Data Monitoring Committee
EGJ	esophagogastric junction
EOC	Executive Oversight Committee
EORTC	European Organisation for Research and Treatment of Cancer
PRO	Patient Reported Outcomes
EQ-5D	eEuroQol-5D
ER	emergency room
ERC	Ethics Review Committee
FBR	Future Biomedical Research
FDA	Food and Drug Administration
FDAAA	Food and Drug Administration Amendments Act
FDAMA	Food and Drug Administration Modernization Act
FFPE	Formalin-fixed, paraffin-embedded
GCP	Good Clinical Practice
GCSF	Granulocyte-Colony Stimulating Factors
GEP	Gene Expression Profile
GI	Gastrointestinal

Abbreviation/Term	Definition
GFR	Glomerular Filtration Rate
HBsAg	Hepatitis B surface Antigen
HCV	Hepatitis C Virus
HEA	Health Economic Assessment
HIV	Human Immunodeficiency Virus
HR	Hazard Ratio
HRQoL	health-related quality of life
IB	Investigator's Brochure
ICF	Informed Consent Form
ICH	International Conference on Harmonization
IHC	Immunohistochemistry
INR	International Normalized Ratio
irAEs	Immune-related Adverse Events
irPD	imaging confirms PD
irRECIST	Immune related RECIST (Modification of RECIST 1.1)
IRB	Institutional Review Board
ITIM	Immunoreceptor Tyrosine-based Inhibition Motif
ITSM	Immunoreceptor Tyrosine-based Switch Motif
ITT	Intention To Treat
IUD	Intrauterine device
IUS	Intrauterine hormone-releasing system
IV	Intravenous
IVRS	Interactive Voice Response System
IWRS	Integrated Web Response System
Kg	Kilogram
LDH	Lactate Dehydrogenase
mAb	Monoclonal Antibody
mcL	Microliters
MEL	Melanoma
mg	Milligram
mg/kg	Milligram per Kilogram
mL	milliliter
MRI	Magnetic Resonance Imaging
MSD	Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
NA or N/A	Not Applicable
NCI	National Cancer Institute
NSAID	Non-Steroidal Anti-inflammatory Drug
NSCLC	Non-Small Cell Lung Cancer
ORR	Objective Response Rate
OS	Overall Survival
OTC	Over-the-counter
PBPK	Physiologically-based Pharmacokinetics
PD	Progressive Disease
PD-1	Programmed Death-1
PD-L1	Programmed Death ligand-1
PE	Physical Exam
PFS	Progression Free Survival
PI	principal investigator
PIN	Personal Identification Number
PK	Pharmacokinetic
PO	Oral Administration
PR	Partial Response

<b>Abbreviation/Term</b>	<b>Definition</b>
PRO	Patient Reported Outcomes
PT	Prothrombin Time
PS	Performance Status
QALYs	quality adjusted life years
QLG	Quality of Life Group
QoL	Quality of Life
RECIST	Response Evaluation Criteria in Solid Tumors
RNA	Ribonucleic Acid
ROC	receiver operating characteristic
RMST	Restricted Mean Survival Time
RPSFT	Rank Preserving Structural Failure Time
Q2W	Every 3 Weeks
Q3W	Every 3 Weeks
Q9W	Every 9 Weeks
SAE	Serious Adverse Events
SAP	Statistical Analysis Plan
sSAP	supplemental SAP
SCC	squamous cell carcinoma
SD	Stable Disease
SGOT	Serum Glutamic Oxaloacetic Transaminase
SGPT	Serum Glutamic Pyruvic Transaminase
SOP	Standard Operating Procedures
TIL	Tumor Infiltrating Lymphocytes
TSH	Thyroid Stimulating Hormone
TTP	Time to Progression
ULN	Upper Limit of Normal
V-type	Variable-type
WHO	World Health Organization

## **13.0 SIGNATURES**

### **13.1 Sponsor's Representative**

TYPED NAME	
TITLE	
SIGNATURE	
DATE SIGNED	

### **13.2 Investigator**

I agree to conduct this clinical trial in accordance with the design outlined in this protocol and to abide by all provisions of this protocol (including other manuals and documents referenced from this protocol). I agree to conduct the trial in accordance with generally accepted standards of Good Clinical Practice. I also agree to report all information or data in accordance with the protocol and, in particular, I agree to report any serious adverse events as defined in Section 7.0 – Assessing and Recording Adverse Events. I also agree to handle all clinical supplies provided by the Sponsor and collect and handle all clinical specimens in accordance with the protocol. I understand that information that identifies me will be used and disclosed as described in the protocol, and that such information may be transferred to countries that do not have laws protecting such information. Since the information in this protocol and the referenced Investigator's Brochure is confidential, I understand that its disclosure to any third parties, other than those involved in approval, supervision, or conduct of the trial is prohibited. I will ensure that the necessary precautions are taken to protect such information from loss, inadvertent disclosure or access by third parties.

TYPED NAME	
TITLE	
SIGNATURE	
DATE SIGNED	